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La vía de estrés ribosomal se describió hace más de una década como una nueva vía 
activadora de p53. Dicha vía monitoriza la homeostasis de la biogénesis ribosomal. Perturbaciones en 
cualquiera de las etapas de la biosíntesis del ribosoma, transcripción del DNA ribosomal, 
procesamiento del RNA ribosomal, ensamblaje o transporte nuclear, conllevan un exceso de proteínas 
ribosomales no unidas al ribosoma. En este contexto, el complejo pre-ribosomal RPL11/RPL5/5S 
rRNA inhibe MDM2, activando así al supresor tumoral p53. La activación de p53 puede resultar en 
diferentes respuestas celulares que impiden que las células dañadas se conviertan en tumorales.  
 
Una de las preguntas que hemos abordado en este trabajo es si las células madre pluripotentes 
de ratón, caracterizadas por altas tasas de división celular, presentan mecanismos que monitoricen la 
homeostasis de la biogénesis ribosomal para salvaguardar la integridad de la progenie. Aquí 
demostramos que dichas células tienen funcional la vía de estrés ribosomal y que esta vía activa p53 
en respuesta al estrés ribosomal y elimina aquellas células dañadas mediante un proceso de apoptosis.  
 
Las células tumorales requieren a una mayor producción de ribosomas para mantener las altas 
tasas de división celular que las caracterizan. En este trabajo hemos llevado a cabo un rastreo de 
compuestos que tengan como diana el nucléolo, la fábrica de ribosomas de la célula, con la finalidad 
de perturbar la producción de ribosomas y eliminar así las células cancerígenas. Hemos testado dos 
colecciones de compuestos químicos y hemos identificado un grupo de derivados de acridina que 
inhiben la transcripción del ADN ribosomal y, por tanto, generan la pérdida de la integridad del 
nucleolo. Esto resulta en la activación de p53 en ausencia de daño a través de la vía de estrés 
ribosomal. Finalmente, estos compuestos ralentizan el crecimiento celular y activan un proceso de 
apoptosis en distintas líneas de células tumorales.  
 
RPL11, proteína clave en la vía de estrés ribosomal, se encuentra mutada en heterozigosis en 
pacientes de anemia de Diamond-Blackfan. Hemos generado un alelo nulo condicional para Rpl11 y 
hemos demostrado que la pérdida de un alelo de Rpl11 en ratones adultos recapitula las principales 
características de la enfermedad, incluyendo un procesamiento inadecuado del ARN ribosomal, 
anemia macrocítica debida a una maduración eritroide defectuosa y una mayor predisposición a 
cáncer. Los ratones haploinsuficientes para Rpl11 muestran una linfomagénesis acelerada, lo que 
puede deberse a dos mecanismos no excluyentes: una vía de estrés ribosomal defectuosa y mayores 
niveles basales de la proto-oncoproteína c-MYC.  
 
En resumen, nuestro trabajo pone de manifiesto la importancia de la vía de estrés ribosomal y, 
en particular de RPL11, en la fisiología, incluyendo células madre embrionarias y el organismo adulto, 
así como para el desarrollo del cancer y su terapia.  
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The ribosomal stress (RbS) pathway was described more than a decade ago as a new p53-
activating pathway. This pathway monitors the homeostasis of the ribosome biogenesis. Perturbations 
in any of the steps comprising ribosome biosynthesis, rDNA transcription, rRNA processing and 
ribosome assembly and export, lead to the accumulation of ribosome-free ribosomal proteins. In this 
situation, RPL11/RPL5/5S rRNA pre-ribosomal complexes bind and inhibit MDM2, thus activating 
p53. Activation of p53 can result in different cellular outcomes that prevent damaged cells from 
becoming malignant.  
 
We wanted to explore whether mouse pluripotent stem cells, characterized by a rapid growth 
rate, present mechanisms to monitor the homeostasis of ribosome biogenesis as a way to ensure an 
optimal quality of their progeny. We have demonstrated that mouse pluripotent stem cells rely on an 
operative ribosomal stress pathway to eliminate damaged cells upon RbS. Importantly, p53 plays a 
key role in this process by eliciting apoptsis in embryonic stem cells following RbS.  
 
Cancer cells require high rates of ribosome biogenesis to sustain their rapid growth. To target 
this Achilles’ heel of cancer cells we have designed a cellular screen that monitors the integrity of the 
nucleolus, the ribosome factory, to identify small molecule compounds that disrupt ribosome 
biogenesis. By performing chemical library screens, we have identified a group of acridine derivatives 
that inhibits rDNA transcription, and thus cause nucleolar disruption. This results in p53 activation 
through the RbS pathway, and in the absence of detectable DNA damage. Remarkably, these 
compounds hamper proliferation and trigger apoptosis of different cancer cell lines, providing new 
therapeutical opportunities against cancer.  
 
Heterozygous mutations of RPL11, a key player in the RbS pathway, have been found in 
Diamond-Blackfan Anaemia (DBA) patients. To that end, we generated a conditional knockout mouse 
model for Rpl11. Here we demonstrate that partial loss of Rpl11 recapitulates the main pathologies of 
DBA, including impaired rRNA processing, macrocytic anaemia and cancer predisposition. Rpl11 
haploinsufficient mice have reduced number of erythroid progenitors and delayed erythroid 
differentiation. These animals show accelerated lymphomagenesis, probably due to two non-exclusive 
mechanisms: defective activation of p53 through the RbS pathway and increased basal levels of c-
MYC.  
 
In summary, our work provide insights into the biological relevance of the RbS pathway and, 
in particular of RPL11, in the physiology, including mouse pluripotent stem cells and the adult 
organism, as well as in cancer development and possible treatments.  
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ActD  Actinomycin D 
ADN  Ácido deoxirribonucleico 
ARN  Ácido ribonucleico 
DBA  Diamond-Blackfan Anaemia 
DDR  DNA Damage Response 
DNA  Deoxyrribonucleic Acid 
DSB  Double Strand Break 
E  Embryonic day 
HSCs  Hematopoietic Stem Cells  
iPSCs  Induced Pluripotent Stem Cells 
MDM2  Mouse Double Minute 2 
MDS  Myelodysplastic Syndrome 
MEF  Mouse Embryonic Fibroblast 
mESCs  Mouse Embryonic Stem Cells  
Pol   Polymerase  
RbS  Ribosomal Stress 
RS  Replicative Stress 
RNA  Ribonucleic Acid 
RP  Ribosomal Protein 
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RPS  Ribosomal Protein (Small subunit) 
rRNA  Ribosomal RNA 
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1. THE TUMOUR SUPPRESSOR P53  
In 1979 four different groups described by the first time the p53 protein as a tumour antigen 
(DeLeo et al., 1979; Kress et al., 1979; Lane and Crawford, 1979; Linzer and Levine, 1979). Levels of 
p53 were shown to be very high in transformed cells and forming a complex with distinct oncoviral 
proteins (Lane and Crawford, 1979; Sarnow et al., 1982; Scheffner et al., 1990). In addition, many of 
the isolated p53 cDNA clones were able to transform cells in combination with the Ras oncogene 
(Eliyahu et al., 1984; Jenkins et al., 1984; Parada et al., 1984). Based on these findings, p53 was 
considered at that time as an oncogene. Ten years later it was verified that those transforming p53 
cDNA clones carried a mutation (Finlay et al., 1989; Hinds et al., 1989). Moreover, their 
transformation potential in combination with Ras was abolished when wt p53 cDNA was expressed at 
the same time (Finlay et al., 1989). These unexpected results led to the credence that, contrary to what 
was previously stated, p53 acts as a tumour suppressor. The tumour suppressor function of p53 was 
firmly established when (Baker et al., 1989) found p53 mutated in one allele and lost in the second 
allele in two human colon cancers. Supporting this, somatic p53 mutations or deletions are reported in 
around 50% of human sporadic cancers, while the remaining percentage presents alterations in its 
signalling pathways (Vogelstein et al., 2000). Mice with genetic deletion of p53 develop spontaneous 
tumours with 100% penetrance (Donehower et al., 1992; Jacks et al., 1994). Moreover, families with 
germline mutations in the TP53 gene, Li-Fraumeni syndrome and Li-Fraumeni-like syndrome, are 
more susceptible to cancer (McBride et al., 2014). Correspondingly, restoration of wild type p53 
function in animal models can induce tumour regression and significantly extend survival (Martins et 
al., 2006; Ventura et al., 2007; Xue et al., 2007). In support of this, mice carrying additional extra 
copies of p53, under its own promoter, show high resistance to spontaneous and chemically-induced 
tumours (Garcia-Cao, 2002). These genetic models have revealed the crucial role of p53 in 
suppressing tumourigenesis  
 
1.1. Tumour suppressive function of p53 – transcriptional activity 
 
p53 prevents genetically compromised cells from becoming malignant by eliciting different 
cellular responses that execute through its activity as a transcription factor. The p53 transcriptional 
program is regulated in a stress-specific manner (Beckerman and Prives, 2010), whereby distinct 
subsets of p53 target genes are induced in response to different p53-activating agents, including 
oncogene activation, chronic DNA damage, oxidative stress, nutrient deprivation, hypoxia, telomere 
erosion or ribosome biogenesis dysfunction. How p53 is able to discriminate between different loci in 
response to a particular stress is the subject of intense research and it is thought that specific patterns 
of p53 post-translation modifications trigger individual transcriptional programs that lead to different 
cellular outcomes (Beckerman and Prives, 2010; Bieging et al., 2014).  
Introduction 
34!
The sequence analysis of the p53 protein revealed two N-terminal transcriptional activation 
domains (TAD), a large DNA binding domain (DBD), a tetramerization domain (4D) and a basic C-
terminal domain (CTD) (Toledo and Wahl, 2006). The DNA binding domain directs the p53 tetramer 
to p53-responsive elements (p53 RE), located in specific RNA pol II-transcribed gene promoters. 
Once p53 is bound to the p53 RE, it recruits, through its transactivation domain, both general and 
specific transcriptional co-regulators whose depending on their nature, co-activator or co-repressor, 
can activate or inhibit expression of different p53 target genes, respectively (Laptenko and Prives, 
2006). Special attention has been placed in the DNA binding domain since most mutations in p53 in 
human cancers occurs in this region (Olivier et al., 2010). For instance, mutations in the arginine 175 
(R175H) or arginine 273 (R273H), both within the DNA binding domain, are hot spot mutations in 
human cancers (Joerger and Fersht, 2007). This suggests that the transcription factor activity of p53 is 
crucial for tumour suppression. 
 
Cell cycle arrest, senescence and apoptosis have been extensively accepted as the major 
mechanisms by which p53 suppresses cancer onset and development. However, these p53-mediated 
responses have been mainly evaluated in response to acute DNA damage, which in addition of being a 
non-physiological stimulus is irrelevant for p53-mediated tumour suppression (Christophorou et al., 
2006; Efeyan et al., 2006; Hinkal et al., 2009). Engineered mouse models in which p53 function can 
be restored in a time controllable manner have revealed that cell cycle arrest, senescence and apoptosis 
are likely to result in tumour suppression depending on the cell type context (Bieging et al., 2014; 
Ventura et al., 2007). However, no single or compound knockout mouse model for p53 target genes 
involved in these cellular responses has recapitulated the dramatic tumour predisposition that 
characterizes p53-null mice. This suggests that p53 executes its tumour suppressive function by 
additional mechanisms. In agreement, it has been shown recently that cell cycle arrest, senescence and 
apoptosis may be dispensable for tumour suppression and that other important cancer-relevant p53 
activities such as metabolic regulation or antioxidant function migth be required to limit tumorigenesis 
(Bieging et al., 2014; Li et al., 2012b; Valente et al., 2013). 
 
1.2. Regulation of p53. p53-MDM2: the negative regulatory feedback loop 
 
The half-life of p53 is extremely short in unstressed cells, being about 30 min, but it is 
extended to longer times, about 24 hours, in SV-40 transformed fibroblasts (Oren et al., 1981). This 
fact led researchers to hypothesize the existence of post-translational mechanisms controlling p53 
stability and in the early 90’s they discovered the main regulator of p53 stability, namely, the proto-
oncoprotein MDM2 (murine double minutes-2) (Momand et al., 1992). Mdm2-null mice die around 
implantation (Jones et al., 1995; Montes de Oca Luna et al., 1995) because of unrestrained p53-
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dependent apoptosis (de Rozieres et al., 2000). The embryonic lethality of Mdm2-null mice is 
overcome in the absence of p53 (Jones et al., 1995; Montes de Oca Luna et al., 1995) highlighting the 
negative regulation of MDM2 on p53 function in vivo, and specially during the extremely proliferative 
gastrulation stage (Snow, 1977). Mmd2 haploinsufficient mice are more resistant to tumour formation 
in an oncogenic context due to high p53 activity (Alt et al., 2003; Mendrysa et al., 2006). On the 
contrary, transgenic mice overexpressing Mdm2 develop carcinoma (Lundgren et al., 1997) and 
lymphomas or sarcomas (Jones et al., 1998) and the onset of tumorigenesis is not accelerated when 
these mice are crossed with p53-null animals. In addition, the Mdm2 gene is amplified in many human 
cancers, especially frequent in osteosarcomas and soft tissue sarcomas (Wade et al., 2013). All these 
reports provide additional evidence for the role of MDM2 in mediating p53 inhibition. 
 
MDM2 and p53 form an autoregulatory feedback loop. P53 stimulates the transcriptional 
expression of MDM2 (Barak et al., 1993; Perry et al., 1993; Wade et al., 2013), which in turn 
negatively regulates p53. MDM2 maintains levels of p53 low in unstressed cells by regulating three 
different aspects: function, stability and subcellular localization of p53. MDM2 binds to the N-
terminal p53 transactivation domain, thus impairing p53 transcriptional activity (Kussie et al., 1996). 
In addition, MDM2 promotes ubiquitylation and proteasome-mediated degradation of p53 (Haupt et 
al., 1997; Honda et al., 1997; Kubbutat et al., 1997). MDM2 contains a C2H2C4 RING (really 
interesting new gene) domain with intrinsic E3 ubiquitin ligase activity that promotes the transfer of 
ubiquitin molecules from an E2 conjugating enzyme to a cluster of lysine residues within the C-
terminus of p53 (Lohrum et al., 2001; Rodriguez et al., 2000). Low levels of MDM2 activity induce 
monoubiquitylation and nuclear export of p53, controlling in this manner p53 subcellular localization, 
while high levels of MDM2 activity promote p53 polyubiquitylation and nuclear degradation (Li et al., 
2003). The phenotype of mice bearing a homozygous MDM2 mutation (C462A) that abolishes the E3 
ubiquitin ligase activity without affecting p53-binding (Itahana et al., 2007) resembles Mdm2-null 
mice. This strongly support p53 degradation rather than impairment of its transcriptional activity as 
the primarily source of MDM2 regulation on p53 function. Furthermore, MDM2 can also negatively 
regulate p53 transcription activity by catalysing the transfer of the NEDD8 ubiquitin-like molecule 
(Xirodimas et al., 2004). Besides MDM2, there are several ubiquitin ligases involved in p53-mediated 
proteosomal degradation and nuclear export, such as Pirh2, COP1 or Ubc13 (Lee and Gu, 2010), 
although their biological relevance remains to be addressed in genetic models. Likewise, additional 
proteins mediating p53 NEDDylation and SUMOylation, such as FBX011 and the family of PIAS 
ligases, respectively, have been described to modulate p53 protein stability (Horn and Vousden, 2007).  
 
Stabilization of p53 is crucial for its tumour suppressor function in response to various types 
of stress and can be achieved through 1) direct p53 deubiquitylation by ubiquitin-specific proteases, 
such as HAUSP or USP10 (Li et al., 2002; Yuan et al., 2010), 2) abrogation of MDM2-mediated 
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ubiquitin ligase activity and, so far the most studied mechanism, 3) inhibition of MDM2-p53 
interaction. A simplified graph of the p53-activating pathways is depicted below (Figure 1).  
 
 
 
1.2.1. Disruption of the MDM2-p53 interaction: MDM2 post-translational modifications 
and binding of basic proteins (ARF and RPs) 
 
Impairment of MDM2-mediated ubiquitylation activity can be accomplished following 
genotoxic stress by MDM2 post-translational modifications (PMTs) that affect its stability and E3 
ligase processivity (Cheng et al., 2009; Wade et al., 2013). Additionally, MDM2 transcripts levels can 
be downregulated by p53-mediated expression of a set of miRNAs (miR-192, 194, and 215) thus 
indirectly contributing to p53 stabilization (Pichiorri et al., 2010). Although MDM2 post-translational 
modifications have been shown to be involved in rapid p53 stabilization upon DNA damage, the p53 
response can only be executed if its interaction with its inhibitor MDM2 is abolished. A group of basic 
Figure 1. p53-activating pathways. 
Insults and mediators triggering activation of p53 are depicted in the figure. Note that MDM2 is central to 
all pathways, denoting its important function in the regulation of p53. At the bottom part, p53 target genes 
involved in the different celular outcomes. Coloured in green are highligthed the classical p53-mediated 
responses while in blue are represented emerging cellular outcomes driven by p53 and relevant for tumour 
suppression.     
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proteins that binds to the acidic domain of MDM2 in response to mitogenic or ribosomal stress disrupt 
MDM2-p53 interaction and impair MDM2-mediated p53 ubiquitylation and nuclear export. The 
central acidic domain of MDM2 is critical for efficient p53 ubiquitylation (Kawai et al., 2003; 
Meulmeester et al., 2003) so interfering with it results in cancellation of the MDM2 E3 ubiquitin 
ligase activity and subsequent p53 activation.  
 
The tumour suppressor p19Arf (p14Arf in humans; ARF thereafter) is among these basic 
proteins and binds MDM2 (Kamijo et al., 1997; Pomerantz et al., 1998; Zhang et al., 1998) in the 
presence of oncogenic stress, such as aberrant expression of E2F1, c-MYC, RAS and the viral 
oncoprotein E1A (Bates et al., 1998; Palmero et al., 1998; Sherr, 1998; De Stanchina et al., 1998; 
Zindy et al., 1998). ARF null mice are prone to cancer to a similar extent as p53 knockout mice 
(Kamijo et al., 1997), highlighting the tumour suppressor role of ARF by inhibiting MDM2. However, 
ARF null animals retain p53 activation in response to DNA damage or pRb inactivation which 
indicates the existence of complementary p53-activating pathways (Kamijo et al., 1999; Tolbert et al., 
2002).   
 
In the presence of oncogenic c-MYC or ribosomal stress (explained in more detail in 
following sections), ribosomal proteins RPL11 and RPL5 bind to the MDM2 acidic domain without 
overlapping ARF binding (Lindström et al., 2007; Macias et al., 2010), forming a quaternary complex 
with p53 (Zhang et al., 2003). Mice with a mutation in MDM2 (C305F) that selectively disrupts 
RPL11/RPL5 binding exhibit accelerated lymphomagenesis in an Eµ-MYC background (Macias et al., 
2010), highlighting the importance of the MDM2-p53 interaction also in response to ribosomal stress.   
 
1.2.2. Disruption of the MDM2-p53 interaction: p53 post-translational modifications.  
 
More than 36 residues can undergo post-translational modifications in p53, including 
phosphorylation, acetylation, ubiquitylation, methylation, sumoylation and neddylation, modulate p53 
function. They are involved in controlling 1) p53 stabilization, 2) DNA binding, and 3) transcriptional 
activation in response to oncogene expression or DNA damage, among other stresses. Post-
transcriptional modifications controlling stability and activation are usually circumscribed to the p53 
transactivation domain and C-terminus domain (TAD and CTD). Ubiquitylation in the CTD largely 
contributes to the regulation of p53 stability, as above discussed, while stress-induced phosphorylation 
of serines in the TAD of p53 attenuates MDM2-p53 interaction, thus prolonging p53 half-life. p53 
phosphorylation occurs very rapidly within the first 30 minutes following different stimuli, most 
notably DNA damage, and can be catalysed by a broad range of kinases, including ATM/ATR/DNA-
PK, CHK1/CHK2, CK2 or JNK (Loughery and Meek, 2013). Experiments in vitro have shown that 
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phosphorylation of certain p53 residues in response to DNA damage disrupts MDM2-p53 association, 
thus stabilizing p53, and is crucial for promoting binding of co-regulators (Loughery and Meek, 2013). 
Finally, acetylation levels of p53 significantly increase in response to stress and correlate well with 
p53 activation and stabilization. Moreover, acetylation of lysine residues in the C-terminus of p53 is 
required for p53 transcriptional activities in a cell type-dependent context (Feng et al., 2005; Tang et 
al., 2008) and p53 deacetylation by SIRT1 and HDAC1 impairs its stability and transcriptional 
activation (Brooks and Gu, 2011). Interestingly, acetylation of p53 occurs in the same lysines targeted 
for MDM2-mediated ubiquitylation so it is considered to prevent p53 degradation.  
 
Although p53 post-translational modifications have been shown to be necessary for p53 
activation in vitro, genetic studies in mice claim that they play a subtle role in the stress-induced 
tumour suppressive function of p53 in vivo. Mutant mice for all major targeted residues of serines in 
the TAD and lysines in the CTD show modest phenotypes and do not prevent p53 activation upon 
genotoxic stress (Bieging et al., 2014; Toledo and Wahl, 2006). This suggests that p53 can still be 
stabilized, by means of other mechanisms, in the absence of post-translational modifications.  
 
1.2.3. Chemical disruption of the MDM2-p53 interaction: Reactivation of p53 in 
tumours with wild-type p53  
 
Half percent of human cancers bear mutations or deletions in the p53 gene while the other half 
percent present alterations in p53-activating pathways. One of the mechanisms preventing activation 
of p53 is overexpression of MDM2 and MDM4. The Mdm2 gene is found amplified in many human 
cancers, being amplification of Mdm2 especially frequent in osteosarcomas and soft tissue sarcomas 
(Oliner et al., 1992; Wade et al., 2013). Numerous attempts have been made to develop small 
molecules that target and block the MDM2-p53 interaction to reactivate p53 levels in p53-proficient 
cancers. The key of the interaction between MDM2 and p53 relies in just three lipophylic residues of 
p53, required for p53 transactivation, that fit deeply into the hydrophobic pocket of the MDM2 N-
terminal domain (Kussie et al., 1996). Fortunately, the size of the MDM2 cleft can be fully occupied 
by small molecules that mimic this interaction. Three groups of chemical compounds, nutlins, 
benzodiazepines and spirooxindole-containing molecules, have been successfully used in vitro to 
restore p53 function in human cancer cells and xenograft models with minimal side effects (Brown et 
al., 2009; Wade et al., 2013; Zhao et al., 2013). Importantly, several of these compounds have been 
advanced into phase I clinical trials for treating multiple human cancers (Ray-Coquard et al., 2012; 
Zhao et al., 2013), such as two nutlin derivatives, RG-7112 and RO5503781 (ROCHE), the 
spirooxindole analog SAR405848 (Sanofi) or the dihydroisoquinolinone derivative CGM097 
(Novartis). RITA is another effective compound that blocks MDM2-p53 interaction by direct binding 
to p53 and induces apoptosis more efficiently than nutlins, although its mechanism of action needs 
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further clarification (Brown et al., 2009). Although the main efforts have been made in chemically 
disrupting p53-MDM2 interaction, the ubiquitin ligase activity of MDM2 has also been targeted 
although with less success. This is the case of the HLI98 inhibitor, which activates p53-dependent 
apoptosis in cancer cells but with low potency and selectivity (Wade et al., 2013).  
 
 Additional cell-based screens have identified chemical compounds that activate p53 by 
indirectly promoting MDM2 inhibition and reduce tumour growth in cancer cell lines and xenografts. 
This is the case, for instance, of tenovins that inhibit the p53 deacetylase SIRT1, tubulin inhibitors 
(taxol and vinca alkaloids), or compounds that inhibit rRNA synthesis (actinomycin D, mycophenolic 
acid or 5-fluorouracil). This last set of compounds cause nucleolar disruption and the release of 
ribosome-free RPL11 and RPL5 that bind and inactivate MDM2 (Sun et al., 2008, 2007; Zhang et al., 
2003).  
 
1.3. p53 and stem cells 
 
Mouse embryonic stem cells (mESCs) possess unlimited self-renewal capacity with the 
potential to differentiate into all cell lineages in the body, including germ cells (Young, 2011). Both 
self-renewal and pluripotentcy are maintained by the coordinated action of a core of transcription 
factors, such as Oct4, Sox2 and Nanog (Mitsui et al., 2003; Nichols et al., 1998). Among other 
features, mESCs are characterized by extremely high rates of proliferation with an average generation 
time of 8-10 hours (Orford and Scadden, 2008; White and Dalton, 2005). Rapid cell divisions are 
achieved by means of their particular cell cycle structure. In contrast to somatic or adult stem cells, 
mESCs do not undergo quiescence or present gap phases so they dedicate the majority of the time 
(around 60%) to alternate between replication and mitosis. mESCs present a very short G1 period that 
lacks the restriction (R-) point control (White and Dalton, 2005). This is possible by elevated levels of 
Cdk activity that maintain RB phosphorylated and absence of Ink4a and Cip/Kip cyclin-dependent 
kinases inhibitors such p16, p21 and p27 (Orford and Scadden, 2008; Sage, 2012; White and Dalton, 
2005). Furthermore, Cdc25A, required for progression from G1 to S phase, cannot be inactivated by 
CHK2 kinase in response to ionizing radiation (Hong and Stambrook, 2004). The inability of mESCs 
to undergo G1/S cell cycle arrest or senescence in response to genotoxic insults would make them 
especially susceptible to accumulate large mutational burdens, which might result in teratogenesis 
during embryo development. However, mESCs present a lower frequency of spontaneous mutations 
(10-6) than differentiated cells (10-4) (Cervantes et al., 2002). This might be due to the fact that mESCs 
can be halted at G2/M (Chuykin et al., 2008), are hypersensitive to DNA damage and readily undergo 
either apoptosis or differentiation to eliminate damaged cells from the pool (Giachino et al., 2013; 
Heyer et al., 2000; Hong and Stambrook, 2004). The exact mechanisms by which mESCs insure that 
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intact genomes are transferred to identical daughter cells have been of interest during many years. 
Special interest has been placed on the tumour suppressor p53 although its role in the maintenance of 
genomic stability in mESCs remains controversial as explained below. 
 
 P53 constitutes a barrier for reprogramming of differentiated cells to induced pluripotent stem 
cells (iPSCs) (Hong et al., 2009; Kawamura et al., 2010; Li et al., 2009; Marion et al., 2009; Utikal et 
al., 2009). mESCs present abundant amounts of cytoplasmic p53 that remains inactive as a 
transcription factor (Aladjem et al., 1998; Sabapathy et al., 1997a; Solozobova et al., 2009). Unlike 
differentiated cells, mESCs cannot activate p53 through ARF-mediated inhibition of MDM2 since the 
locus comprising ARF, Ink4/Arf locus, is epigenetically silenced in mESCs and iPSCs (Li et al., 
2009). In addition, several studies have reported the absence of a p53-dependent G1/S checkpoint or 
apoptosis following ionizing radiation of mESCs (Aladjem et al., 1998; Chao et al., 2000a; Chuykin et 
al., 2008; Corbet et al., 1999; Hong and Stambrook, 2004; Solozobova et al., 2009). All these facts 
together could lead us to consider that p53 is dispensable for maintenance of genomic integrity and 
pluripotency features in mESCs. Lack of p53 does not affect self-renewal of mESCs, however, it 
causes developmental abnormalities and accelerated appearance of tumours (Donehower et al., 1992; 
Jacks et al., 1994), suggesting an important role for p53 during embryo development. Contrary to what 
stated above that p53 is not required for keeping stem cells in check following DNA damage, p53 can 
be functional depending on the nature of the genotoxic insult. In this manner, p53 can be translocated 
to the nucleus (Han et al., 2008; Solozobova et al., 2009), mainly in response to UV radiation (Corbet 
et al., 1999; Sabapathy et al., 1997b) and oxidative stress (Han et al., 2008). UV and oxidative stress 
and the radiomimetic compound doxorubicin elicit p53-dependent apoptosis or differentiation in 
mESCs, respectively (Chao et al., 2000b; Corbet et al., 1999; Han et al., 2008; Li et al., 2012a; 
Sabapathy et al., 1997a). mESCs differentiation results from p53-mediated repression of the 
pluripotency factor NANOG (Lin et al., 2005) and other stemness master regulators (Li et al., 2012a). 
Additionally, studies through early gastrulation (E6.5 to E7.5) show that low dose of radiation (<0.5 
Gy) cause a ATM- and p53-dependent apoptosis (Heyer et al., 2000). A summary table of p53 
responses in mESCs is shown below (Table 1).  
 
Highly proliferating mESCs need to increase ribosome biogenesis rate in order to meet the 
elevated energetic demands. Consistent with this, ribosomal proteins are more abundantly expressed in 
mESCs compared to differentiated cells (Kondrashov et al., 2011), and, interestingly, a decrease in 
rDNA transcription is associated to differentiation in certain type of cells (Larson et al., 1993). In 
somatic cells, proliferative signals, such as serum stimulation or activation of the MAPK signalling 
pathway, result in elevated rDNA transcription to support cell growth and replication (Drygin et al., 
2010). In addition, ribosome biogenesis and cell cycle are tightly coupled processes, being levels of 
rRNA synthesis increased during S and G2 phases, when cells demand newly synthesized proteins to 
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progress into mitosis (Drygin et al., 2010). Data from hepatectomized mice deficient for the 40S 
ribosomal protein S6 (RPS6) have revealed that normal protein synthesis but ribosome dysfunction 
prevents re-entry in the cell cycle (Volarevic et al., 2000), indicating that both ribosome biogenesis 
and cell cycle are coupled. Somatic cells count on the p53-activating ribosomal stress pathway 
(explained in following sections), to safeguard homeostasis of ribosome biogenesis and ensure intact 
genetic transmission to daughter cells. But, do mESCs also count on the p53-activating ribosomal 
stress pathway? Due to the controversial role of p53 in mESCs, this question is fundamental to us in 
order to better understand the mechanisms that mESCs use to preserve the pool of “bona fide” stem 
cells.  
!
Table 1. Summary of the p53 responses in mESCs following different stresses.  
 
DNA damage type  Activation of p53 Cellular outcome References 
 
Non-ionizing radiation 
 
UV radiation  Nuclear translocation N/A (Solozobova et al., 2009) 
 Yes (phospho-S315) Differentiation (Lin et al., 2005) 
 Yes Apoptosis (Corbet et al., 1999) 
 Yes Apoptosis (Sabapathy et al., 1997a) 
 Yes Apoptosis (Chao et al., 2000b) 
 
Ionizing radiation 
 
γ-irradiation Transient stabilization Reduced clonogenic survival (Corbet et al., 1999) 
 Transient stabilization N/A (Solozobova et al., 2009) 
 Transient stabilization N/A (Chao et al., 2000a) 
 Stabilization + phosphoS23 Absence of G1 arrest (Hong and Stambrook, 2004) 
 No Apoptosis (Aladjem et al., 1998) 
 No Absence of G1 arrest (Chuykin et al., 2008) 
 Yes Apoptosis (E6.5) (Heyer et al., 2000) 
 
Other stresses 
 
rNTP depletion No Apoptosis (Aladjem et al., 1998)  
 
Doxorubicin  No Apoptosis (Aladjem et al., 1998) 
 Yes Differentiation (Li et al., 2012a) 
 
Oxidative stress Mitochondrial translocation Apoptosis (Han et al., 2008) 
 
 
2. RIBOSOME BIOGENESIS 
Ribosome biogenesis is one of the most demanding energetic processes of a proliferating cell. 
In a yeast cell, approximately 40 nascent ribosomes per second are exported from the nucleolus, the 
major site of ribosome biogenesis, into the cytoplasm. Per generation, a cell produces 1-2 millions of 
ribosomes (Warner, 1999). Ribosome biogenesis consumes up to the 80% of the energy of a 
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eukaryotic cell (Schmidt, 1999) and requires a complete synchronization of all three RNA 
polymerases. RNA polymerase I (RNA pol I) transcribes the clusters of rDNA genes, repeated in 
tandem, generating long primary transcripts (47S) that will be afterwards processed into mature 28S, 
18S and 5.8S rRNAs. RNA polymerase III (RNA pol III) is in charge of transcribing the fourth rRNA 
specie (5S) that integrates the ribosome, as well as small nuclear RNAs (snRNAs) that participate in 
rRNA processing and transfer RNA (tRNA) that are required for protein synthesis. Simultaneously, 
RNA polymerase II (RNA pol II) transcribes the r-proteins or ribosomal proteins (RPs) as well as 
other factors that participate in the maturation of the primary rRNA, assembly and exporting of the 
ribosomal subunits. Ribosomes are made of equimolar amounts of the four rRNA species (28S, 18S, 
5.8S and 5S rRNA) and more than 70 RPs. 18S rRNA along with 30 r-proteins makes the small 
ribosomal subunit (40S) while the 28S, 5.8S and 5S rRNA together with 45 r-proteins compose the 
large ribosomal subunit (60S).  
 
Ribosome biogenesis comprises three different steps: 1) rDNA transcription, 2) rRNA 
processing and 3) ribosome subunits assembly and export. All these three steps, except nuclear 
transport, are carried out in the nucleolus. In mammalian cells, the synthesis of ribosomes is tightly 
regulated to cell cycle progression. rDNA transcription is absent during mitosis, where nucleoli are 
disassembled (Dousset et al., 2000), and gradually increases during G1, peaking S and G2 phases 
(Russell and Zomerdijk, 2005). The length of the cell cycle mainly depends on the time employed by 
the cell to pass through the G1 phase. During G1 phase cells need to surpass the restriction point (-R 
point) to proceed into DNA replication and they need to grow sufficiently in order to do so. 
Consequently, an accelerated or delayed G1/S phase progression results from accelerated or delayed 
achievement of an appropriate ribosome production during G1 (Derenzini et al., 2005). Nucleolar size 
increases between G1 and G2 phases (Russell and Zomerdijk, 2005) and, accordingly, proliferating 
cells display larger nucleoli than the corresponding resting cells (Derenzini et al., 2009). Increase in 
nucleolar size is mainly due to elevated rates of rDNA transcription, positively regulated by mitogens, 
nutrient availability and growth factors, through a complex signalling network that integrates the 
mammalian target of rapamycin (mTOR), phosphatidyl inositol-3 kinase (PI3K) and mitogen-
activated protein kinase (MAPK) signalling pathways (James and Zomerdijk, 2004; Zhong et al., 
2004).  
 
2.1. The Nucleolus 
 
The nucleolus is “an organelle formed by the act of building a ribosome” (Mélèse and Xue, 
1995). Thus, nucleoli are the ribosome factories of the cell. Unlike cytoplasmic organelles, such as the 
Golgi apparatus or the mitochondria, nucleoli are not enveloped by a membrane. Thus, nucleoli are 
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not isolated inside the nucleus, although they are very distinct from the surrounding nuclear material, 
being about twice as dense and roughly 100,000 times more viscous than the nucleoplasm 
(Brangwynne et al., 2011). The particular density of the nucleolus is due to the multiple interactions of 
macromolecular complexes (more than 4,000 proteins) that msotly participate in ribosome biogenesis 
(Ahmad et al., 2009). The high density and great refractive index allow the nucleolus to be easily 
visualized by phase contrast microscopy and electron microscopy.  
 
Nucleoli assemble around specific genetic loci, called nucleolar organizer regions (NORs), 
firstly described by B. McClintock (1934) in plant cells. NORs comprise tandemly repeated clusters of 
rDNA genes located in different chromosomes in mammals and with number variation across species 
(Goodpasture and Bloom, 1975). In humans, each NOR contain around 40 repeats consisting of 18S, 
5.8S and 28S rRNA coding sequences, transcribed internal and external spacers (ITS and ETS), a non-
transcribed intergenic spacer, an origin of replication, transcriptional terminators and a replication fork 
barrier that prevents collisions between replication and transcription (Fatica and Tollervey, 2002; 
Labib and Hodgson, 2007). Only 50% of the approximately 400 rDNA repeats in the human diploid 
genome are transcriptionally active. Counter-intuitively, when cells need higher rDNA transcription 
rates for growth they increase the efficiency of transcription from active rDNA repeats instead of 
activating those transcriptionally “silent” repeats (McStay and Grummt, 2008). The number, size and 
position of nucleoli depend on the cellular metabolic activity.  
 
The nucleolus carries out three different steps during the synthesis of ribosomes: 
 
1. rDNA transcription. Transcription of rDNA requires the recruitment and assembly of the 
preinitiation complex (PIC) during G1 phase to the rDNA core promoter. This complex is 
comprised by the RNA pol I and, in mammals, at least 3 other basal factors: the transcription 
initiation factor I A (TIF-IA), the selectivity factor complex (SL1 in humans, TIF-IB in mouse), 
and the upstream binding factor (UBF). UBF bends the DNA and bring into close proximity the 
core promoter and the upstream control element, as well as recruits RNA pol I to rDNA promoter 
and stabilizes TIF-IA and SL1 binding (Grummt, 2003). TIF-1A, SL1, and UBF are essential for 
transcription by RNA Pol I and are modulated by different signalling pathways in response to 
changes in environmental conditions. For example, in response to nutrients availability mTOR 
promotes pre-rRNA synthesis by regulating the localization and/or activity of TIF-1A, SL1, and 
UBF, as well as translation of RPs (Mayer and Grummt, 2006).  
 
2. rRNA processing. rRNA is firstly transcribed as an immature precursor (47S) species that needs 
to be modified (pseudourylation and methylation) for further processed into 18S, 28S and 5.8S by 
endo- and exonucleolytic cleavages. Maturation of rRNA and assembly of pre-ribosomal units 
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occur in the nucleolus before export. More than 700 non-ribosomal factors, conserved from yeast 
to humans, participate in this complex process (Couté et al., 2006). These factors include small 
nucleolar ribonucleoproteins (snoRNPs) and numerous non-ribosomal proteins that process or 
modify the pre-RNAs (i.e. endo- and exonucleases, pseudouridine synthases or 
methyltransferases), mediate RNP folding/remodelling (RNA helicases, RNA chaperones) or 
facilitate protein association/dissociation (GTPases, AAA-ATPases) (Zemp and Kutay, 2007).  
 
3. Ribosome assembly and nuclear transport. RPs, similar to the rest of RNA pol II-transcribed 
genes, are translated in the cytoplasm. For assembly, newly synthesized RPs must be firstly 
imported into the nucleus. Nuclear import of RPs is controlled, among others, by importin β, 
transportin, RanBP5 and RanBP7 (also known as importin 7, IPO7) (Jäkel and Gürlich, 1998). 
The mTOR kinase activity has been recently described to be essential in nuclear import of RPs 
(Kazyken et al., 2014). Once inside the nucleus, RPs accumulate in the nucleolus, bind to rRNA 
precursors and participates in their processing while they assembly together (Kressler et al., 
2010). 60S and 40S pre-ribosomal subunits need to be exported to the cytoplasm for final 
maturation before achieving translational competence. Both subunits interact with the nuclear 
export receptor exportin 1 (XPO1) and are exported as independent entities through the nuclear 
pore complex in a Ran-GTP-dependent manner (Zemp and Kutay, 2007). Nuclear transport is 
tightly controlled by c-MYC and p53. c-MYC, a master regulator of ribosome biogenesis, 
upregulates the transcription of IPO7 and XPO1 while p53 transcriptionally represses both 
(Golomb et al., 2012). Finally in the cytoplasm, in order to achieve translational competence, 
non-ribosomal protein factors are released from the 60S ribosome subunit, while 20S rRNA in the 
40S ribosome subunit is further processed by dimethylation and cleavage into the final mature 
18S rRNA (Zemp and Kutay, 2007).  
 
2.1.1. The tripartite structure and function of the nucleolus 
 
In high eukaryotes, the nucleolus has a tripartite structure that comprises three distinguishable 
regions by electron microscopy: the fibrillar centre (FC), the dense fibrillar component (DFC) and the 
granular component (GC) (Hernandez-Verdun et al., 2010). Each topological region in the nucleolus is 
in charge of a different function during ribosome biogenesis. rDNA transcription occurs at the 
interface between the FC and the DFC, early rRNA processing in the DFC and finally, late rRNA 
processing and ribosomal subunits assembly ensue in the GC (Figure 2).  
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2.1.2. Nucleolar stress 
 
The nucleolus is well known to be a hub in the stress response. Approximately 70% of the ~4000 
nucleolus-associated proteins are involved in functions other than ribosome biogenesis, including cell 
cycle control, apoptosis, DNA repair or the assembling and storage of the components of the 
telomerase complex (Boulon et al., 2010). Thus, the nucleolus is an important integrator between 
ribosome synthesis, cell cycle progression and stress signalling. Because of the high energetic 
demands for ribosome biogenesis, almost any perturbation that slows down cell growth or protein 
synthesis will lead to an immediate shutdown of rDNA transcription. Perturbations affecting rDNA 
transcription and early rRNA processing produce structural alterations in the dynamics of nucleolar 
proteins and rRNA, typically segregation (condensation followed by separation) of the nucleolar 
compartments and formation of “nucleolar caps” around the nucleolus remnant (Shav-tal et al., 2005). 
These structural changes were visualized many decades ago, in 1964, by phase-contrast microscopy. 
Cell treatment with actinomycin D, an inhibitor of rDNA and gene transcription, dramatically reduced 
the nucleolar size and changed the nucleolar morphology from irregular to spherical, what it was 
denominated as nucleolar “caps” (Reynolds et al., 1964). Nowadays, it is known that “nucleolar caps” 
are condensed remnants of FC or DFC components, such as UBF or fibrillarin, and that proteins 
located in the granular compartment diffuse throughout the nucleoplasm, such as nucleophosmin, 
being excluded from the residual nucleolar structures (Kurki et al., 2004; Shav-tal et al., 2005) (Figure 
3). This total vanishing of nucleoli is referred to as “nucleolar disruption” and it is different from 
nucleolar fragmentation, which occurs following inhibition of either RNA pol II (by daunorubicin or 
CK2 inhibitors) or protein kinases leading to unravelling to the FC into necklace structures (Boulon et 
al., 2010).  
 
It is well established that nucleolar disruptions occur in response to DNA damage (i.e. UV 
irradiation or inhibition of topoisomerase II by drugs such as etoposide) or Pol I-mediated 
Figure 2. The tripartite structure of the nucleolus. 
The different structural and functional regions 
identified by electron microscopy are depicted in the 
illustrations. Also, the task carried out by each of them 
is shown. 
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transcription inhibition (i.e. ActD) (Al-Baker et al., 2005; Shav-tal et al., 2005). In a very elegant 
manner, Rubbi and Milner showed that UV-induced DNA damage triggers p53 activation by 
disrupting the nucleolus (Rubbi and Milner, 2003). The precise mechanisms by which DNA damage 
can alter nucleolar morphology still remain elusive. Many chemotherapeutic drugs that activate p53 
cause nucleolar disruption by blocking rDNA transcription or early steps of rRNA processing (Burger 
et al., 2010; Hein et al., 2013). Similarly, depletion or overexpression of mutant nucleolar proteins, 
such as TIF-IA ablation (Yuan et al., 2005) or the  dominant negative mutant Bop1 (Pestov et al., 
2001), leads to destabilization of nucleolar morphology and activation of p53-mediated cell cycle 
arrest and apoptosis. In turn, p53 represses RNA pol I transcription by preventing binding of SL1 to 
UBF (Zhai and Comai, 2000), as well as elicits a p53-mediated cell cycle arrest that hampers rDNA 
transcription, reinforcing the halt on ribosome synthesis. Interestingly, blockage of nuclear import of 
ribosomal proteins or nuclear export of ribosomal subunits by genetic ablation of IPO7 and XPO-1, 
respectively, also cause nucleolar disruption and activates p53 (Golomb et al., 2012). !
 
2.1.3. Nucleoli and cancer 
 
Notably, changes in number, size and morphology of nucleoli have been long recognized as a 
reliable feature of cancer cells. Cancer cells are characterized by presenting large nucleoli, described 
by pathologists more than 100 years ago as “prominent nucleoli” (Derenzini et al., 2009). Proliferating 
and cancer cells have higher demands on protein synthesis due to growth factors signalling and 
oncogenes that increase proliferation and upregulate rRNA synthesis, thus increasing the size and 
number of nucleoli. Therefore, the size and number of nucleoli is a reflection of how active ribosome 
production is in a cell. Cancer cells of a given type of tumour have larger nucleoli than the 
corresponding benign lesion and, therefore, a malignant lesion can be distinguished from a benign 
lesion in the same tissue on the basis of different nucleolar size. As an example, aggressive breast 
cancer cell lines increase their nucleolar size around 30% resulting in elevated ribosome biogenesis 
(Belin et al., 2009). In contrast, terminally differentiated cells, such as lymphocytes, present small 
nucleoli. UBF levels are, in many cases, indicative of high ribosome biogenesis in cancer cells 
Figure 3. Nucleolar Disruption.   
Following ribosomal stress, proteins located in 
the dense fibrillar centre, such as fibrillarin, 
condense in nucleolar caps around the remaining 
nucleolar component, while proteins in the 
granular compartment, such as nucleophosmin 
(NPM), diffuse throughout the nucleoplasm. dfc, 
dense fibrillar center; gc, granular component. 
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(Derenzini et al., 1998). For instance, hepatocellular carcinoma samples often overexpress UBF which 
is sufficient to activate rDNA transcription and accelerate tumour growth (Huang et al., 2002). 
 
Silver-staining has been used to detect nucleolar size based on the argyrophilic nature of 
nucleolar proteins. This particular staining is known as AgNOR staining (Trerè, 2000). Nucleolar size 
evaluated by AgNOR staining is considered as an independent prognosis factor for many human 
cancers, the larger size of the nucleolus the worse the prognosis of the disease (Derenzini et al., 2009) 
(Figure 4).  
 
 
 
Cancer cells can regulate the nucleolus activity by means of overexpression of proto-
oncogenes and repression of tumour suppressors. In this manner, oncogenic c-MYC stimulates 
ribosome biogenesis by activating RNA pol I transcription (Arabi et al., 2005; Grandori et al., 2005). 
Particularly, two major tumour suppressors, retinoblastoma protein (pRb) and p53 can control 
nucleolar function by inhibiting rDNA transcription. pRb binds to UBF and p53 to SL1 and, in both 
cases, the formation of the UBF-SL1 complex, required for RNA pol I recruitment at rDNA gene 
promoters, is hampered and consequently, ribosome biogenesis is downregulated (Hannan et al., 2000; 
Voit et al., 1997; Zhai and Comai, 2000). Accordingly, tumours bearing deletion in Rb or inactivated 
pRb or mutated p53 present larger nucleolus than tumours with normal Rb and p53 status (Derenzini 
et al., 2009). Moreover, activation of the tumour suppressor PTEN has been shown to block 
recruitment of SL1 complexes to the promoter of rDNA genes, thus reducing Pol I transcription 
(Zhang et al., 2011a). In agreement, repression of PTEN is often observed in cancer and enhances cell 
growth, proliferation and survival. The tumour suppressor ARF, in addition to inhibit MDM2 activity 
and activate p53, can directly control rDNA transcription by altering phosphorylation of UBF and thus 
preventing its ability to recruit the PIC, and by preventing Pol I transcription termination factor (TTF-
1) nucleolar import (Ayrault et al., 2006; Lessard et al., 2010). 
 
Figure 4. Nucleolar size as a prognosis 
factor.   
Disease-free survival curves (Kaplan-
Meier estimates) for 504 breast cancer 
paperns with respect to the nucleolar area 
per cell nucleus, measured by image 
analysis on specifically silver-stained 
tissue sections, granular component. Figure 
taken from Derenzini et al., 2009. 
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2.1.4. Drugs targeting nucleoli 
 
 Chemotherapeutic drugs have been developed to halt proliferation of cancer cells. Cancer cells 
require increased ribosome biogenesis to fulfil the energetic needs of highly proliferating cells. Many 
of the current drugs used in the clinics mostly target ribosome biogenesis at different levels (Burger et 
al., 2010). For example, ActD (Dactinomycin) is a natural antibiotic approved for Wilms tumour that 
intercalates into GC-rich DNA regions, commonly found in rDNA genes, and prevents elongation of 
rDNA transcription by Pol I (Fetherston et al., 1984). As a consequence of inhibited transcription, 
ActD causes nucleolar disruption and activates p53 (Choong et al., 2009). Similar to ActD, the 
ellipticine derivative 9-hydroxyellipticine (9-HE) intercalates into GC-rich regions of the rDNA and 
prevents the interaction between SL-1 and the rDNA promoter (Andrews et al., 2013). Cisplatin 
inhibits Pol I transcription by cross-linking DNA at HMG-protein affinity sites thus preventing UBF 
from association with the rDNA promoter (Treiber et al., 1994). Topoisomerase I inhibitors 
(camptothecin, irinotecan and topotecan) also disrupt Pol I transcription (Garg et al., 1987). In 
addition, 5’-fluorouracil (5’-FU), an inhibitor of nucleotide synthesis, disrupts rRNA processing 
(Ghoshal and Jacob, 1997).  
 
 Alternatively, inhibitors of certain kinases controlling cellular growth and proliferation 
signalling pathways have been shown to inhibit ribosome biogenesis. In this manner, Cdk2 inhibitors 
(roscovitien and olomoucine), the casein kinase 2 (CK2) inhibitor 5,6-dichoro-1-beta-ribofuranosyl 
benzimidazole (DRB) or the Cdk9 inhibitor flavopiridol disrupt nucleolar integrity and hinder rRNA 
processing (David-Pfeuty et al., 2001; Louvet et al., 2006). As previously mentioned, mTOR kinase is 
one the key players in modulating rDNA transcription in response to nutrients and growth factors 
availability. mTOR signalling pathway phosphorylates TIF-IA and UBF promoting their binding to 
SL-1 (Hannan et al., 2003; Mayer et al., 2004). Accordingly, the mTORC1 inhibitor, rapamycin, 
suppress rDNA transcription by impairing signalling downstream of mTORC1 (Hannan et al., 2003; 
Mayer et al., 2004). Additionally, inhibitors of the protein kinase AKT (AKTi-1/2 and MK-2206), 
upstream mTORC1, also suppress rDNA and have effectively shown anti-tumorigenic properties in c-
MYC driven lymphomas, characterized for higher rDNA transcription rates (Chan et al., 2011; Devlin 
et al., 2013).  
 
An important approach to target nucleolar function is impairing the formation of the rDNA 
pre-initiation complex. In this regard, several drugs targeting components of the Pol I machinery have 
been described. The most noteworthy examples are the small molecule compounds CX-3543 and CX-
5461, developed by Cylene Pharmaceuticals, and BMH-21. CX-3543 (quarfloxin) binds to G-
quadruplex regions, higher order structures formed within G-rich regions of rDNA, and prevents 
nucleolin (NCL) interactions thus inhibiting elongation of Pol I transcription (Drygin et al., 2009). 
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NCL stabilizes G-quadruplex structures in the rDNA gene and facilitates rapid Pol I transcription by 
preventing renaturation of template DNA in the GC-rich rDNA. CX-3543 has shown anti-tumorigenic 
properties in a broad panel of cancer cell lines, as well as in xenograft models of breast and pancreatic 
cancers (Drygin et al., 2009), and has progressed into phase I and phase II clinical trials (but they were 
withdrawn due to bioavailability problems). CX-5461 directly binds to SL-1 complexes impairing its 
binding to rDNA promoters and further recruitment of RNA Pol I co-factors thus blocking Pol I 
transcription initiation (Drygin et al., 2011). CX-5461 is a highly selective inhibitor of Pol I activity 
(300-400 fold more selective than for Pol II or Pol III activity) and its anti-proliferative efficacy has 
been exhibited over a broad panel of cancer cell lines, in melanoma and pancreatic xenograft models 
and in engineered models of c-MYC driven B-cell lymphomas (Bywater et al., 2012; Drygin et al., 
2011). Importantly, the apoptotic effect of CX-5461 is specific for c-MYC overexpressing lymphoma 
cells without damaging normal B-lymphocyte cells and does not cause genotoxic stress (Bywater et 
al., 2012). Currently, CX-5461 is being tested in patients with advanced haematological malignancies 
(phase I; clinical trial ID ACTRN12613001061729). Lastly, BMH-21, an acridine derivative, causes 
nucleolar disruption and activates p53 in the absence of DNA damage (Peltonen et al., 2010, 2014). 
BMH-21 intercalates into GC-rich regions of rDNA, similar to ActD, and promotes degradation of the 
catalytic subunit of the RNA pol I, RPA194 (Peltonen et al., 2014). The efficacy of these drugs in vivo 
reinforce that cancer cells depend on enhanced ribosome biogenesis characterized by increased rDNA 
transcription rates and Pol I machinery abundance.  
 
2.2. The ribosomal stress pathway (RP-MDM2-p53) 
 
The surveillance RP-MDM2-p53 pathway, also known as the ribosomal/nucleolar stress 
pathway, emerged more than ten years ago as a new p53-signalling pathway that monitor coupling 
between cell growth and cell cycle. The stimulus that activates this pathway is the so-called nucleolar 
or ribosomal stress. Ribosomal stress (RbS) results from perturbations at any level of the ribosome 
biogenesis. Ribosome is formed by equimolar amounts of the four rRNA species and the ribosomal 
proteins. These perturbations generate an imbalance in ribosome biosynthesis leading to the release of 
free ribosomal proteins from the nucleolar into the nucleoplasm. In turn, free ribosomal proteins and 
pre-ribosomal complex, in particular the RPL11/RPL5/5S rRNA pre-complex, bind and inhibit 
MDM2 ubiquitin ligase activity (Figure 4). Of note, coordinated downregulation of rRNA and RPs 
synthesis, by serum deprivation or rapamycin treatment, does not lead to free RPL11 so p53 is not 
activated (Donati et al., 2011). Several RPs has been shown to bind and inhibit MDM2 activity: 
RPL23 (Dai et al., 2004), RPS7 (Chen et al., 2007), RPS3 (Yadavilli et al., 2009), RPS14 (Zhou et al., 
2013), RPS27 and RPS27-like (Xiong et al., 2011), RPL37, RPS15 and RPS20 (Daftuar et al., 2013), 
although an increasingly numbers of reports claim that inhibition of MDM2 relies solely on the 
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interaction with the RPL11/RPL5/5S rRNA pre-complex (Bursać et al., 2012a; Dai and Lu, 2004a; 
Donati et al., 2013; Horn and Vousden, 2008; Lohrum et al., 2003; Zhang et al., 2003). This is 
proposed based on 1) interaction studies in yeast in which orthologs RPL11 and RPL5 are detected in 
a pre-ribosomal complex together with 5S rRNA before being incorporated into the nascent 90S 
processome (Zhang et al., 2007), 2) dependence on 5S rRNA for RPL11/RPL5 binding to MDM2 and 
cooperation between RPL11 and RPL5 to fully activate p53 (Donati et al., 2013; Fumagalli et al., 
2012; Horn and Vousden, 2008), and 3) RPL11 and RPL5 mutually protects each other from 
proteosomal degradation (Bursać et al., 2012a). In addition, only depletion of RPL11 or RPL5, but not 
other RPs shown to bind MDM2 (i.e. RPS7 or RPL23), rescues the p53-mediated cell cycle arrest 
provoked by ribosome biogenesis imbalance (Fumagalli et al., 2012). 
 
Notably, none RP has been described to bind MDMX, an MDM2-related ubiquitin ligase that 
also modulates p53 transcriptional activity. MDM2 and MDMX share a similar structure; however, 
RPL11 selectively binds to the C4 zinc finger domain of MDM2 (Zheng et al., 2015), but not to 
MDMX (Gilkes et al., 2006). Specific binding to MDM2 is due to the presence of hydrophobic 
residues (PPLP motif) in its C4 zinc finger domain, not present in MDMX, that are required for 
RPL11 interaction (Zheng et al., 2015). Importantly, human cancer-derived mutations, such as C305F 
(found in osteosarcomas) targeting the cysteine residues (C4) in the MDM2 central zinc finger, 
abrogate RPL11 and RPL5, but not ARF, binding (Lindström et al., 2007; Macias et al., 2010; Zheng 
et al., 2015). The MDM2 C305F mutant retains p53 ubiquitylation and transcriptional repression 
activities but attenuates p53 degradation due to impaired nuclear export (Lindström et al., 2007). This 
rises the possibility that RPL11 and RPL5 may help MDM2 to undergo nuclear export, in addition to 
prevent MDM2 from ubiquitinating p53 and repressing its transactivation (Zhang et al., 2003). Thus, 
MDM2 with mutations disrupting RPL11 and RPL5 binding could evade ribosomal stress-induced 
growth arrest, which could explain the origin of these zinc finger mutations in human cancer.  
 
In vivo studies of RPs deletion strongly support the notion that impairment in ribosome 
biogenesis activates p53. Genetic inactivation of p53 in Rps6 and Rpl22 heterozygous mice and in 
Rpl24 (Belly Spot and Tail, Bst) mutant mice rescues all the pathological phenotypes observed in 
these animals, suggesting that they are caused by p53 activation (Bursac et al., 2014).  
 
Insults affecting rDNA transcription or early rRNA processing activate p53 through the RbS 
pathway in the absence of nucleolar disruption. This is the case, for instance, of low doses (1-5 nM) of 
actinomycin D (ActD), that selectively stalls RNA pol I-mediated rDNA transcription (Perry and 
Kelley, 1970), resulting in the release of free RPs from the nucleolus into the nucleoplasm and the 
subsequent inhibition of MDM2 (Choong et al., 2009; Dai and Lu, 2004b; Dai et al., 2004; Jin et al., 
2004; Lohrum et al., 2003; Zhang et al., 2003). Similar to ActD, additional drugs affecting rDNA 
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transcription, such as CX-5461, CX-3543, or the immunosuppressant mycophenolic acid (MPA), 
cause nucleolar disorganization and activate the RPL11/RPL5-MDM2-p53 pathway (Bywater et al., 
2012; Sun et al., 2008). Genetic models also support this notion. Deletion of the RNA pol I 
transcription initiation factor TIF-IA (Yuan et al., 2005) or silencing the Polr1a gene coding for the 
Pol I catalytic subunit (RPA 194) (Donati et al., 2011) leads to nucleolar disruption and elicits a p53-
mediated cell cycle arrest and apoptosis through the RbS pathway. Notably, ARF does not play a 
substantial role in this scenario (Yuan et al., 2005), indicating that RPL11 is the main p53 activator 
when ribosome biogenesis is disturbed.  
 
On the other hand, insults affecting later steps during ribosome biogenesis or equimolar 
amounts of RPs can drive the RbS pathway in the presence or absence of nucleolar disruption, 
depending on the particular stimulus. Drugs affecting later steps in rRNA processing, such as 5’-
fluorouracil (5’-FU), activate the RbS pathway in the absence of nucleolar disruption (Sun et al., 
2007). Depletion of IPO7 and XPO1, involved in nuclear transport of RPs and subunits, also activates 
the RbS pathway by causing nucleolar stress (Golomb et al., 2012). Regarding the assembly of the 
distinct ribosomal subunits, impaired assembly of the 60S large ribosomal subunit by knockdown of 
certain large-subunit ribosomal protein, such as RPL23 or RPL37 (Fumagalli et al., 2012; Llanos and 
Serrano, 2010), results in ribosome free-RPL11 that binds to MDM2 in the absence of nucleolar 
disruption while depletion of RPL29 or RPL30, which equally activates the ribosomal stress pathway, 
provokes nucleolar disorganization (Sun et al., 2010). Interestengly, depletion of small-subunit 
ribosomal proteins (i.e. RPS6, RPS7 or RPS14) activates the RbS pathway, in the absence of nucleolar 
disruption, through a novel mechanism. Knockdown of RPS proteins selectively enhances the 
translation of a group of mRNAs containing a 5’ terminal oligopyrimidine tract (5’ TOP) in the leader 
sequence, including the RPL11 mRNA, which results in higher amounts of available RPL11 to inhibit 
MDM2 (Dutt et al., 2013; Fumagalli et al., 2009).  
 
In addition to inactivation of MDM2 by binding of RPL11/RPL5/5S rRNA complex, there are 
other mechanisms that collaborate in the p53 activation upon ribosome dysfunction. MDMX forms 
oligomers with MDM2 and prevents MDM2 self-ubiquitylation (Tanimura et al., 1999). RPS15 and 
RPS20 interact with MDMX and downregulate its protein levels, while RPL37 downregulates Mdmx 
mRNA levels (Daftuar et al., 2013), thus contributing to full p53 activation. RPL11 promotes MDMX 
degradation upon ribosomal stress in an MDM2-dependent manner, and concomitantly, MDMX 
overexpression abrogates p53 activation and prevents growth arrest (Gilkes et al., 2006). An additional 
regulator of the ribosomal stress pathway is the Myb-binding protein 1a (MYBBP1A). MYBBP1A 
localizes in the nucleolus and, following impairment of ribosome biogenesis, is translocated, in an 
RPL11- and RPL5-dependent manner, to the nucleoplasm where it increases the interaction between 
p53 and p300/CBP to enhance p53 acetylation (Kuroda et al., 2011). The promyelocytic leukemia  
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(PML) tumour suppressor is also implicated in regulation of p53 acetylation upon ribosomal stress by 
low doses of ActD. PML co-localizes with p53, acetylated p53 and MDM2 in disrupted nucleoli in an 
RPL11- and RPL5-dependent manner (Bursać et al., 2012b). These observations indicate that the 
ribosomal stress pathway also modulate p53 transactivation by promoting its acetylation. Also, p53 
activity can be boosted by augmented p53 mRNA translation. Ribosomal protein L26 (RPL26) binds 
to the duplex 5’/3’-UTR of p53 mRNA following ionizing radiation and enhances translation of the 
p53 mRNA without affecting global translation, thus increasing the number of cells undergoing p53-
dependent G1 cell cycle arrest and apoptosis (Chen and Kastan, 2010; Takagi et al., 2005).  
 
The most convincingly work, besides cell-based studies, demonstrating the biological 
relevance of the ribosomal stress pathway in vivo is the mouse model engineered by Macias and co-
workers (Macias et al., 2010). They generated mutant C305F MDM2 mice, in which RPL11 and RPL5 
binding to MDM2 is abolished and thus, that fail to activate p53 in response to ribosomal stress (ActD, 
5’-FU and MPA), but not to DNA damage (Doxorubicin, UV and whole body ionizing radiation). 
Remarkably, mutant MDM2 mice develop an accelerated lymphomagenesis in an Eµ-MYC oncogenic 
Figure 4. Perturbations in ribosome biogenesis activate the Ribosomal Stress Pathway.  
Chemical compounds (yellow boxes) or genetic depletion (green boxes) affecting the different steps of 
ribosome biosynthesis (rDNA transcription, rRNA processing, ribosome assembly, nucleolar transport and 
availability of RPs) can lead to ribosome-free RPL11 or increased translation of 5’TOP mRNAs, including 
Rpl11. Then, ribosome-free RPL11 can bind and inhibit MDM2, thus activating p53. 
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context. cMYC stimulate translation of ribosomal proteins (van Riggelen et al., 2010) and under 
oncogenic conditions it may produce an excess of ribosomal proteins that activate the ribosomal stress 
pathway. This study highlights the important contribution of the ribosomal stress pathway, in parallel 
with the ARF/MDM2/p53 pathway, in p53-mediated tumour suppression. Notably, mutant MDM2 
mice do not present accelerated onset of tumorogenesis in other oncogenic contexts, such as 
inactivation of pRb or RAS overexpression (Pan et al., 2011), which indicates a context-dependency 
of the biological activity of the ribosomal stress pathway.  
 
2.2.1. The Ribosomal Protein L11 (RPL11) 
 
 The ribosomal protein L11 (RPL11) is encoded by chromosome 1 (1p36.1-p35; Homo 
sapiens) in human and chromosome 4 in mouse (4; 4 D3; Mus musculus). In healthy tissues, RPL11 
mRNA expression varies, being strikingly high in ovary and relatively low in the nervous system 
(GTEx Portal; RPL11 Entrez Gene ID: 6315). RPL11 is part of the large subunit of the ribosome. 
RPL11 together with RPL5 and 5S rRNA are part of the 60S protrusion of the large ribosome subunit 
that binds 28S rRNA (Zheng et al., 2015).  
 
 Beyond its function as part of the ribosome, the ribosome-free RPL11/RPL5/5S rRNA pre-
complex activates p53 through the so-called ribosomal/nucleolar stress pathway (Bursać et al., 2012b; 
Donati et al., 2013; Horn and Vousden, 2008; Zhang and Lu, 2009). In addition, RPL11 enhances p53 
activation by promoting MDM2 self-ubiquitylation (Dai et al., 2006). Moreover, upon ribosome 
biogenesis dysfunction, RPL11 is rapidly but transiently recruited at the promoter sites of p53 target 
genes, in an MDM2-dependent manner, and helps recruiting the p53 co-activators p300/CBP that 
subsequently induce p53 K382 acetylation (Mahata et al., 2012). 
 
 RPL11 has a hand-like conformation structure conserved from prokaryotes to eukaryotes. It 
selectively binds to MDM2, but not MDMX, through the C4 zing finger domain of MDM2 in a similar 
manner to that of 28S rRNA (Zheng et al., 2015). Hydrophilic critical residues for binding to MDM2 
have been identified in the centre of the palm of RPL11 (Dai et al., 2006; Zhang et al., 2011b, 2003; 
Zheng et al., 2015). Mutations in several of these residues, for instance Lysine 52, Arginine 75 and 
Aspartate 136, abolish binding of RPL11 to MDM2 (Zhang et al., 2011b), therefore inactivating the 
ribosomal stress pathway. So far, 46 mutations in RPL11 have been described in several cancers, 
including melanoma and prostate cancer (COSMIC, International Cancer Genome Consortium 
(ICGC)), although it seems that key residues for MDM2 binding are not affected. Rpl11 mRNA 
expression is particularly high in blood malignancies and Ewing sarcoma (Cancer Cell Line 
Enciclopedia). Unlike Rpl5, Rpl10 and Rps15, which have been found recurrently mutated in T cell-
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acute lymphoblastic leukaemia (T-ALL) and chronic lymphocytic leukaemia (CLL) patients (De 
Keersmaecker et al., 2013; Landau et al., 2015), mutations in Rpl11 have not been described in blood 
malignancies yet. On the other hand, Rpl11 mutations resulting in Rpl11 heterozygosity have been 
found in Diamond-Blackfan Anemia (DBA) patients (Boria et al., 2010; Cmejla et al., 2009; Gazda et 
al., 2008; Quarello et al., 2010). Strikingly, mutations in Rpl11 are preferentially associated to thumb 
malformations, in particular triphalangeal or dysplastic thumbs and additional bilateral small thumbs 
(Cmejla et al., 2009; Gazda et al., 2008; Quarello et al., 2010). 
 
Depletion of Rpl11 has been performed in vitro in somatic and tumor cells, but so far, deletion 
of Rpl11 only has been conducted in a few studies in Zebrafish (Amsterdam et al., 2004a; Chakraborty 
et al., 2009; Danilova et al., 2011; Zhang et al., 2013b). Ablation of Rpl11 by morpholinos in 
Zebrafish causes brain development, hematopoietic and metabolic defects (Chakraborty et al., 2009; 
Danilova et al., 2011; Zhang et al., 2013b). Importantly, the hematopoietic related phenotype 
recapitulates DBA symptoms. Contrary to what was observed in cells, Rpl11 haploinsufficiency-
associated pathologies (brain development and hematopoietic defects) are totally or partially alleviated 
in a p53 null background (Chakraborty et al., 2009; Danilova et al., 2011). This supports the existence 
of a p53 checkpoint in vivo that monitors homeostasis of the ribosome biogenesis. All these studies 
have mainly focused on developmental and hematopoietic defects upon deletion of Rpl11 but cancer 
predisposition, an important feature of DBA patients, has not been assessed yet.  
 
2.2.2. Regulation of RPL11 
  
NEDDylation 
Neddylation is a “tagging” protein process that controls localization and stability of many 
proteins. The ubiquitin-like protein NEDD8 is conjugated to its target proteins by specific E1 and E2 
enzymes (Enchev et al., 2015). In normal conditions, NEDDylation of RPL11 by MDM2 protects it 
from degradation and retain its nucleolar localization (Sundqvist et al., 2009). However, impairment of 
ribosome biogenesis by treatment with ActD causes rapid de-NEDDylation of RPL11 and, 
subsequently, its re-localization from the nucleolus to the nucleoplasm where it binds to MDM2, thus 
increasing p53 stability (Sundqvist et al., 2009).  
 
PICT1  
PICT1 (protein interacting with the C terminus 1 of the tumour suppressor PTEN; also known 
as GLTSCR2) is a negative regulator of the RPL11-dependent p53 activation (Sasaki et al., 2011). 
PICT1 retains RPL11 in the nucleolus preventing, in this manner, binding to MDM2 in the 
nucleoplasm and activation of the ribosomal stress pathway. In line with this, patients with 
oligodendrogliomas with PICT1 haploinsufficiency have a better prognosis than their counterparts 
Introduction 
55!
(Cairncross et al., 1998; Mariani et al., 2006; Smith et al., 1999). Likewise, colon and oesophageal 
cancer patients bearing tumours that retain p53 wild-type and lower expression of PICT1 have a better 
prognosis (Sasaki et al., 2011). Similarly, PICT1 heterozygous mice are more resistant to develop 
chemically-induced papillomas when compared to wild-type mice (Sasaki et al., 2011). 
 
c-MYC, ribosome biogenesis and RPL11: a negative feedback loop 
MYC is a proto-oncogene discovered three decades ago (Dang, 2012). c-MYC is one of the 
members of the Myc family of transcription factors, that also includes MYCN (n-MYC) and MYCL 
(l-MYC). Overexpression of c-MYC is found in 20% of many different human cancers; being 
chromosomal translocation, as observed in human Burkitt’s lymphoma, one of the major causes of c-
MYC deregulation (Dang, 2012). c-MYC modulates around 15% of genome transcription, controlling 
cell growth and proliferation, among other vital cellular processes (Patel et al., 2004). c-MYC 
activates or represses transcription mainly by chromatin remodelling. In one hand, c-MYC dimerizes 
with MAX and binds to E-boxes DNA sequences in gene promoters when chromatin is partially open 
(Guccione et al., 2006). MYC/MAX complexes recruit co-regulatory factors, such as GCN5, TIP60 
and TRRAP, which promote acetylation of nucleosome histones, resulting in further opening of the 
chromatin and greater levels of gene transcription (Cole and Nikiforov, 2006). On the other hand, 
MYC/MAX heterodimers can also repress transcription of MIZ1 target genes, including cyclin-
dependent kinase inhibitors p21 (CDKN1A) and p15 (CDKN2B), by binding to the transcriptional 
factor MIZ-1 and recruitment of DNA methyltransferase DNMT3a, ultimately resulting in epigenetic 
silencing (Brenner et al., 2005). Transactivation of genes involved in cell growth and proliferation, as 
well as transcriptional repression of tumour suppressors, count for the oncogenic role of cMYC in the 
onset and development of tumorogenesis.  
 
 Additionally, c-MYC is considered a master regulator of ribosome biogenesis (van Riggelen 
et al., 2010). In this regard, c-MYC facilitates rDNA transcription by chromatin remodelling of rDNA 
loci and recruitment of RNA pol I co-factors to rDNA promoters (Arabi et al., 2005; Grandori et al., 
2005; Shiue et al., 2009), promotes transcription of ribosomal proteins and other factors involved in 
ribosome biogenesis by RNA pol II (Golomb et al., 2012; van Riggelen et al., 2010; Schlosser et al., 
2003), and activates RNA pol III-mediated transcription of 5S rRNA and tRNA (Gomez-Roman et al., 
2003). Supporting the role in controlling ribosome biogenesis, Eµ-MYC mice with Rpl24 half gene 
dose presented a slower onset of tumorogenesis, possibly because of the inability of c-MYC to 
upregulate nascent ribosome biogenesis due to limiting amounts of RPL24 (Barna et al., 2008). 
Alternatively, Rpl24 deletion could result in activation of the ribosomal stress pathway; so increased 
levels of p53 and/or downregulation of c-MYC by ribosome-free RPL11 might explain the decelerated 
tumorogenesis in these mice. Rpl11 is a “bona-fide” c-MYC transcriptional target and, in turn, RPL11 
represses c-MYC transcriptionally activity by multiple mechanisms. RPL11 directly binds to c-MYC 
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at c-MYC target gene promoters inhibiting the recruitment of the c-MYC co-activator TRRAP to these 
regions by competing with TRRAP for c-MYC binding (Dai et al., 2007a). In this manner, RPL11 can 
reduce histone acetylation of the target gene promoters (open conformation) and suppress c-MYC 
transcriptional activity. RPL11 knockdown increases c-MYC mRNA and protein levels and 
overexpression of RPL11 re-locate ectopic c-MYC into the nucleolus (Dai et al., 2007b). Association 
of RPL11 to c-MYC in the nucleolus might prevent c-MYC functions. Also, ribosome-free RPL11 
promotes c-MYC mRNA degradation by binding to c-MYC 3’UTR and recruitment of mir-
24/miRISC complex, and this mechanism is further enhanced upon ribosomal stress (Challagundla et 
al., 2011). Importantly, activation of p53, which can be elicited by increased ribosome-free RPL11 
levels, can repress c-MYC transcription (Ho et al., 2005; Sachdeva et al., 2009). An illustration 
summarizing the c-MYC-RPL11 feedback loop is shown (Figure 5). 
 
3. RIBOSOMOPATHIES 
Ribosomopathies refers to a group of inherited diseases caused by haploinsuficiency of genes 
involved in ribosome biogenesis, such as RPs or factors involved in rRNA processing (Narla and 
Ebert, 2010). Most of the diseases comprising this group are characterized by similar pathologies, 
including bone marrow failure, anaemia and higher predisposition to cancer (Table 2). Diamond-
Blackfan anaemia (DBA) and the 5q- myelodysplasic syndrome (5q- MDS) are caused by mutations 
in RP genes, while other congenital syndromes, such as Schwachman-Diamond syndrome (SDS), X-
Figure 5. c-MYC-RPL11 feedback regulation.  
c-MYC promotes ribosome biogenesis by controlling all the RNA polymerases involved in this cellular 
process. In turn, RPL11 negatively modulates c-MYC activity by different mechanisms, including p53 
activation, impaired recruitment of c-MYC co-activators and c-MYC mRNA miRISC-mediated degradation.  
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linked dyskeratosis congenital (DKC), cartilage hair hypoplasia (CHH) and Treacher Collins 
syndrome (TCS), present mutations in non-RPs factors.  
 
It is now widely accept that p53 activation is one of the molecular mechanisms underlying the 
pathologies of ribosomopathies (Teng et al., 2013a). In this manner, p53 has been found activated in 
animal models and patient samples of DBA, 5q- MDS and SDS (Dutt et al., 2013; Elghetany and 
Alter, 2002; Pellagati et al., 2015), as well as in RPS19 and RPS14-depleted human cells (Dutt et al., 
2013) and in Rps19, Rps14 and Tcof1 haploinsufficient mouse models for DBA, 5q- MDS and TCS, 
respectively (Barlow et al., 2010; Jaako et al., 2011; McGowan et al., 2008). Interestingly, macrocytic 
anaemia in Rps6 haploinsufficient mice, similar to that of DBA and 5q- MDS patients, is rescued in a 
p53-null background (McGowan et al., 2011). In this model it was also shown that p53 activation 
depends on the ribosomal stress pathway (Dutt et al., 2013; Fumagalli et al., 2009).   
 
Patients with ribosomopathies present higher risk to develop cancer and are particularly 
inclined towards blood malignancies (acute myeloid leukaemia and myelodysplastic syndrome) 
(Table 2). It is counter-intuitive the fact that deficient protein synthesis by ribosome dysfunction 
incline cells to oncogenic events, as observed in patients with ribosomopathies. Ablation of Rps6 in 
Drosophila and deletion of several RPs in Zebrafish lead to tumour predisposition (Amsterdam et al., 
Table 2. Ribosomopathies: characterization and molecular features.   
Molecular features as well as the pathologies and cancer risk of the different diseases comprising the 
group of ribosomopathies are shown in this table. Adapted from Teng et al., 2013.   
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2004b; Stewart and Denell, 1993; Watson et al., 1992), providing in vivo evidences for an oncogenic 
role of aberrant ribosome biogenesis.  
 
3.1. Diamond-Blackfan Anaemia (DBA) 
 
Diamond-Blackfan anaemia (DBA; OMIM105650) is a rare inherited disease characterized by 
normocytic or macrocytic anaemia and defects in erythroid progenitors (Ruggero and Shimamura, 
2015). DBA affects to 5-10 persons per million and is usually diagnosed in the first year of life 
according to the Diamond-Blackfan Anaemia Registry (DBAR) of North America. Patients are 
severely anaemic although they can have a healthy life under blood transfusion therapy, corticosteroid 
treatment or bone marrow transplant. In addition to anaemia, 47% of DBA patients present congenital 
anomalies, including malformations in head, hand, heart, kidney, urinary tract and genital organs. 
Malformations are more frequently associated to specific mutated genes, such as the case for cleft 
palate and thumb abnormalities associated to RPL5 and RPL11 mutations, respectively (Boria et al., 
2010; Cmejla et al., 2009; Gazda et al., 2008). Currently, thirteen genes encoding for both large 
(RPL5, RPL11, RPL35a, RPL19, RPL26 and RPL31) and small ribosomal proteins (RPS19, RPS24, 
RPS26, RPS17, RPS7, RPS10 and RPS29) and GATA1 gene have been identified by deep sequencing 
mutated in around 50% of DBA patients, while the genetic cause remains unknown for the rest of 
patients (Boria et al., 2010; Chae et al., 2014; Doherty et al., 2010; Farrar et al., 2014; Gazda et al., 
2012; Kuramitsu et al., 2012; Landowski et al., 2013; Mirabello et al., 2014; Sankaran et al., 2012). 
More than 25% of DBA patients bear mutations in RPS19, followed by a 7% and 5-10% in RPL5 and 
RPL11, respectively (Vlachos et al., 2013). Minor symptoms include elevated levels of erythrocyte 
adenosine deaminase activity (eADA) and fetal haemoglobin (HbF).   
 
DBA is also a cancer predisposition syndrome. 22% of DBA patients develop some type of 
cancer by age 46 years, including leukaemia and solid tumours (Vlachos et al., 2012). The age at 
which cancer appears in DBA patients is sooner than that observed for the type of cancers in the 
healthy population. So far, cancer predisposition has been underestimated in DBA community, mainly 
because of the lack of proper follow-ups and research.   
 
3.1.1. Modelling DBA  
 
To date, it is widely accepted that DBA is a disease resulting from ribosome dysfunction. 
Animal models, cells from DBA patients and DBA derived-iPSCs have helped in unravelling the 
molecular mechanisms underlying this disease. Mice with mutant Rps19 or reduced Rps19 gene dose 
develop symptoms like patients with DBA. In both animal models, as well as in Rps19, Rpl11, Rpl5, 
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Rpl19, Rps7, Rps10, Rps26, Rps24, Rps29, Rpl26, Rpl35a and Rpl31 mutant DBA patient-derived 
cells and in RP-depleted cells, impaired rRNA processing is observed (Choesmel et al., 2008; Devlin 
et al., 2010; Doherty et al., 2010; Farrar et al., 2014; Flygare et al., 2007; Garçon et al., 2013; Gazda et 
al., 2008, 2012; Jaako et al., 2011; Mirabello et al., 2014; Robledo et al., 2008a).  
 
Regarding the erythroid defects, macrocytic anaemia and reduction in the number of erythroid 
progenitors (BFU-Es), but not other lineages, is reported in Rps19 mutant or deficient models 
(Danilova et al., 2008; Devlin et al., 2010; Ebert et al., 2005; Flygare et al., 2005; Garçon et al., 2013; 
Jaako et al., 2011; Miyake et al., 2008; Moniz et al., 2012), as well as in Rps29 null Zebrafish (Taylor 
et al., 2012). Some studies show that anaemia in Rps19 haploinsufficient mice is due to impaired 
erythroid differentiation (Danilova et al., 2008; Ebert et al., 2005; Flygare et al., 2005; Jaako et al., 
2011), while others do not report abnormalities during maturation (Miyake et al., 2008; Moniz et al., 
2012). Most of these reports state that erythroid defects in Rps19 haploinsufficient progenitors are 
caused by p53 activation. In this regard, normal erythroid behaviour is restored in Rps19 deficient 
mice either by rescuing the anaemia in a p53-null background or by treating with pifithrin α, an p53 
inhibitor (Danilova et al., 2008; Dutt et al., 2011; Jaako et al., 2011; McGowan et al., 2008; Miyake et 
al., 2008; Moniz et al., 2012; Sieff et al., 2010). However, there is some controversy concerning the 
Rps19 deficient DBA Zebrafish model. While Danilova and colleagues claim that the erythroid 
phenotype is caused by p53 activation and, concomitantly, defects are amelliorated by p53 suppression 
(Danilova et al., 2008), Torihara and co-workers can not rescue the erythroid defects when they 
deplete p53 (Torihara et al., 2011). In the case of Rps29 deficient Zebrafish, erythroid defects are 
rescued in a p53 null background (Taylor et al., 2012).  
 
Strikingly, Rps19 heterozygous mice are normal and they do not develop hematopoietic or 
erythroid defects (Matsson et al., 2006). Similarly, Rps7 disruption in mice do not lead to anaemia, 
although it causes several malformations and neuroanatomical defects that are rescued in a p53-null 
background (Watkins-Chow et al., 2013). This suggests that Rps19 or Rps7 mutations in DBA patients 
act as dominant negative or compensatory effects exist in mice, but not in humans, for retaining a 
normal RP activity.  
 
 Special relevance must be given to Rpl11 and Rpl5 deficient models. Since these two proteins 
are key in the p53-activating ribosomal stress pathway it is expected that erythroid failure is not 
caused by p53 accumulation. However, contrary to in vitro studies with cell lines, DBA Rpl11 
mutation caused a dramatic decrease in erythroid progenitor and a delayed differentiation because of 
augmented p53-mediated apoptosis and cell cycle arrest (Moniz et al., 2012). Concomitantly, 
erythroid defects observed in Rpl11 mutant Zebrafish were partially alleviated following p53 depletion 
(Danilova et al., 2011). Brain development defects reported upon Rpl11 knockdwon in Zebrafish were 
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also rescued upon p53 abrogation (Chakraborty et al., 2009). In the case of RPL5, Rpl5 mutant DBA 
patient-derived iPSCs present erythroid defects which can be corrected by gene targeting (Garçon et 
al., 2013). Nonetheless, p53 levels remain normal in Rpl5 mutant ES cells and suppression of p53 do 
not rescue the observed G2/M cell cycle arrest (Singh et al., 2014).  
 
Although numerous studies have been carried out in cells from DBA patients and several 
animal models recapitulating the erythroid failure have been generated, DBA pathogenesis is not 
clearly understood. Yet some disagreement can be encountered in certain DBA models, activation of 
p53 seems to largely be a common molecular feature observed in DBA RP-deficient cells. Indeed, p53 
levels are increased in other RP-deficient mice that present anaemia, such as is the case of Rpl24 or 
Rps6 (Anderson et al., 2007; Barkić et al., 2009; Dutt et al., 2011; McGowan et al., 2008). This 
indicates that p53 safeguards erythroid cells in a ribosome dysfunctional context.   
 
3.1.2. Current DBA treatments and hints from DBA models  
 
Existing treatments for DBA patients present side effects, some of them can negatively impact 
on their health status (Vlachos and Muir, 2010). Corticosteroids medication, such as dexamethasone, 
enhances production of red blood cells by increasing self-renewal of burst-forming unit erythroid 
progenitors (Zhang et al., 2013a). It has been shown recently that glucocorticoids improve red blood 
cells production by dampening the p53 response in affected erythroid cells (Sjögren et al., 2015). 
However, corticosteroids can cause short-term and long-term side effects, ranging from swelling to 
pathological fractures and physical and neurocognitive development in children. Moreover, not all 
DBA patients respond to corticosteroids and those who do not remain on corticosteroid treatment or 
are steroid non-responsive (20%) are subjected to blood transfusions. Iron overload is frequently 
observed in DBA patients dependent on chronic blood transfusions as consequence of improper 
recycling in new blood cells, which are not generated due to impaired erythropoiesis. Importantly, 
excess of iron can damage organs if not removed by iron chelators after few blood transfusions. Other 
than transplantation-related mortality, transfusion-associated iron overload is the leading cause of 
death for DBA patients. Stem cell transplant is the alternative to overcome DBA. However, this 
medical procedure involves serious risks, including the finding of an HLA-matched related donor, the 
administration of chemotherapy and radiation for killing the unhealthy patient’s bone marrow or the 
possibility of dying because of complications of the treatment.  
 
Harmless compounds are being tested in phase I/II clinical trials for amelioration of anemia, 
such as the nutrional supplement L-leucine (ClinicalTrials.gov identifiers:! NCT02386267 and 
NCT01362595). L-leucine is a branched-chain aminoacid that enhances protein synthesis in skeletal 
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muscle and adipose tissues. DBA results from ribosome dysfunction, being compromised the 
translation of transcripts involved in erythroid maturation (Devlin et al., 2010; Horos et al., 2012; 
Ludwig et al., 2014). Dietary L-leucine administration alleviates anaemia in DBA Rps19-deficient 
animals and in other anaemic RP-deficient mice by activating mTOR and thus, boosts translation of 
proteins in a p53-independent manner (Jaako et al., 2012; Narla et al., 2014; Payne et al., 2012; Yip et 
al., 2013). Presumably, L-leucine supplementation would also restore normal levels of this aminoacid, 
which could be potentially affected in DBA mouse models since they present reduced translation of 
the branched-chain aminotransferase 1 (BCAT1), required for proper branched-chain aminoacid 
synthesis (Pereboom et al., 2014). Notably, L-leucine administration caused remission of DBA in the 
first patient tested in a pilot study (Pospisilova et al., 2007).  
 
Lastly, the thalidomide-related immunosuppressant lenalidomide has displayed large 
effectiveness in 5q- MDS patients. Because of both DBA and 5q- MDS share many common 
pathological features, lenalidomide is being currently tested in a pilot study with blood transfusion-
dependent DBA patients (ClinicalTrials.gov Identifier: NCT01034592). Lenalidomide administration 
to Rps6 deficient mice, which present an erythroid phenotype similar to both DBA and 5q- MDS, 
improves their anaemia (Keel et al., 2012). Remarkably, lenalidomide promotes p53 degradation by 
inhibiting MDM2 self-ubiquitylation in 5q- MDS erythroid precursors (Wei et al., 2012). 
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El objetivo principal de esta tesis ha sido la caracterización de la vía de estrés ribosomal en tres 
contextos diferentes:  
 
1. Integridad de la biogénesis ribosomal en pluripotencia. 
1a. Estudio de la funcionalidad de la vía de estrés ribosomal en células embrionarias 
pluripotentes de ratón. 
 
2. Activación no genotóxica de la vía de estrés ribosomal mediante compuestos químicos en 
células tumorales 
2a. Identificación de nuevos agentes disruptivos del nucleolo para activar la vía de estrés 
ribosomal en ausencia de daño detectable en células tumorales.  
2b. Caracterización del mecanismo de acción de los candidatos.  
 
3.  Relevancia de la integridad de la vía de estrés ribosomal en la fisiología y en el desarrollo 
de cáncer.  
3a. Generación y caracterización de un modelo de ratón con deficiencia condicional para 
Rpl11. 
3b. Análisis de los defectos en eritropoyesis tras la pérdida de un alelo de Rpl11. 
3c. Estudio de la implicación de un alelo de Rpl11 en linfomagénesis.  
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The main goal of this Thesis was the characterization of the ribosomal stress pathway in three 
different settings: 
 
1.- Ribosome integrity in pluripotency.  
 1a. To study the functionality of the ribosomal stress pathway in mouse pluripotent stem cells. 
 
2.-Non-genotoxic activation of the ribosomal stress pathway in cancer cells with small 
molecule compounds.              
 2a. Identification of novel nucleolar disruptors that trigger the ribosomal stress pathway in the 
 absence of DNA damage in cancer cells.  
2b. Characterization of the mechanism of action of the identified compounds.  
 
3.  Biological relevance of the ribosomal stress pathway in cancer and disease.  
 3a. Generation and characterization of a conditional knockout mouse model for Rpl11. 
 3b. Analysis of the erythropoiesis defects upon partial loss of Rpl11. 
 3c. Study of the implication of partial loss of RPL11 in lymphomagenesis. 
 
 !
 
  
 !
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
AND RESULTS 
 
 
  
 !
  
 73!
MANUSCRIPT I 
 
 
Ribosomal stress induces L11- and p53-dependent apoptosis in mouse pluripotent stem cells 
Lucia Morgado-Palacin, Susana Llanos and Manuel Serrano 
Cell Cycle 11:3, 1-8; February 1, 2012 
 
Objetivo: ESTUDIO DE LA VIA DE ESTRES RIBOSOMAL EN CELULAS 
PLURIPOTENTES DE RATON 
 
Las células madre embrionarias de ratón (mESCs, de sus siglas en inglés) se caracterizan por 
su alta capacidad de auto-renovación sin perder la capacidad de dar lugar a todos los linajes celulares. 
La tasa de crecimiento celular es muy alta en dichas células, al igual que la tasa de biogénesis 
ribosomal. Ambos procesos deben estar íntimamente acoplados para no interferir en las funciones 
celulares de las mESCs. Nosotros hipotetizamos que la vía de estrés ribosomal debe estar operativa en 
las mESCs para garantizar la calidad de los ribosomas y la síntesis de proteínas y así preservar la 
integridad genómica y correcta función de dichas células.   
 
El supresor tumoral p53 puede activarse en mESCs en respuesta a ciertos tipos de daño en el 
ADN o en respuesta a estrés oxidativo. Uno de los activadores de p53 es la proteína ARF, que se une e 
inhibe MDM2 ante señales aberrantes de crecimiento. Sin embargo, ARF no puede operar en mESCs 
debido a que su promotor está silenciado epigenéticamente. Por tanto, la vía de estrés ribosomal cobra 
una mayor importancia en el contexto de supresión tumoral en células mESCs. En este trabajo hemos 
demostrado que la vía de estrés ribosomal es funcional en células madre embrionarias y en células 
madre pluripotentes inducidas y responde a perturbaciones en el proceso de biogénesis del ribosoma. 
Además, mostramos que la activación de p53 a través de la unión de RPL11 a MDM2 provoca la 
apoptosis de las células embrionarias pluripotentes. Nuestros resultados aportan claridad al 
controvertido papel de p53 en células embrionarias pluripotentes.  
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The p53 protein is a key tumor suppressor that is activated 
in response to a variety of cellular insults, triggering cellular 
responses that ultimately prevent the proliferation of damaged 
cells.1,2 In normal cells, p53 activity is limited by the proto-onco-
protein Mdm2, an ubiquitin-ligase that targets p53 for degrada-
tion in the absence of cellular stress.3,4 Inhibition of Mdm2 is a 
universal requirement for p53 activation that occurs in response 
to genotoxic and oncogenic stresses.1,2 In addition, disruption of 
ribosomal biogenesis has recently emerged as a new p53-activating 
stress.5,6 This new pathway, known as the ribosomal stress path-
way, is initiated when ribosome assembly is unbalanced, which 
results in free ribosomal proteins that shuttle from nucleoli to the 
nucleoplasm.5 Importantly, some specific free ribosomal proteins 
have the capacity to bind and inhibit Mdm2. In particular, L11 
has been extensively reported as a main inhibitor of Mdm2.7-10 In 
addition to L11, other ribosomal proteins, such as L5, L23 and 
S7, also have the ability to bind and inhibit Mdm2.11-14
During the last years, a number of human syndromes have 
been identified associated to deficiencies in ribosomal proteins, 
which are characterized by a wide range of pathologies, from 
bone marrow failure to craniofacial defects.15 In addition, several 
animal models with ribosomal deficiencies have been reported 
showing a variety of phenotypes, from mild growth retardation 
to embryonic lethality.16 Interestingly, most of these phenotypes 
can be rescued at least partially by genetic inactivation of p53, 
thus demonstrating in vivo the existence of a p53-dependent 
checkpoint that monitors the integrity of ribosome biogenesis.16
Ribosome biogenesis is the most demanding energetic process in proliferating cells, and it is emerging as a critical 
sensor of cellular homeostasis. Upon disturbance of ribosome biogenesis, specific free ribosomal proteins, most notably, 
L11, bind and inhibit Mdm2, resulting in activation of the tumor suppressor p53. This pathway has been characterized 
in somatic and cancer cells, but its function in embryonic pluripotent cells has remained unexplored. Here, we show 
that treatment with low doses of actinomycin D or depletion of ribosomal protein L37, two well-established inducers 
of ribosomal stress, activate p53 in an L11-dependent manner in mouse embryonic stem cells (ESCs) and in induced 
pluripotent stem cells (iPSCs). Activation of p53 results in transcriptional induction of p53 targets, including p21, Mdm2, 
Pidd, Puma, Noxa and Bax. Finally, ribosomal stress elicits L11- and p53-dependent apoptosis in ESCs/iPSCs. These results 
extend the functionality of the ribosomal stress pathway to pluripotent cells, and therefore it could be a relevant cellular 
checkpoint during early embryogenesis.
Ribosomal stress induces L11- and  
p53-dependent apoptosis in mouse pluripotent 
stem cells
Lucia Morgado-Palacin, Susana Llanos and Manuel Serrano*
Spanish National Cancer Research Center (CNIO); Madrid, Spain
Key words: ribosomal stress, embryonic stem cells, induced pluripotent stem cells, p53, apoptosis
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The ribosomal stress pathway can be experimentally induced 
in cultured cells by depletion of many ribosomal proteins or 
nucleolar components as well as by chemicals that disturb ribo-
some biogenesis, most notably including low doses of actinomycin 
D.5 In addition, the ribosomal stress pathway is connected to the 
genotoxic and oncogenic p53-activating pathways. In particular, 
there are evidences indicating that many types of DNA damag-
ing agents activate the ribosomal stress pathway, which contrib-
utes to the full activation of p53 in concert with the canonical 
DNA damage pathway.14,17 Also, it has been recently reported in 
mice that oncogenic c-Myc engages the ribosomal stress pathway 
and contributes to activation of p53-mediated tumor suppres-
sion.10 Therefore, the ribosomal stress pathway participates in the 
activation of p53 by genotoxic and by oncogenic stresses.
Mouse embryonic stem cells (ESCs) present special adapta-
tions in their cell cycle that afford them extremely rapid pro-
liferation rates (8–10 h per division cycle).18,19 It is conceivable 
that this intense proliferative activity could render them particu-
larly susceptible to alterations in ribosome biogenesis, which, in 
turn, is the most energy-consuming process in the cell (spend-
ing more than 60% of the cell resources).6 Protein p53 is par-
ticularly abundant in ESCs compared with differentiated cells;20 
however, its functional relevance in response to stress remains 
to be clarified. For example, UV and oxidative damage produce 
p53-dependent apoptosis in ESCs,21-23 whereas ionizing radia-
tion or radiomimetic agents activate p53, but apoptosis occurs 
independently of p53.21,24-26 Based on this, we have considered of 
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phosphorylation at serine 18, which is a residue normally asso-
ciated with p53 activation through the DNA damage response 
pathway.3 These results were confirmed by immunofluorescence 
on ESC colonies, where we also used nutlin-3a (N3a) as a positive 
control to induce the stabilization of p53 (Fig. 1B). It is impor-
tant to mention that cells treated with low doses of ActD (0.5 nM 
and 1 nM) maintained normal levels of Oct4 and a normal ESC 
morphology, thus indicating that low doses of ActD are not pro-
ducing a general loss of stemness despite the decreased levels of 
Nanog (Fig. S1). To directly implicate the ribosomal stress path-
way in the stabilization of p53, we performed co-immunoprecip-
itation assays of endogenous Mdm2 in the absence or presence 
of ActD. As anticipated, in the presence of ActD the total levels 
of p53 were increased together with the levels of Mdm2, which 
is a well-established transcriptional target of p53, while the lev-
els of L11 were not induced by ActD (Fig. 1C). Interestingly, 
the amount of L11 bound to Mdm2 was clearly increased upon 
relevance to determine whether the ribosomal stress pathway is 
operative in mouse embryonic stem cells and whether it induces 
p53-dependent apoptosis.
Results
Activation of the ribosomal stress pathway by low doses of 
actinomycin D. It has been well-established that low doses of 
actinomycin D (ActD), lower than 5 nM, selectively impair the 
transcription of rRNAs by RNA polymerase I, thus resulting in 
activation of the ribosomal stress pathway.5,7,8 We began by test-
ing whether low doses of ActD activate p53 in mouse embryonic 
stem cells (ESCs). Indeed, p53 was strongly activated 24 h after 
treatment with 0.5 nM of ActD (Fig. 1A). Activation of p53 was 
accompanied by upregulation of its transcriptional target p21 and 
repression of Nanog, which is known to be repressed by p53.27 Of 
note, the degree of activation of p53 was not proportional to its 
Figure 1. Actinomycin D induces binding of L11 to Mdm2. (A) ESCs were treated for 24 h with increasing concentrations of ActD. The levels of the 
indicated proteins were detected by immunoblotting. (B) ESCs were treated for 24 h with nutlin-3a (N3a, 5 μM), as a control for p53 activation, or with 
increasing concentrations of ActD, and fixed for immunofluorescence against p53. (C) ESCs were treated with 1 nM of ActD and, 6 h later, identical 
amounts of cellular lysates were inmunoprecipitated with anti-Mdm2 antibody. Protein levels were determined by immunobloting.
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differentiated cells.17 Treatment of ESCs with a siRNA against 
L37 (siL37, for 48 h) increased p53 and p21 levels, although less 
efficiently than ActD (Fig. 2A). Importantly, concomitant inhi-
bition of L11 cancelled the effects of siL37 on p53 and p21 and 
partially reverted the effects of ActD (Fig. 2A). These observa-
tions were corroborated by immunofluresence, where the induc-
tion of p53 by ActD or siL37 was reduced in the presence of 
simultaneous treatment with siL11 (Fig. 2B). The activation of 
the p53 transcriptional program by siL37-induced ribosomal 
treatment with ActD (Fig. 1C). Similar results were obtained 
when cells were treated with ActD in the presence of the pro-
teasome inhibitor MG132 (data not shown). These observations 
strongly suggest that low doses of ActD induce the activation of 
p53 in ESCs through the ribosomal stress pathway.
Activation of the ribosomal stress pathway by depletion 
of L37. We wanted to use a more direct inducer of ribosomal 
stress, and for this, we depleted the levels of the ribosomal 
protein L37, which engages the ribosomal stress pathway in 
Figure 2. The ribosomal stress pathway is operative in ESCs. (A) ESCs were interfered with the indicated siRNAs for 48 h. ActD was added 32 h post-
transfection and maintained o/n (16 h). Levels of the indicated proteins were determined by immunoblotting. The immunoblotting is representative of 
three independent experiments. (B) ESCs were transfected with the indicated siRNAs for 48 h (siNT, non-targeting siRNA) and ActD was added 32 h 
post-transfection and maintained o/n (16 h). Cells were fixed and immunostained for p53 and DAPI. (C) ESCs were transfected with the indicated 
siRNAs for 48 h and mRNA levels of the indicated genes were quantified by qRT-PCR. Values were corrected by Gapdh and fold change was calculated 
relative to siNT. Data are mean ± SD of three independent experiments. Unpaired two-tailed Student’s t-test was performed and p-values of the result-
ing tests are indicated.
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radiomimetic agents activate p53 in ESCs without producing 
p53-dependent apoptosis.24-26 In this context, we considered 
important to determine the response of pluripotent stem cells 
to ribosomal stress and the involvement of p53. It should be 
mentioned that a recent report has shown that ablation of the 
nucleolar protein Pict1 results in free nucleoplasmic L11 and in 
p53-dependent apoptosis of ESCs.29
Here, we demonstrate that the ribosomal stress pathway 
can be activated in ESCs and in induced pluripotent stem cells 
(iPSCs) by two standard procedures, namely, low concentra-
tions of actinomycin D (1 nM ActD)5 or depletion of ribosomal 
protein L37.17 Activation of the pathway in ESCs results in asso-
ciation of the critical effector protein L11 with Mdm2, which 
is the hallmark of the ribosomal stress pathway responsible for 
the activation of p53.5 We show that the ribosomal stress path-
way in ESCs/iPSCs results in upregulation of the p53-transcrip-
tional program, including p21, Mdm2, Pidd, Puma, Noxa, Bax 
and Sestrin2, and this transcriptional program requires L11 and 
p53. Finally, we demonstrate that the ribosomal stress pathway 
efficiently triggers apoptosis in pluripotent stem cells and this 
occurs in a manner dependent on L11 and p53. We also exam-
ined Puma-null or Bax-null iPSCs, and, interestingly, we did not 
observe ribosomal stress-induced apoptosis, suggesting that these 
p53 transcriptional targets are relevant mediators of p53-induced 
apoptosis. Collectively, these data add the ribosomal stress path-
way as a relevant pathway to ensure the optimal fitness of pluripo-
tent stem cells and identify L11 and p53 as its critical mediators. 
It is conceivable that the ribosomal stress pathway could consti-
tute an important checkpoint during early embryogenesis, when 
pluripotent stem cells undergo an intense proliferative activity.
The fact that ESCs/iPSCs are sensitive to the ribosomal stress 
pathway could help to explain apparently paradoxical results about 
the role of p53 in ESCs. Namely, ESCs undergo p53-dependent 
apoptosis in response to UVC21-23 but not in response to ionizing 
radiation (IR).21,24-26 Suggestively, a key difference between these 
stimuli is that UVC induces ribosomal stress in cancer cells,17,30-32 
while IR does not.32 Based on this, we speculate that the activa-
tion of the ribosomal stress pathway by UV could explain its abil-
ity to induce p53-dependent apoptosis in ESCs.
Materials and Methods
Cells and reagents. Wild-type C57BL/6 mouse ESCs (clone 
BL3.10) were isolated at the CNIO from blastocyst-stage 
embryos using established methods. ESCs were cultured on a 
feeder monolayer in DMEM with Glutamax, high glucose and 
sodium pyruvate supplemented with 103 U/mL LIF (ESGRO, 
Millipore ESG1107), 15% of fetal bovine serum (FBS), non-
essential amino acids, β-mercaptoethanol and penicillin/strepto-
mycin (all from Invitrogen). Media was replaced daily, and ESCs 
were passed every 2 d by trypsinization. WT, p53-null, Bax-null 
and Puma-null iPSCs were obtained from the corresponding 
C57BL/6 mouse embryonic fibroblasts (MEFs), respectively, by 
retroviral transduction with the three reprogramming factors 
pMXs-Sox2 (Addgene, 13367), pMXs-Oct4 (Addgene, 13366), 
and pMXs-Klf4 (Addgene, 13370), as previously described.33 
stress was documented by examining several p53 transcriptional 
targets, including p21, Mdm2, the Mdm2 inhibitor Pidd28 and 
the pro-apoptotic genes Puma, Noxa and Bax (Figs. 2C and S2). 
In all these cases, induction of ribosomal stress by siL37 resulted 
in upregulation of the mRNA levels of these genes, and this was 
cancelled by the simultaneous presence of siL11 (Fig. 2C).
We also wanted to extend these data to induced pluripotent 
stem cells (iPSCs). Treatment of wild-type iPSCs with ActD or 
siL37 efficiently increased p53 and p21 protein levels (Fig. 3A 
and B) and the mRNA levels of p21, Mdm2, Pidd, Puma, Noxa 
and Bax (Fig. 3C). We also examined the antioxidant p53 targets 
Sestrin1 and Sestrin2, although we only saw significant induction 
in the case of Sestrin2 (Fig. S3). Importantly, all the effects of 
siL37 were cancelled by the concomittant presence of siL11 (Figs. 
3B and C and S3). Moreover, we took advantage of p53-null 
iPSCs to demonstrate that the effects of ActD and siL37 were 
dependent on p53. As expected, p53-null iPSCs did not show 
upregulation of p21 protein levels in response to ActD or siL37 
and did not show changes in the above mentioned p53 transcrip-
tional targets (Figs. 3A–C and S3). Together, these results indi-
cate that impairment of ribosome biogenesis by depletion of L37 
activates the p53 transcriptional program in an L11-dependent 
manner.
Induction of p53-dependent apoptosis by the ribosomal 
stress pathway. Finally, we wanted to determine the impact of 
the ribosomal stress pathway on the viability of ESCs/iPSCs. 
We first observed that treatment of ESCs with siL37 resulted in 
a significant induction of apoptosis that was almost completely 
rescued by the simultaneous knockdown of L11 (Fig. 4A). 
Interestingly, similar results were obtained in wt iPSCs treated 
with ActD or with siL37, but no apoptosis was observed in 
p53-null iPSCs (Fig. 4B). In an attempt to determine the role 
of the pro-apoptotic p53-transcriptional targets, we examined 
Puma-null and Bax-null iPSCs. Interestingly, we did not observe 
ribosomal stress-induced apoptosis in Puma-null or in Bax-null 
iPSCs (Fig. S4), suggesting that these p53 transcriptional targets 
are relevant mediators of p53-induced apoptosis. Together, these 
results demonstrate that the ribosomal stress pathway induces 
p53-dependent apoptosis in pluripotent stem cells.
Discussion
The ribosomal stress pathway has emerged as a new p53-acti-
vating pathway, whose relevance is now firmly established.5,6,15,16 
Ribosome biogenesis is the most demanding energetic process 
of the cell,6 and therefore, it is well placed to sense whether a 
cell is optimally fitted for intense proliferation, acting as a qual-
ity checkpoint. Embryonic pluripotent stem cells are unique 
because of their extremely fast proliferation rates (8–10 h), reach-
ing cell cycles of less than 5 h in the epiblast.18,19 However, the 
operation of the ribosomal stress pathway in pluripotent stem 
cells has remained unexplored. Moreover, the role of p53 in 
embryonic stem cells (ESCs) remains to be clarified, and it may 
depend on the particular stress or pathway that activates p53. 
For example, treatment of ESCs with UV or oxidative damage 
triggers p53-dependent apoptosis,22,23 but ionizing radiation or 
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whole lysates were resolved in 4–12% SDS/PAGE gels (NuPAGE 
Invitrogen) and transferred to nitrocellulose membranes. Blots 
were incubated with the primary antibodies anti-p53 (1C12, 
Cell Signaling), anti-phosphoSer18 p53 (Cell Signaling, 9284), 
anti-p21 (C-19, SCBT), anti-Nanog (Millipore, AB5731), anti-
β-actin (AC-15, Sigma), and subsequently incubated with the 
corresponding secondary anti-IgG HRP antibodies (DAKO). 
Blots were developed with ECL (Amersham).
Immunofluorescence. ESCs/iPSCs (1 x 105 cells per 24-well 
plate) were seeded on a feeder monolayer onto glass coverslips 
and treated with ActD or transfected in suspension for siRNA 
interference. Cells were fixed at 24 or 48 h with 4% paraformal-
dehyde for 15 min and permeabilized with 0.1% Triton X-100 
30 min. Then, cells were blocked in 5% BSA during 1 h at R.T. 
and incubated o/n at 4°C with the primary antibodies anti-p53 
(1C12, Cell Signaling), anti-Nanog (NOVUS, NB100-588), or 
anti-Oct3/4 (BD Biosciences, 611203). Alexa-555 or Alexa-488 
conjugated goat anti-mouse or anti-rabbit antibodies (Molecular 
Probes) were used for detection of the reported proteins by confo-
cal microscopy. Nuclei were counterstained with DAPI bath and 
coverslips mounted with ProLong (Molecular Probes). Sections 
of 1 μm were acquired with a Leica TCS-SP5 multiphoton con-
focal microscope.
Immunoprecipitation. ESCs grown on gelatin were treated 
with ActD (1 nM) for 6 h and subsequently collected for immu-
noprecipitation. Endogenous Mdm2 was immunoprecipitated 
with 5 μg of antibody to Mdm2 (SMP14, Santa Cruz) and 
TrueBlot anti-mouse IgG beads (eBioscience) starting from 1 
mg of whole lysate. The immuprecipitated proteins were detected 
with a monoclonal antibody to Mdm2 (2A10, Abcam), a mono-
clonal antibody to p53 (1C12, Cell Signaling), a polyclonal anti-
body to L11 (SCBT catalog #25931) and a monoclonal antibody 
to β-actin (AC-15, Sigma). TrueBlot anti-mouse IgG (eBiosci-
ences) and anti-goat IgG HRP (DAKO) were used as second-
ary antibodies for detection of proteins with ECL (Amersham). 
Forty μg of whole lysates were loaded as inputs.
Annexin V staining. ESCs/iPSCs were collected for 
Annexin V staining 48 h after siRNA transfection. Cells were 
trypsinized, washed once in cold PBS at 1,500 rpm for 5 min 
and then resuspended in 300 μL of Annexin V binding buf-
fer 1x (BD Pharmigen). Three μL of FITC-Annexin V (BD 
Pharmigen) were added, and cells were incubated in dark for 
15 min. Then, cells were stained with 2 μL of DAPI and, at 
least, 10,000 events were analyzed by flow cytometry on a LSR-
Fortessa (BD Biosciences) with FACSDiva software. Early-stage 
apoptotic cells were quantified as FITC-Annexin V positive (+) 
DAPI negative (-) with the FlowJo 7.6.1. program.
iPSCs were cultured on feeders in the same manner as ESCs, 
except that 15% Knockout Serum Replacement (Invitrogen) was 
used instead of FBS in the culture media. Feeders were obtained 
from MEFs inactivated with 10 μg/mL of Mitomycin C (Sigma). 
ESCs/iPSCs were adapted to non-feeder conditions onto gelatin-
coated plates (0.1% porcine gelatin, Sigma), previous treatment 
with actinomycin D (ActD) or interference with siRNA. ActD 
was purchased from Sigma and added at the indicated concentra-
tions to the culture media. After 24 h, cells were harvested for 
protein extraction or immunofluorescence analysis.
RNA interference. ESCs/iPSCs (2.5 x 105 cells per 6-well 
plate) were transfected in suspension with 100 nM of siRNA 
using DharmaFECT1 (Dharmacon) and harvested 48 h later for 
RNA, protein extraction or immunofluorescence analysis. siRNA 
duplexes were purchased from Dharmacon (L37: GCG CAA 
GAG GAA GUA UAA C; L11 ON-TARGET plus J-064528-11-
0010; and non-targeting ON-TARGET plus D-001810-01-20). 
ActD was added 32 h post-transfection and maintained in the 
culture media o/n (16 h).
Quantitative real-time PCR (qRT-PCR). Total RNA was 
isolated from ESCs/iPSCs using TRIzol reagent (Invitrogen) fol-
lowing the manufacter’s instructions. Five μg of total RNA was 
retrotranscribed into cDNA using Ready-To-Go You-Prime First 
Strands beads (GE Healthcare). Real-time PCR was performed 
using FAST SYBR Green master mix (Applied Biosystems) in 
a 7500 Fast Real-Time PCR system (Applied Biosystems). All 
reactions were performed in triplicates and normalized to Gapdh, 
as an endogenous control. Levels of mouse mRNAs were ana-
lyzed using the following specific primers: L37-Fw, CAT CCT 
TTG GTA AGC GTC GCA; L37-Rv, TGG CAC TCC AGT 
TAT ACT TCC T; L11-Fw, ATG GCG CAA GAT CAA GGG 
G; L11-Rv, GAC TGT GCA GTG AAC AGC AAT; p21-Fw, 
GTG GGT CTG ACT CCA GCC C; p21-Rv, CCT TCT CGT 
GAG ACG CTT AC; Mdm2-Fw, GGT CCC TGT CCT TTG 
ATC CGA G; Mdm2-Rv, GCA GTG TGA TGG AAG GGG 
AGG A; Pidd-Fw, GGG AAC CAG TTG AAC TTG GAC; 
Pidd-Rv, CCG CAA AAA CTC CAC TTG CAG; Puma-Fw, 
AGC AGC ACT TAG AGT CGC C; Puma-Rv, CCT GGG 
TAA GGG GAG GAG T; Noxa-Fw, GCA GAG CTA CCA 
CCT GAG TTC; Noxa-Rv, CTT TTG CGA CTT CCC AGG 
CA; Bax-Fw, GAC AGG GGC CTT TTT GCT A; Bax-Rv, 
TGT CCA CGT CAG CAA TCA TC; Sesn1-Fw, GTC TGG 
ATA ACA TCA CAT TAG; Sesn1-Rv, CCA GGT AGG AAC 
ACT GAT GC; Sesn2-Fw, CTC ACA GCT GGT CTG TGT 
G; Sesn2-Rv, CCT CCG TGT GGC AAT ACC; Gapdh-Fw, 
TTC ACC ACC ATG GAG AAG GC; Gapdh-Rv, CCC TTT 
TGG CTC CAC CCT.
Immunoblotting. Cells were harvested after ActD treatment 
or siRNA transfection in RIPA buffer. Identical amounts of 
Figure 3. The ribosomal stress pathway is operative in iPSCs. (A) WT iPSCs clones (n = 2, upper part) and p53-null iPSCs clones (n = 2, bottom part) 
were transfected with non-targeting (NT) or L11 siRNAs and, 32 h later, cells were treated with ActD (1 nM) for an additional 16 h. Levels of the indicat-
ed proteins were detected by immunoblotting. (B) WT iPSCs clones (n = 2, upper part) and p53-null iPSCs clones (n = 2, bottom part) were transfected 
with the indicated siRNAs for 48 h. Levels of the indicated proteins were detected by immunoblotting. (C) WT or p53-null iPSCs were transfected with 
the indicated siRNAs and mRNA levels of the indicated genes were quantified by qRT-PCR. Values were corrected by Gapdh and fold change was 
calculated relative to siNT. Data are mean ± SD of three independent clones per genotype. Unpaired two-tailed Student’s t-test was performed and 
p-values of the resulting tests are indicated.
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Figure 4. The ribosomal stress pathway induces p53-dependent apoptosis in ESCs and iPSCs. (A) ESCs were transfected with the indicated siRNAs for 
48 h and early-stage apoptotic cells were quantified by FACS analysis as Annexin V positive (+) DAPI negative (-). Data are mean ± SD of four indepen-
dent experiments. Early-stage apoptotic cell population is labeled inside the red box (right part; representative FACS profiles). (B) WT and p53-null 
iPSCs were transfected with the indicated siRNAs for 48 h or treated with ActD o/n 32 h post-transfection. Early-stage apoptotic cells were measured 
as in (A). Data are mean ± SD of five independent clones per genotype. Unpaired two-tailed Student’s t-test was performed and p-values of the result-
ing tests are indicated.
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Objetivo: IDENTIFICACIÓN DE NUEVOS AGENTES DISRUPTIVOS DEL 
NUCLEOLO PARA ELIMINAR CELLULAR TUMORALES A TRAVÉS DE LA VÍA 
DE ESTRÉS RIBOSOMAL  
 
Las células tumorales dependen de elevados niveles de biogénesis ribosomal para satisfacer 
las altas demandas energéticas que implica su mayor tasa de síntesis proteica. La biogénesis ribosomal 
tiene lugar en el nucleolo. Perturbaciones de la integridad nucleolar activan p53 a través de la vía de 
estrés ribosomal (RPL11/RPL5-MDM2-p53), resultando en la parada o apoptosis de las células 
tumorales. Muchos de los agentes quimioterapéuticos empleados para el tratamiento del cáncer han 
sido seleccionados por su capacidad de causar daño genotóxico, aunque posteriormente se ha 
demostrado que muchos de ellos causan además estrés ribosomal. El daño genotóxico sistémico que 
suponen los tratamientos quimioterapeúticos es responsable de la alta incidencia de cáncer de novo en 
los pacientes tratados. Sería ideal disponer de drogas quimioterapeúticas que activen p53 y que no 
produzcan daños en el ADN. 
 
El objetivo de este trabajo ha sido la identificación de nuevos agentes disruptivos de nucleolo 
que activaran p53 en ausencia de de daño detectable en el ADN. Para ello, hemos diseñado un cribado 
de sustancias químicas en células de osteosarcoma que expresan la construcción GFP-RPL37. La 
proteína ribosomal L37 (RPL37, de sus siglas en inglés) se acumula en el nucleolo y nos sirve para 
monitorizar su estructura. Los candidatos de dicho cribado han sido seleccionados en base a su 
potencia para generar pérdida de la integridad nucleolar. Entre ellos, hemos caracterizado el 
mecanismo de acción de un grupo de derivados de acridinas, los cuales inhiben la transcripción 
mediada por la ARN polimerasa I, encargada de la síntesis de ARN ribosomales. La inhibición de la 
transcripción de ARN ribosomales causa la pérdida de la integridad del nucleolo y esto conlleva la 
activación de p53 a través de la unión de RPL11 a MDM2. Es reseñable el hecho de que la activación 
de p53 ocurre en ausencia de daño detectable en el DNA y sin embargo es capaz de causar la muerte 
celular de las diferentes líneas tumorales evaluadas. 
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Nucleolar disruption has recently emerged as a relevant means to 
activate p53 through inhibition of HDM2 by ribosome-free RPL11. 
Most drugs that induce nucleolar disruption also possess impor-
tant genotoxic activity, which can have lasting mutagenic effects. 
Therefore, it is of interest to identify compounds that selectively 
produce nucleolar disruption in the absence of DNA damage. 
Here, we have performed a high-throughput screening to search 
for nucleolar disruptors. We have identified an acridine derivative 
(PubChem CID-765471) previously known for its capacity to acti-
vate p53 independently of DNA damage, although the molecular 
mechanism underlying p53 activation had remained uncharacter-
ized. We report that CID-765471 produces nucleolar disruption by 
inhibiting ribosomal DNA transcription in a process that includes 
the selective degradation of the RPA194 subunit of RNA polymer-
ase I. Following nucleolar disruption, CID-765471 activates p53 
through the RPL11/HDM2 pathway in the absence of detectable 
DNA damage. In a secondary screening of compounds approved 
for medical use, we identify two additional acridine derivatives, 
aminacrine and ethacridine, that operate in a similar manner as 
CID-765471. These findings provide the basis for non-genotoxic 
chemotherapeutic approaches that selectively target the nucleolus.
Introduction
Highly proliferative cells have an enormous demand of ribosome 
biogenesis (1). The relevance of monitoring ribosome biogenesis 
is highlighted by the fact that there is a dedicated molecular path-
way connecting ribosomal perturbations with p53 (2). In particular, 
unbalanced ribosome assembly results in free preribosomal complex 
RPL11/RPL5/5SrRNA, which binds and inhibits HDM2, thereby 
resulting in stabilization and activation of p53 (3–6). Increasing exper-
imental and mutational data supports the relevance of this pathway for 
cancer protection. In mice, a genetically engineered mutant HDM2 
that cannot bind RPL11 and RPL5 results in failure to sense riboso-
mal unbalances and favors cMyc-driven lymphoma (7). In humans, 
RPL5 is somatically mutated in a small percentage of glioblastomas 
(3% [8]) and T-cell leukemias (2% [9]); and RPL11 is mutated in 
endometrial cancers (2%) (http://icgc.org). When analysed, these 
cancer-associated mutations have been found in heterozygosis (9), 
consistent with the fact that RPL11 and RPL5 are essential for cell 
viability (10) and suggesting that a partial decrease in their levels is 
sufficient to favor cancer. Indeed, patients with germline heterozygous 
mutations in ribosomal genes have an increased incidence of cancer 
(11). Impaired activity of the ribosomal stress pathway can be advan-
tageous to cancer cells because it partially alleviates surveillance of 
ribosome integrity by p53. According to this rationale, the ribosomal 
stress pathway has emerged as an attractive target for p53 activation 
and cancer therapy (12).
Most genotoxic chemotherapeutic agents not only produce DNA 
damage, but also produce ribosomal stress, which is often visualized 
by the disruption of nucleoli (12–15). Accordingly, genotoxic drugs 
activate p53 through two simultaneous pathways, namely, the DNA 
damage response (DDR) pathway and the ribosomal stress pathway 
(16–18). Despite its undeniable benefits, genotoxic chemotherapy has 
serious drawbacks, most prominently the mutational load imposed on 
surviving cells and the ensuing risk of de novo tumorigenesis. In this 
regard, it is of high interest to identify chemotherapeutic agents that 
activate p53 without producing DNA damage. Here, we perform a drug 
screening to search for compounds that activate p53 through the ribo-
somal stress pathway and in the absence of detectable DNA damage.
Materials and methods
Cell culture and drugs
Cell lines U2OS (human osteosarcoma), its derivative expressing GFP-RPL37 
(U2OS/GFP-RPL37 [16]), and HCT116 (human colon carcinoma) p53WT 
and p53KO (19) were maintained in DMEM, supplemented with 10% fetal 
bovine serum and antibiotic-antimicotic (all from Gibco), and incubated in 
20% O2 and 5% CO2 at 37°C. Human cell lines were purchased from ATCC 
and were authenticated after completion of this work. Cell line authentication 
was performed by analysing a total of 10 microsatellites at the authentica-
tion service (Genomic Unit) of the Institute of Biomedical Research ‘Alberto 
Sols’ in Madrid. CID-765471 (2,4,7,9-tetramethylbenzo[b][1,8] naphthyridin-
5-amine), actinomycin D (ActD), doxorubicin (Doxo), nutlin-3 (N3), MG132 
(proteosome inhibitor) and hydroxyurea (HU) were purchased from Sigma. 
Aminacrine and ethacridine lactate were purchased from Selleckchem. The 
ataxia telangiectasia and Rad3-related protein inhibitor (ETP-46464 [20]) 
was obtained from the Spanish National Cancer Research Centre (CNIO). For 
those assays using cyclohexamide (CHX), cells were treated with 20 µM CHX 
(Sigma) during the indicated time.
High-throughput screening
We tested two libraries of chemical compounds. The first library (CNIO-640 
library) comprises 640 compounds representative of the full collection (50 000 
compounds) of the Experimental Therapeutics Programme at the Spanish 
National Cancer Research Centre (CNIO). The second library was acquired 
from the Johns Hopkins University (Johns Hopkins Clinical Compound 
Library or JHCCL, version 1.3) and comprises 1524 compounds approved for 
medical use. U2OS cells expressing GFP-RPL37 (U2OS/GFP-RPL37) were 
seeded in cell-carrier black 384-well microplates (Perkin Elmer) at a density 
of 5000 cells per well 24 h before adding the compounds. Compounds were 
weighed out and diluted with dimethyl sulfoxide (DMSO) to a final concen-
tration of 10 mM. From here, a ‘mother plate’ was prepared at 80× the final 
concentration in the culture, resulting the final concentration of DMSO in the 
tissue culture media in 1.25%. Viability of cells was previously tested in a 
dose curve with increasing concentrations of DMSO. The appropriate volume 
of the compound solution (1.5 μl) was added automatically (Beckman FX 96 
tip) to media to make it up to the final concentration (5 μM) for each drug. 
This concentration was assayed in triplicate. After 4.5 h of incubation with the 
compounds, cells were fixed in 4% paraformaldehyde in phosphate-buffered 
saline (PBS) for 15 min at room temperature and washed three times with 
PBS. The last wash of PBS was left in the wells to prevent drying of cells, and 
microplates were sealed with aluminium adhesive foil to avoid fading away 
of GFP fluorescence. Those compounds that killed cells at 5 μM for 4.5 h 
were retested at a lower concentration (2.5 μM). For the validation assays, 
two different U2OS/GFP-RPL37 clones were seeded in μClear black 96-well 
microplates (Greiner Bio-One) at a density of 25 000–30 000 cells per well 
in triplicates, and they were assessed at 5 μM and 2.5 μM in the case of the 
CNIO-640 library or at 5 µM in the case of the JHCCL screening for 4.5 h. 384-
well and 96-well microplates were run in the Opera High Content Screening 
(HCS) system (Perkin Elmer) by taking images of 27 or 42 random fields per 
well, respectively, with a ×20 magnification lens. Images were then analysed 
with Definiens Developer XD software by using a morphology-based script 
that classifies nucleoli (defined by GFP signal) in two classes depending on 
Abbreviations: ActD, actinomycin D; CNIO, Spanish National Cancer 
Research Centre; DAPI, 4′,6-diamidino-2-phenylindole; DDR, DNA damage 
response; DMSO, dimethyl sulfoxide; NPM, nucleophosmin; PBS, phosphate-
buffered saline.
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their roundness (>0.15 as irregular, ‘normal’, and ≤0.15 as round, ‘disrupted’, 
spots). At least, 5000 nucleoli per well were analysed. After classification, the 
average of normal and disrupted nucleoli per well was calculated to assign a 
‘nucleolar disruption score’ (ratio between the number of disrupted and nor-
mal nucleoli). The Z’-factor to statistically measure the assay quality of the 
screening was calculated as defined (1 − 3 × (σp + σn)/|μp − μn| where σp and σn 
are the standard deviations of the positive and negative controls, and μp and μn 
are the means of the positive and negative controls), taking the nucleolar dis-
ruption score of ActD-treated cells as the positive control and DMSO-treated 
cells as the negative control. Z’-factor was 0.65 for the screen.
RNA extraction and quantitative real-time PCR
Total RNA was isolated from cells using TRI-reagent (Sigma) following the man-
ufacturer’s instructions. 2.5 μg of total RNA was reverse transcribed into cDNA 
using iScript Advanced First Strand cDNA synthesis kit (BioRad). Real-time PCR 
was performed using FAST SYBR Green master mix (Applied Biosystems) in a 
7500 Fast Real-Time PCR (Applied Biosystems). All reactions were performed 
in triplicates and normalized to β-Actin mRNA levels as an endogenous control. 
Sequences of the human primers used for quantitative real-time PCR in this 
work are listed: P21-Fw: 5′-GAT TAG CAG CGG AAC AAG GAG T-3′, P21-
Rv: 5′-TAC AGT CTA GGT GGA GAA ACG GG-3′; HDM2-Fw: 5′-TAC AGG 
GAC GCC ATC GAA TC-3′, HDM2-Rv: 5′-TGA AGT GCA TTT CCA ATA 
GTC AGC-3′; GADD45A-Fw: 5′-GGC TGG AGA GCA GAA GAC CGA A-3′, 
GADD45A-Rv: 5′-CTG ACG CGC AGG ATG TTG ATG-3′; BAX-Fw: 5′-CTC 
AGG ATG CGT CCA CCA AGA A-3′, BAX -Rv: 5′-CTC CCG GAG GAA GTC 
CAA TGT C-3′; ITS1 rRNA-Fw: 5′-AGT CGG GTT GCT TGG GAA TG-3′, 
ITS1 rRNA-Rv: 5′-GAC ACG CCC TTC TTT CTC TC-3′; 5S rRNA-Fw: 5′-GTC 
TAC GGC CAT ACC ACC CTG-3′, 5S rRNA-Rv: 5′-AAA GCC TAC AGC ACC 
CGG TAT-3′; UBF-Fw: 5′-GGC CAG ATG CCA CTA CGA-3′, UBF-Rv: 5′-
CTC CAG GGC CTT ATG AAT CCA-3′; Nucleolin-Fw: 5′-ACC CAG GGG 
ATC ACC TAA TG-3′, Nucleolin-Rv: 5′-CCT TTG GAG GAC CCA GTT 
TC-3′; NPM1-Fw: 5′-GTA CAG CCA ACG GTA A-3′, NPM1-Rv: 5′-AGA CCG 
CTT TCC AGA T-3′; β-Actin Fw: 5′-GGC ACC ACA CCT TCT ACA ATG-3′, 
β-Actin-Rv: 5′-GTG GTG GTG AAG CTG TAG CC-3′.
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Fig. 1. A cell-based high-content screen for nucleolar disruptors. (A) Outline of the screening. (B) Result of the primary screening with 640 compounds (all at 
5 µM for 4.5 h) in 384-well microplates. A zoom in of the 15 best-scored compounds is shown at the right top corner. Values correspond to the average ± SD of 
technical triplicates (n=3). CNIO compound 15760 corresponds to CID-765471. (C) Validation of the primary hits in a secondary screen in 96-well microplates. 
Compounds were tested in triplicates (all at 5 µM for 4.5 h) in two different clones of U2OS/GFP-RPL37 cells. Values correspond to the average ± SD of 
the two biological replicates (n=2) normalized to DMSO treatment. Statistical significance was calculated by the Student’s t-test: **P ≤ 0.01; ***P ≤ 0.005. 
Representative images of the GFP fluorescence. (D) Immunofluorescence of NPM, which marks the granular component of nucleoli, 72 h after treatment of 
U2OS cells with ActD (5 nM) or the indicated CNIO compounds (5 μM).
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Northern Blot analysis of pre-RNA intermediates
U2OS cells were treated for 6 h with the indicated compounds and then 
collected and processed for isolation of total RNA by using TRI-reagent 
(Sigma) and following the manufacturer’s instructions. 3 μg of total RNA, 
resuspended in formamide, were loaded into a 1.2% MOPS/formaldehyde 
agarose gel and run in the same buffer at 30V o/n. RNAs were transferred 
to a Hybond N+ nylon membrane (Amersham) and fixed by UV cross-
linking. Membranes were prehybridized and incubated with the 5′ITS1 
(5′-CCT CGC CCT CCG GGC TCC GTT AAT GAT C-3′) and ITS2 (an 
equal amount of 5′- CTG CGA GGG AAC CCC CAG CCG CGC A-3′ 
and 5′-GCG CGA CGG CGG ACG ACA CCG CGG CGT C-3′) probes as 
described (21).
RNA interference
U2OS cells were plated the day before of transfection. siRNA duplexes 
(Dharmacon) against a non-targeting sequence (ON-TARGET plus D-001810-
01-20) or human RPL11 (sequence: 5′- AAG GUG CGG GAG UAU GAG 
UUA UU-3′) were added at 100 nM by using DharmaFECT1 (Dharmacon), 
and transfection media was replaced 24 h later by fresh media containing the 
corresponding drugs. Cells were incubated with the corresponding drugs for 
additional 24 h and then collected for immunoblotting. For the lentiviral assay, 
we used MISSION non-target shRNA control SHC016 and MISSION shRNA 
against RPL11 clone ID: NM_000975.2-287s1c1 (sequence: 5′- CCG GGC 
GGG AGT ATG AGT TAA GAA A-3′).
Immunoblotting
Cells were harvested after treatment with the indicated compounds or siRNA 
transfection in RIPA buffer. Identical amounts of whole lysates were resolved 
in 4–12% SDS/PAGE gels (NuPAGE Invitrogen) and transferred to nitrocel-
lulose membranes. Blots were incubated with the primary antibodies anti-p53 
(DO-1, SCBT), anti-p21 (C-19, SCBT), anti-HDM2 (clone SMP14, SCBT), 
anti-RPL11 (Proteintech), anti-RPA194 (H-300, SCBT), anti-RPA135 (H-15, 
SCBT), anti-NPM (7H10B9, NOVUS Biologicals), anti-β-actin (AC-15, 
Sigma), and subsequently incubated with the corresponding secondary anti-IgG 
HRP antibodies. For uncropped images of the blots and links to the commercial 
antibodies, see Supplementary Figure 7, available at Carcinogenesis online.
Immunofluorescence
Cells were plated onto glass coverslips or Greiner Bio-One μClear black 
96-well plate (7.5 × 104 cells per well) and treated with the indicated 
drugs for 6 or 72 h. Then, cells were fixed with 4% paraformaldehyde for 
15 min, permeabilized with 0.1% Triton X-100 for 30 min and blocked 
in 5% bovine serum albumin during 1 h at room temperature. Incubation 
with primary antibodies against fibrillarin (C13C3, Cell Signaling), nucle-
ophosmin (NPM) (7H10B9, NOVUS Biologicals), p53 (DO-1, SCBT),or 
γH2A.X Ser139 (JBW301, Millipore) were carried out o/n at 4°C. 
Alexa-555 or Alexa-488 conjugated anti-mouse or anti-rabbit antibodies 
(Molecular Probes) were used for detection of the reported proteins by con-
focal microscopy. Nuclei were counterstained with 4′,6-diamidino-2-phe-
nylindole (DAPI) bath. In the case of coverslips, samples were mounted 
with ProLong and sections of 1 μm were acquired with a ×40 magnification 
lens in a Leica TCS-SP5 (WLL) multiphoton confocal microscope. A total 
of 27 fields per well were acquired with a ×40 magnification lens for those 
samples run in the Opera HCS system (Perkin Elmer). In the case of p53 
and γH2A.X, images were segmented using the DAPI staining to generate 
masks matching cell nuclei from which fluorescence intensity signals were 
calculated by using Acapella High Content Imaging and Analysis software 
(Perkin Elmer). In the case of nucleophosmin, images were segmented 
using the DAPI staining and the coefficient of variation of nucleophos-
min intensity per nucleus was calculated using Definiens Developer XD 
software.
Immunoprecipitation
U2OS cells were treated with CID-765471 (5 and 10 µM) for 24 h and with 
MG132 (25 μM) during 3 h before collecting them. RPL11 was immunprecipi-
tated with 5 µg of antibody to RPL11 (Proteintech) and TrueBlot anti-rabbit 
IgG beads (eBioscience) starting from 1 mg of whole lysate. The immunopre-
cipitated proteins were detected with a monoclonal antibody to HDM2 (clone 
SMP14, SCBT) and a polyclonal antibody to RPL11 (Proteintech). TrueBlot 
anti-rabbit IgG (eBiosciences) and anti-mouse IgG HRP (DAKO) were used as 
secondary antibody for detection of proteins with ECL (Amersham). Twenty 
micrograms of whole lysates were loaded as input.
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Fig. 2. CID-765471 activates p53 in the absence of DNA damage. (A) U2OS cells were treated as indicated and protein levels of p53 and p21 were measured by 
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Flow cytometry assays
For flow cytometry assays, 3 × 105 or 5 × 105 of U2OS or HCT116 (p53WT 
or p53KO) cells, respectively, were seeded in multi six-well plates and com-
pounds were added the following day or 24 h after RNA interference. For 
cell cycle profiles, cells were collected 24 h after addition of compounds and 
fixed in 70% EtOH o/n, washed twice in PBS and stained in propidium iodide 
solution (25 μg/ml, Sigma, in PBS) with RNase A  (0.2 mg/ml, Qiagen) for 
3–4 h. About 20 000 events were at least acquired with FACS Calibur (BD 
Bioscience; FACSDiva software) and data were analysed with FlowJo 9.6.2 
software. For apoptosis experiments, cells were collected 96 h after addition of 
compounds, washed once in cold PBS (1500 r.p.m. for 5 min) and incubated 
in TMRE (30 nM in PBS) for 10 min at 37°C in waterbath (protecting samples 
from light). Then, cells were spun down and incubated in dark for 20 min at 
room temperature in 300 µl of Annexin V binding buffer with 3 µl of APC-
Annexin (BD Pharmigen). DAPI was used as viability marker. At least 10 000 
events were collected in LSR-Fortessa (BD Biosciences; FACSDiva software) 
and apoptotic cells were quantified as DAPI negative (-) TMRE negative (-) 
APC-Annexin V positive (+) with FlowJo 9.6.2 software.
Results
High-content screening for drugs that induce nucleolar disruption
Ribosomal proteins accumulate in nucleoli when they are newly 
synthesized (22) and associate to precursor rRNAs (23). We took 
advantage of U2OS cells stably expressing the ribosomal protein 
L37 (RPL37) fused to GFP (16) to monitor nucleolar integrity in a 
high-content screen based on automated confocal microscopy. In 
the absence of nucleolar stress, GFP-RPL37 marks foci of irregular 
shape and rough borders (Figure 1A), which correspond to nucleoli 
as demonstrated by their colocalization with fibrillarin and NPM 
(Supplementary Figure 1A and B, available at Carcinogenesis online). 
Shortly upon treatment with ActD, a well-characterized nucleolar 
disruptor (13,15), the GFP-RPL37 signal became compacted and 
rounded (Figure 1A) and nucleolar proteins changed their localiza-
tions: fibrillarin segregated into caps around the GFP-RPL37 foci and 
NPM mislocalized over the nucleoplasm (Supplementary Figure 1A 
and B, available at Carcinogenesis online). All these changes consti-
tute hallmarks of nucleolar disruption (24). Several parameters were 
tested to quantify nucleolar disruption, including fluorescence inten-
sity, and we found that the morphological change was the most robust 
feature altered upon loss of nucleolar integrity. Changes in nucleolar 
morphology were quantified with a ‘roundness’ algorithm that clas-
sified nucleoli into two classes: irregular or rounded (Supplementary 
Figure  1C, available at Carcinogenesis online). This served as the 
basis to calculate the ratio between disrupted (rounded) and normal 
(irregular) nucleoli in a given cell population and we refer to this ratio 
as ‘nucleolar disruption score’.
In agreement with previous reports (15), we observed that nucleolar 
disruption by ActD occurs very rapidly, reaching a maximum in 1 h 
and being stably maintained for at least 6 h (Supplementary Figure 1D, 
available at Carcinogenesis online). Based on this, we set the readout 
Fig. 3. CID-765471 inhibits ribosomal DNA transcription. (A) Northern blot analysis of pre-rRNA intermediates in U2OS cells treated with the indicated 
compounds for 6 h. Probes against ITS1 or ITS2 regions were used to identify all the intermediates, as indicated to the left (asterisks correspond to non-specific 
signals). Mature 28S and 18S rRNA levels were detected by staining with ethidium bromide. This Northern blot is representative of two independent assays.  
(B) RNA levels of 47S ITS1 (RNA pol I-transcribed) and 5S rRNA (RNA pol III-transcribed) were measured by quantitative real time PCR in HCT116-WT and 
HCT116-p53KO cells treated as indicated for 24 h. Nutlin-3 (N3) was used at 20 µM, as a positive control for p53 activation. Values correspond to the average ± 
SD of two independent assays (n=2). (C). Immunofluorescence of fibrillarin in U2OS/GFP-RPL37 cells after treatment (6 h) with CID-765471 (5 µM). In normal 
cells (DMSO treated), fibrillarin marks the dense fibrillar center of nucleoli and coincides with GFP-RPL37. Upon nucleolar disruption, fibrillarin segregates 
and forms the so-called fibrillarin caps around the remaining central body of nucleoli (containing GFP-RPL37). (D) RPA194 and RPA135 protein levels were 
measured by immunoblotting following the indicated treatments for 24 h. The immunoblot is representative of three independent assays.
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of our screening at 4.5 h after addition of the compounds to the cells. 
We tested an in-house made library of 640 compounds chosen to 
cover a large chemical space (CNIO-640 chemical library). This pri-
mary screening on U2OS/GFP-RPL37 cells yielded seven hits with 
high nucleolar disruption scores (Figure 1B) and two of them were 
confirmed in a subsequent validation assay (Figure 1C). Compound 
CNIO-15760 (which we will refer to by its PubChem identifier 
CID-765471) and CNIO-47023 also induced nucleolar disruption in 
parental U2OS cells (not carrying GFP-RPL37), as demonstrated by 
the dissolution of NPM foci (Figure 1D), and nucleolar disruption 
was detectable at least 22 h after treatment (not shown). These two 
compounds presented a similar dose-response profile at µM range, 
being CID-765471 more efficient than CNIO-47023 (Supplementary 
Figure 1E, available at Carcinogenesis online). Based on the better 
capacity of CID-765471 to induce nucleolar disruption, we focus 
hereafter on this compound.
CID-765471 activates p53 in the absence of DNA damage
Nucleolar disruption by ActD or other chemotherapeutic agents results 
in the activation of the tumour suppressor p53 (13,15). As expected, 
CID-765471 also increased p53 and p21 levels (Figure  2A and 
Supplementary Figure 2A and B, available at Carcinogenesis online). 
Interestingly, CID-765471, an acridine derivative whose chemical 
structure is 2,4,7,9-tetramethylbenzo[b][1,8] naphthyridin-5-amine, 
had been previously identified in two screenings for p53-activating 
compounds under the names of BMH-22 (25) and SID-17433115 
(26). Also, acridine and a number of derivatives closely related to 
CID-765471 have been found to be efficient activators of p53 (27). 
As suggested by their planar heteroaromatic ring structure, acridine 
derivatives are DNA intercalating agents and indeed CID-765471 has 
been directly demonstrated to intercalate into DNA (25). Many DNA 
intercalators carry reactive groups and are genotoxic, thereby effi-
ciently triggering a DDR and activating p53. Intriguingly, however, 
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some acridine derivatives and, in particular, CID-765471 have been 
reported to activate p53 in the absence of genotoxic damage and 
independently of the DDR pathway (25–27). We wanted to confirm 
if this was the case in our experimental system. In agreement with the 
above-mentioned reports, we did not observe γH2A.X foci, indica-
tive of DNA damage, in cells treated with CID-765471 (Figure 2B 
and C). In contrast to this, non-intercalating genotoxic agents that 
efficiently activate the DDR and p53, such as ataxia telangiectasia 
and Rad3-related protein inhibitors or hydroxyurea, were unable to 
produce nucleolar disruption (Supplementary Figure 2C, available at 
Carcinogenesis online). These observations support the notion than 
nucleolar stress can be triggered in the absence of genotoxic damage.
CID-765471 inhibits rDNA transcription
Previous studies have indicated that DNA intercalators cause nucleolar 
disruption by inhibiting rDNA transcription by RNA polymerase I (15). 
Based on our nucleolar disruption screen, we hypothesized that CID-
765471 could cause nucleolar disruption in association with inhibition 
of rDNA transcription. Northern blot analysis of rRNA from U2OS 
cells treated with ActD or CID-765471 revealed that both drugs dramat-
ically reduced the levels of the longest rRNA intermediate (45S) and its 
smaller derivatives (Figure 3A). These results were confirmed by quan-
titative real-time PCR amplification of the internally transcribed spacer 
1 (ITS1) present in 45S and in many of its derivatives (Figure 3B). Of 
note, no effect was observed on the levels of 5S rRNA (transcribed by 
RNA polymerase III), neither on the mRNA levels of three important 
regulators of ribosome biogenesis (transcribed by RNA polymerase II), 
namely, UBF, nucleolin and NPM1 (Supplementary Figure 3, available 
at Carcinogenesis online). Additionally, the inhibition of RNA polymer-
ase I-mediated rDNA transcription by ActD and CID-765471 does not 
appear to be secondary to p53 because activation of p53 with nutlin-3 
(N3) did not affect ITS1-containing transcripts (Figure 3B). Moreover, 
immunofluorescence of fibrillarin, which localizes in the dense fibrillar 
center in normal conditions, revealed that treatment with CID-765471 
provokes its segregation to nucleolar caps (Figure 3C), which is a hall-
mark of rDNA transcriptional inhibition (24).
While this work was in preparation, another non-genotoxic acridine 
derivative, BMH-21, was reported to produce nucleolar disruption and 
to inhibit RNA polymerase I in a process that includes the degradation 
of RPA194, an essential and specific subunit of the RNA polymer-
ase I (28). Of note, nucleolar disruption by ActD is not accompanied 
by the degradation of RPA194 (28). In agreement with the above, 
RPA194 protein levels were remarkably diminished following treat-
ment with CID-765471, but not with ActD (Figure 3D). As a control, 
the levels of RPA135, which strongly interacts with RPA194 (29), 
remained stable (Figure 3D). Collectively, these findings support the 
notion that the primary effect of CID-765471 is to inhibit RNA poly-
merase I-mediated rDNA transcription.
CID-765471 induces p53-dependent transcription
To investigate whether CID-765471 initiates a p53-dependent tran-
scriptional program, we tested the effects of this compound on well-
established p53 transcriptional targets. Treatment with CID-765471 
and ActD strongly increased p21 mRNA levels in WT, but not in 
p53KO, HCT116 cells (Figure 4A). A similar trend was observed for 
p53-transcriptional targets HDM2, GADD45A and BAX (Figure 4A). 
No changes were observed in the levels of p53 mRNA (data not 
shown). In agreement with the above, protein levels of p21 and 
HDM2 were also significantly increased after treatment with ActD or 
CID-765471 in a p53-dependent manner (Figure 4B).
To explore the cellular consequences of CID-765471-mediated p53 
activation, we analysed the cell cycle profiles of cells treated with this 
compound. We observed that ActD and CID-765471 significantly 
decreased the percentage of HCT116-WT cells in S-phase, but had 
not effect on HCT116-p53KO cells (Figure  4C and Supplementary 
Figure 4A, available at Carcinogenesis online). The analysis of the 
proliferation rates of both U2OS and HCT116 cell lines confirmed 
that CID-765471 impairs cell proliferation and it is more effec-
tive in p53-proficient cells (Supplementary Figure  4B, available at 
Carcinogenesis online). Apoptosis was measured by cell cytometry of 
alive cells (DAPI-negative) that have lost plasma membrane phospho-
lipid asymmetry (AnnexinV-positive) or that have lost mitochondiral 
function (TMRE-negative). After prolonged exposure of cells to CID-
765471 (4  days), apoptosis was more pronounced in HCT116-WT 
compared to HCT116-p53KO cells (Figure 4D). Cell death was con-
firmed by live imaging using TO-PRO-3 iodide as a dead cell indica-
tor (Supplementary Figure 4B, available at Carcinogenesis online). It 
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should be pointed out that nucleolar disruption is incompatible with 
cell proliferation regardless of the status of p53, but proliferation arrest 
and cell death are remarkably faster in the presence of functional p53 
(see for example [30]). Together, we conclude that inhibition of ribo-
some biogenesis by CID-765471 activates a full p53 response.
CID-765471 activates p53 through binding of RPL11 to HDM2
Nucleolar stress causes the accumulation of the preribosomal complex 
RPL11/RPL5/5SrRNA that binds to HDM2, causing its inhibition and 
resulting in the stabilization of p53 (3–5). Based on this, we wondered 
whether the activation of p53 by CID-765471 is mediated by RPL11. For 
this, we interfered U2OS cells with a siRNA against the ribosomal protein 
L11 (siRPL11) that was able to reduce RPL11 protein levels by about 50%. 
Interestingly, RPL11 knockdown abolished the accumulation of p53 after 
treatment with ActD or CID-765471, and it also decreased the accumula-
tion of p21 and HDM2 (Figure 5A). Similar results were obtained with a 
lentiviral construct expressing an shRNA targeting a different sequence of 
the RPL11 mRNA (Supplementary Figure 5A, available at Carcinogenesis 
online). Inhibition of RPL11 also protected cells from cell-cycle arrest 
upon treatment with ActD or CID-765471 (Figure 5B and Supplementary 
Figure 5B, available at Carcinogenesis online). Finally, imunoprecipitation 
of RPL11 revealed increased binding to HDM2 after treatment with 10 µM 
CID-765471, consistent with the concept that CID-765471 triggers the 
RPL11-HDM2-p53 pathway (Figure 5C). Taken together we conclude that 
CID-765471 activates p53 through the RPL11/HDM2 pathway.
Identification of non-genotoxic p53-activating acridines approved 
for medical use
Based on the above and previous data on the ability of some acrid-
ine derivatives to activate p53 in a non-genotoxic manner (25–28), 
we considered of interest to identify acridine derivatives that have 
been approved for medical use and with capacity to activate p53 
without causing DNA damage. For this, we screened the Johns 
Hopkins Clinical Compound Library that comprises 1524 compounds 
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approved for medical use. The screening was performed using U2OS/
GFP-RPL37 cells in the same manner as before (see above Figure 1). 
We identified a total of six compounds in the primary screening, 
two of which were confirmed in a validation assay and, remarkably, 
these two compounds correspond to acridine derivatives aminacrine 
and ethacridine (Figure 6A). This finding reinforces once more the 
concept that acridine derivatives are potent nucleolar disruptors. We 
performed dose-response assays measuring nucleolar disruption (by 
nucleophosmin immunofluorescence dispersion) and cell viability in 
U2OS, HCT116-WT and HCT116-p53KO cells. For each acridine 
derivative, the obtained EC50 values were similar across the three 
cell lines; and, when compared, the three compounds had EC50s 
within a similar range although with a reproducible nucleolar dis-
ruption potency ranking of aminacrine>CID-765471>ethacridine 
(Supplementary Figure 6A, available at Carcinogenesis online). Cell 
viability assays confirmed the same potency ranking (Supplementary 
Figure 6B, available at Carcinogenesis online). Of note, cell viability 
inhibition was more pronounced in HCT116-WT than in U2OS cells, 
and HCT116-p53KO cells were less sensitive than HCT116-WT 
(Supplementary Figure 6B, available at Carcinogenesis online). As 
expected, aminacrine and, to a lesser extent, ethacridine were both 
efficient activators of p53 (Figure 6B) in the absence of detectable 
DNA damage (Figure  6C). Moreover, in agreement with previous 
observations with BMH-21 (28) and CID-765471 (see Figure 3D), 
both aminacrine and ethacridine efficiently induced the degradation of 
RPA194 (Figure 6D). Therefore, aminacrine and ethacridine are two 
medically-approved compounds that upregulate p53 in a non-geno-
toxic manner. These data also suggest that destruction of RPA194 is 
a hallmark of ribosomal RNA inhibition by non-genotoxic acridines.
Discussion
The identification of compounds that produce nucleolar disruption 
with minimal or no DNA damage is of interest because of their pos-
sible antitumoral activity without undesirable mutagenic effects. 
Acridine is a DNA intercalating agent that has given rise to a large 
family of derivatives. Some acridine derivatives carry reactive groups 
with potent genotoxic activity (31). Interestingly, there is an emerg-
ing group of acridine derivatives, including acridine itself and CID-
765471, that activate p53 in the absence of genotoxic activity (25–28) 
(see also Figure 2). However, the mechanism by which these com-
pounds activate p53 had remained unexplored. Here, we show that 
CID-765471 inhibits ribosomal DNA transcription and this results in 
activation of p53 through the HDM2 inhibitor RPL11. Moreover, we 
have found two acridine derivatives approved for medical use, namely 
aminacrine and ethacridine, that also produce nucleolar disruption 
and non-genotoxic activation of p53.
Our current findings on CID-765471 are in-line with the recent 
identification of CX-5461 (32). This novel acridine-unrelated com-
pound inhibits rDNA transcription, produces nucleolar disruption, 
does not produce genotoxic damage and activates p53 through the 
RPL11 ribosomal stress pathway (32). Therefore, CID-765471 and 
possibly other acridines share with CX-5461 a similar mechanism of 
activation of p53.
Recently, it has been reported that another acridine derivative, 
BMH-21, inhibits ribosomal DNA transcription through a mecha-
nism that includes the degradation of the RNA polymerase subunit 
RPA194 (28). Notably, this feature is not common to other inhibitors 
of ribosomal transcription, such as ActD (28). We have found that 
CID-765471, aminacrine and ethacridine induce the degradation of 
RPA194. Therefore, RPA194 destruction could be a distinctive fea-
ture of nucleolar disruption by non-genotoxic acridines.
In summary, we identify the ribosomal stress pathway as the mech-
anism by which compound CID-765471 activates p53 in a non-geno-
toxic manner. We also identify two acridine derivatives approved for 
medical use, aminacrine and ethacridine, with similar effects as CID-
765471. The clarification of the mechanism of action of CID-765471 
on p53 sets the bases for further studies on the possible chemothera-
peutic value of non-genotoxic acridine derivatives.
Supplementary material
Supplementary Figures 1–7 can be found at http://carcin.oxfordjour-
nals.org/
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Supplementary Figure 1 
A. Immunofluorescence of fibrillarin in U2OS/GFP-RPL37 cells. In control cells 
(DMSO), fibrillarin marks the dense fibrillar component of nucleoli. After 
treatment with ActD (5 nM), for 4.5 h, fibrillarin segregates to nucleolar caps and 
GFP-RPL37 concentrates in the central body of the nucleolus. In the merged image, 
green corresponds to GFP-RPL37 and red corresponds to fibrillarin (see also 
magnification). 
B. Immunofluorescence of nucleophosmin (NPM) in U2OS/GFP-RPL37 cells. In 
control cells (DMSO), NPM marks the granular component of nucleoli. After 
treatment with ActD (5 nM), for 4.5 h, NPM diffuses throughout the nucleoplasm 
and GFP-RPL37 concentrates in the central body of the nucleolus. In the merged 
image, green corresponds to GFP-RPL37 and red corresponds to NPM. 
C. Schematic explanation of the nucleolar disruption score. The Definiens Developer 
XD software identifies nucleoli and calculates their roundness. 
D. Individual nucleoli were classified as normal or disrupted, according to panel C, 
and their relative abundance is plotted over time upon treatment with ActD (5 nM).  
E. Dose-response curve for CNIO-15760 (CID-765471) and CNIO-47023 compounds 
in U2OS/GFP-RPL37 cells treated with the indicated concentrations, for 4.5 h. 
 
Supplementary Figure 2 
A. Immunofluorescence of p53 in U2OS/GFP-RPL37 cells treated for 72 h with the 
indicated compounds (ActD at 5 nM and CID-765471 at 5 µM). 
B. U2OS/GFP-RPL37 cells were treated for 6 h with the indicated compounds and 
concentrations. Levels of p53 were detected by immunofluorescence and quantified 
by a script using Acapella High Content Image Analysis software. Doxorubicin (1 
µM) is abbreviated as Doxo. 
C. Nucleolar disruption score calculated for U2OS/GFP-RPL37 cells treated with the 
indicated compounds and concentrations. This experiment was performed in 
duplicates in two different U2OS/GFP-RPL37 clones.  
 
Supplementary Figure 3 
Fold change of the mRNA levels of the indicated nucleolar processing factors measured 
by qRT-PCR, 24 h after treatment with the indicated compounds. All mRNA levels 
were normalized by the endogenous β-actin mRNA levels. Fold induction is relative to 
controls (DMSO treatment). Values correspond to the average ± SD of two independent 
assays (n=2). Statistical significance was calculated by the Student t-test: ** P≤ 0.01; * 
P≤ 0.05. 
 
Supplementary Figure 4 
A. Sub-G1, G0/G1, S, G2/M phases and polyploidy are shown for HCT116 (WT and 
p53KO) treated with the indicated compounds and concentrations for 24 h.  
B. Proliferation assay was carried out by staining with crystal violet at the indicated 
times. Cells were plated in triplicates.  
C. Live imaging was performed for 54.5 hours in U2OS/GFP-RPL37 cells treated with 
DMSO or CID-765471 (5 µM). Green marks nucleoli (GFP-RPL37) and red is the 
viability dye (To-Pro-3 iodide) (dead cells incorporate the dye). Representative 
frames are shown.  
 
Supplementary Figure 5 
A. U2OS/GFP-RPL37 cells were lentivirally transduced with an shRNA against 
RPL11 (different from the siRNA used in main Figure 5). Cells were puromycin-
selected for 4 days and cells were treated as indicated for 4 h. Protein levels were 
measured by immunoblotting.  
B. Sub-G1, G0/G1, S, G2/M phases and polyploidy are shown for U2OS interfered 
with siNT or siRPL11 treated with the indicated compounds and concentrations for 
24 h.  
 
Supplementary Figure 6 
A. EC50 values for nucleolar disruption of the indicated compounds in the three cell 
lines used in this study. Nucleolar disruption was measured in triplicates by 
immunofluorescence against nucleophosmin using a dedicated software (see 
Materials and Methods). 
B. Cell viability assays of the indicated compounds in the three cell lines used in this 
study. Cell viability was measured using the MTS method. The assay was 
performed once in quatriplicates. Values correspond to the average and standard 
deviation (n=4 technical replicates). 
 
Supplementary Figure 7 
Uncropped blots of bands shown in the main figures and supplementary figure 5. 
Membranes were sliced to incubate upper and bottom parts with different antibodies. 
Links to antibodies datasheets, where articles in which antibodies have been 
successfully used, are as follows: anti-p53 DO-1 SCBT (http://datasheets.scbt.com/sc-
126.pdf), anti-p21 C-19 SCBT (http://datasheets.scbt.com/sc-397.pdf), anti-HDM2 
SMP14 SCBT (http://datasheets.scbt.com/sc-965.pdf), anti-RPL11 Proteintech 
(http://www.ptglab.com/Products/RPL11-Antibody-16277-1-AP.htm), anti-RPA194 H-
300 SCBT (http://datasheets.scbt.com/sc-28714.pdf), anti-RPA135 H-15 SCBT 
(http://datasheets.scbt.com/sc-17914.pdf), anti-NPM1 7H10B9 NOVUS Biologicals 
(http://www.novusbio.com/Nucleophosmin-Antibody-7H10B9_NBP1-47354.html), and 
anti-β-actin AC-15 SIGMA (http://www.sigmaaldrich.com/content/dam/sigma-
aldrich/docs/Sigma/Datasheet/6/a5441dat.pdf).  
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SUPPLEMENTARY MATERIALS AND METHODS 
 
Dose-response curves 
For the determination of the nucleolar disruption score in a dose-response curve, at least 
12-points of increasing concentrations of the indicated compounds were added for 4.5 
hours to two clones of U2OS/GFP-RPL37 cells previously plated in triplicates. 
GraphPad Prism 5 software was used to plot data to log(concentrations).   
 
Proliferation and viability assays 
U2OS and isogenic HCT116 cells (WT and p53KO) were seeded in triplicates at a 
density of 3,000 and 5,000 cells/well respectively in 96-well flat bottom tissue culture 
plates. Then, cells were fixed at the indicated days with 1% glutaraldeyde in PBS for 15 
min. at R.T., washed twice with PBS, and stained with 0.1% cristal violet in PBS for 30 
min. After removing excess of crystal violet and drying the plates, 10% acetic acid was 
added and the colorimetric signal was measured at an optical density of 590 nm. Values 
were normalized by day 0 (baseline).  
 
For cell viability, U2OS and isogenic HCT116 cells (WT and p53KO) were seeded in 
quadruplicates at a density of 2,500 and 2,000 cells/well respectively in 96-well flat 
bottom tissue culture plates. Then, MTS was added to the cells and, after incubation for 
1 hour at 37 ºC 5% CO2, absorbance at 490 nm was measured. Values were normalized 
by day 0 (baseline).  
 
Time-lapse videomicroscopy 
U2OS/GFP-RPL37 cells were seeded 2 days before of time-lapse analysis at a density 
of 7,500 cells/well in chamber slides (Lab-Tek II) and maintained in tissue culture in a 
humidified incubator at 37 ºC and 5% CO2. DeltaVision Live-cell microscope was set 
up to maintain the same temperature and CO2 conditions than in tissue culture. To-Pro-
3 iodide (Life Technologies) was added to the media culture at the beginning of the 
experiment at a final concentration of 1 µM. Images from 10 different positions in each 
well were acquired every 6 min. by using the fluorescence FITC and Cy5 channels. Z 
position was defined as the best focus for each fluorescence channel. After 1 hour of 
live imaging, DMSO or CID-765471 were added at 2X, containing To-Pro-3 iodide, by 
a syringe-system connected to the chambers. Final concentration of CID-765471 was 5 
µM. Live imaging continued for additional 53.5 hours adjusting focus every day. 
Analysis was performed with FIJI software. !
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MANUSCRIPT III 
 
Partial loss of Rpl11 in adult mice recapitulates Diamond-Blackfan anemia and promotes 
lymphomagenesis 
Lucia Morgado-Palacin, Gianluca Varetti, Susana Llanos, Gonzalo Gómez-López, Dolores 
Martinez and Manuel Serrano 
Cell Reports 13:4, 712-722; October 27, 2015 
 
Objetivo: ESTUDIO DE LA DEFICIENCIA DE Rpl11 EN ERITROPOYESIS Y 
CANCER. UN MODELO DE ANEMIA DE DIAMOND-BLACKFAN (DBA)  
 
La proteína ribosomal L11 (RPL11, de sus siglas en inglés) es una de las proteínas 
ribosomales más extensamente estudiadas. Además de ser parte de la subunidad mayor del ribosoma, 
RPL11 activa p53 en respuesta a estrés ribosomal o nucleolar. El interés en RPL11 ha aumentado 
notablemente en los últimos años al describirse mutaciones en heterozigosis que comprometen la 
función de dicha proteína en pacientes de anemia de Diamond-Blackfan (DBA, de sus siglas en 
inglés). Los pacientes de DBA presentan anemia severa y una mayor predisposición al cáncer, entre 
otros síntomas.  
 
Hasta ahora, sólo se ha descrito in vivo en el modelo animal zebrafish que la deficiencia de 
RPL11 recapitula parte de la patogénesis de DBA. Sin embargo, no existen modelos de ratón 
deficientes en RPL11 y aún quedan muchas preguntas abiertas en relación a los mecanismos 
moleculares que gobiernan esta enfermedad, especialmente aquellos relacionados con la 
predisposición al cáncer. En este trabajo, hemos generado y caracterizado un modelo inducible de 
ratón deficiente para RPL11. Hemos descrito que la pérdida constitutiva de un alelo de Rpl11 es 
incompatible con el desarrollo embrionario, al igual que la deleción de ambos alelos en el ratón adulto. 
Cuando se produce en el ratón adulto, la eliminación de ambos alelos de Rpl11 provoca atrofia 
intestinal y aplasia en la médula ósea. La pérdida de un alelo de Rpl11 en ratones adultos recapitula 
gran parte de la sintomatología observada en los pacientes de DBA. Los ratones adultos RPL11 
heterozigotos presentan anemia macrocítica debida a una disminución en progenitores eritroides y a 
una diferenciación eritropoyética defectuosa. Los eritroblastos de estos ratones tienen niveles elevados 
de los ARN mensajeros de p21 y Bax, un inhibidor del ciclo celular y un gen implicado en apoptosis, 
respectivamente. Además, hemos observado una reducción en los niveles de ARN mensajero de genes 
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implicados en desarrollo y función de los eritrocitos, como Uros o Gypa. También, hemos detectado 
que el procesamiento del ARN ribosomal es anormal en los fibroblastos y tejidos de estos animales. Es 
destacable que los ratones adultos desarrollan linfomas de timo con mayor celeridad ante un protocolo 
de radiación ionizante. Nuestros resultados indican que esta mayor predisposición al cáncer en los 
ratones RPL11 heterozigotos puede atribuirse, al menos en parte, a dos mecanismos no excluyentes, 1) 
una deficiente activación de p53 en respuesta a estrés ribosomal, tal y como hemos observado en 
fibroblastos de estos ratones, y 2) unos mayores niveles de la oncoproteína c-MYC en fibroblastos y 
tejidos hematopoyéticos de los ratones RPL11 heterozigotos. Dichos hallazgos proporcionan una 
evidencia molecular para explicar la elevada propensión a lcáncer pacientes de DBA con mutaciones 
en RPL11. 
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SUMMARY
Diamond-Blackfan anemia (DBA) is characterized by
anemia and cancer susceptibility and is caused by
mutations in ribosomal genes, including RPL11.
Here, we report that Rpl11-heterozygous mouse em-
bryos are not viable and that Rpl11 homozygous
deletion in adult mice results in death within a few
weeks, accompanied by bonemarrow aplasia and in-
testinal atrophy. Importantly, Rpl11 heterozygous
deletion in adult mice results in anemia associated
with decreased erythroid progenitors and defective
erythroid maturation. These defects are also present
in mice transplanted with inducible heterozygous
Rpl11 bone marrow and, therefore, are intrinsic to
the hematopoietic system. Additionally, heterozy-
gous Rpl11 mice present increased susceptibility to
radiation-induced lymphomagenesis. In this regard,
total or partial deletion of Rpl11 compromises p53
activation upon ribosomal stress or DNA damage in
fibroblasts. Moreover, fibroblasts and hematopoietic
tissues from heterozygous Rpl11 mice present
higher basal cMYC levels. We conclude that Rpl11-
deficient mice recapitulate DBA disorder, including
cancer predisposition.
INTRODUCTION
The ribosomal protein L11 (RPL11) is one the most relevant and
extensively studied ribosomal proteins. Interest in this protein
has notably increased during the last years because of its con-
nections with Diamond-Blackfan anemia (DBA) and with onco-
genic pathways. In particular, a subset of Diamond-Blackfan
anemia (DBA) patients carry loss-of-function haploid mutations
in the RPL11 gene (Boria et al., 2010; Cmejla et al., 2009; Gazda
et al., 2008; Quarello et al., 2010). Mutations in several other ribo-
somal proteins also produce DBA, being RPS19 the most
frequently mutated gene in DBA (Boria et al., 2010). DBA is a
congenital diseasemainly characterized by amoderate to severe
anemia and by increased susceptibility to cancer (Narla and
Ebert, 2010; Teng et al., 2013). A major feature of the red blood
cell aplasia in DBA patients is a reduction in erythroid progenitors
and impaired erythroid maturation (Miyake et al., 2008; Moniz
et al., 2012). In addition, mutations in RPL11 are associated
with characteristic thumb malformations (Gazda et al., 2008).
Beyond its function as part of the ribosome, ribosome-free
RPL11 activates p53 through the so-called ribosomal/nucleolar
stress pathway. Specifically, conditions that perturb ribosome
biogenesis, such as certain DNA damaging agents or cMYC
overexpression, result in ribosome-free RPL11, which binds to
and inhibits MDM2, thereby stabilizing p53 (Bhat et al., 2004;
Bursa!c et al., 2012; Donati et al., 2013; Lohrum et al., 2003; Ma-
cias et al., 2010; Zhang et al., 2003b). This pathway has received
additional support by the recent resolution of the 3D structure of
the RPL11/MDM2 complex (Zheng et al., 2015). Another
emerging role of ribosome-free RPL11 is to decrease the levels
and activity of cMYC. This has been reported to occur through
binding of RPL11 to the cMYC mRNA and recruitment of the
RISC complex (Challagundla et al., 2011) and also by direct bind-
ing of RPL11 to cMYC protein and competition with transcrip-
tional coactivators (Dai et al., 2007, 2010). Therefore, ribosome-
freeRPL11may bepart of a tumor suppressive response through
its combined ability to activate p53 and inhibit cMYC.
Work in zebrafish has demonstrated that inhibition of RPL11
recapitulates DBA anemia (Danilova et al., 2011; Zhang et al.,
2013). However, there are no mouse models of RPL11 defi-
ciency. Here, we have generated mice with an inducible Rpl11-
null allele, and we show that heterozygous loss of Rpl11 in adult
mice recapitulates DBA, including a higher predisposition to
cancer. We present evidence suggesting that impaired p53
activity and abnormally high levels of cMYC could underlie the
cancer susceptibility associated with Rpl11 deficiency.
RESULTS
Rpl11 Heterozygosity Cannot Sustain Embryonic
Development
To evaluate the impact of Rpl11 deficiency in vivo, we generated
a conditional knockout mouse model in which deletion of the
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Rpl11 gene can be controlled by theCre recombinase (Figure 1A;
Figures S1A–S1F). We first crossed Rpl11+/lox mice with a ubiq-
uitous Cre recombinase (Tg.pCAG-Cre) constitutively expressed
from early developmental stages (Sakai and Miyazaki, 1997).
However, we could not detect any Rpl11+/D pup in the offspring
of these animals (Figure 1B). Therefore, a single gene dose of
Rpl11 is not sufficient to support embryonic development.
Rpl11 Deficiency Impairs rRNA Processing and Cellular
Proliferation
To bypass the lethality of Rpl11+/D embryos, we combined the
Cre-excisable Rpl11 allele (Rpl11lox) with a ubiquitous tamox-
ifen-inducible Cre transgene (Tg.UbC-CreERT2 (Ruzankina
et al., 2007)). We isolated mouse embryonic fibroblasts (MEFs)
at E13.5 from embryos of the three relevant Rpl11 genotypes
(+/+, +/lox, lox/lox) carrying transgenic Cre in hemizygosity,
and treated them with 4-hydroxy-tamoxifen (4OHT). First, we
evaluated whether Cre activation in Rpl11+/lox and Rpl11lox/lox
cells resulted in a measurable reduction in RPL11 protein levels.
After 3 days of treatment with 4OHT, RPL11 was essentially un-
detectable in the nuclear fraction of 4OHT-Rpl11lox/lox cells, and
its levels were dramatically reduced in the cytoplasmic fraction
(Figure 1C). In the case of 4OHT-Rpl11+/lox cells, there was a par-
tial, but clear, reduction in RPL11 levels both in the nuclear and in
the cytoplasmic fractions (Figure 1C). RPL11 participates in the
maturation of rRNA precursors and, particularly, in the process-
ing of the 32S and 12S precursors into mature 28S and 5.8S
rRNAs, respectively (Gazda et al., 2008; Robledo et al., 2008;
Sloan et al., 2013). To assess the functional impact ofRpl11 defi-
ciency, wemeasured the levels of 32S and 12S rRNA precursors
by northern blotting. Of note, we observed a remarkable accu-
mulation of the 32S and 12S precursors in 4OHT-Rpl11lox/lox
cells (Figure 1D). Accumulation of these precursors was also
evident in 4OHT-Rpl11+/lox cells albeit at lower levels than in
4OHT-Rpl11lox/lox cells (Figure 1D). These observations were
paralleled by a severe reduction of proliferation in 4OHT-
Rpl11lox/lox cells and a partial reduction in 4OHT-Rpl11+/lox cells
(Figure 1E). Therefore, deletion of Rpl11 in cells impairs rRNA
processing and cell proliferation, being the effects severe upon
total Rpl11 deletion and moderate upon heterozygous deletion.
Deletion of Rpl11 in Adult Mice
To test the impact of RPL11 elimination in adult organisms, mice
of the three relevant genotypes (Rpl11+/+, Rpl11+/lox, and
Rpl11lox/lox, all carrying the Tg.UbC-CreERT2 transgene in hemi-
zygosity) were fed a tamoxifen (TAM) diet starting 1.5–2 months
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Figure 1. Diploid Rpl11 Is Required for
Embryo Development and Complete Loss
of Rpl11 Severely Compromises Cell
Proliferation
(A) Scheme of the wt (+), lox, and delta (D) Rpl11
alleles. Upon Cre recombinase activation, exons 3
and 4 of the Rpl11lox allele are excised resulting in
the Rpl11D allele where exon 2 is spliced out-of-
frame with exon 5.
(B) Observed and expected Mendelian ratios for
viable genotypes. The Cre recombinase used is
under a strong synthetic promoter (CAG), being
expressed constitutively and ubiquitously in the
organism from early developmental stages.
(C) Immunoblot analysis of RPL11 protein levels in
cytosolic (C) and nuclear (N) fractions from
immortalized MEFs of the indicated genotypes,
bearing the Tg.hUbC-CreERT2 transgene, in the
absence or presence of 4OHT for 72 hr. GAPDH
and LAMIN A/C were used as cytosolic and nuclear
markers, respectively. Similar results were ob-
tained with two additional clones per genotype.
(D) Northern blot analysis of 32S and 12S rRNA
precursors in immortalized MEFs as in (C). A probe
specific for the ITS2 region was used to detect
rRNA intermediates. The mature 28S and 18S
forms were visualized by ethidium bromide stain-
ing. Similar results were obtained with two addi-
tional clones per genotype.
(E) Quantification of EdU-labeled cells in Rpl11+/+,
Rpl11+/lox, and Rpl11lox/lox primary MEFs, bearing
the Tg.hUbC-CreERT2 transgene, grown in the
absence or presence of 4OHT for 72 hr. For each
genotype, the percentage of EdU+ cells was
normalized to the untreated cells (set as 100%).
Data correspond to the average ±SDof two to three
independent MEF clones per genotype. Statistical t
test analysis was performed to calculate signifi-
cance (*p < 0.05, **p < 0.01). See also Figure S1.
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of age. Deletion of the Rpl11lox allele was detected in the
genomic DNA of the tail (Figure S2). More importantly, Rpl11
mRNA levels were markedly reduced in TAM-Rpl11lox/lox mice
(remaining levels in the range of 5%–30% depending on the tis-
sue) and partially reduced in TAM-Rpl11+/lox mice (remaining
levels in the range of 60%–75%) (Figure 2A). Of relevance,
Rpl11 reduction had a detectable impact on the maturation of
rRNA as reflected by a clear accumulation of 32S and 12S
rRNA precursors in the spleen of Rpl11+/lox and Rpl11lox/lox
mice after 1 week of TAM treatment (Figure 2B). Therefore,
mice carrying the inducible Rpl11lox allele constitute a suitable
model for the analysis of the in vivo effects of RPL11 deficiency
in a mammalian organism.
Adult Homozygous Deletion of Rpl11 Is Lethal
Treatment of mice with TAM starting at 1.5 months of age re-
sulted to be lethal in the case of Rpl11lox/lox mice with no animals
surviving beyond 8 weeks of TAM treatment (Figure 2C). Upon
extensive histological analyses, the most obvious defects in
these mice consisted in intestinal atrophy (which probably
caused malnutrition) and bone marrow aplasia (Figures 2D and
2E). This suggests that highly proliferative tissues are the first
to manifest defects upon severe reduction of RPL11. At the
time of death, TAM-Rpl11lox/lox mice presented signs of devel-
oping anemia, including a pronounced decrease in bonemarrow
(BM) erythroblasts, as measured by nucleated TER119+ cells
(Figure 2F), and a noticeable accumulation of hemosiderin in
the spleen and iron in the liver, both consistent with defective
erythropoiesis (Figure 2G). Therefore, complete loss of Rpl11 is
lethal in adult mice, probably due to intestinal atrophy, and it is
accompanied by erythropoietic defects.
Adult HeterozygousDeletion ofRpl11Results in Chronic
Anemia
Continuous TAM treatment of Rpl11+/lox mice did not compro-
mise viability, at least during the first year of life (Figure 2C).
DBA patients typically present macrocytic anemia (Ruggero
and Shimamura, 2014), consisting in reduced red blood cell
(RBC) counts with increased cellular size (mean corpuscular vol-
ume or MCV). Considering the involvement of human RPL11
Figure 2. Adult Homozygous Deletion of
Rpl11 Is Lethal and Is Associated with Intes-
tinal Atrophy and Bone Marrow Aplasia
(A) Rpl11 mRNA levels measured by qRT-PCR in
different tissues of TAM-mice of the indicated
genotypes. Data correspond to +/+ or +/lox
treated with TAM for 8 weeks (n = 4–5) or lox/lox
treated with TAM for 1 week (n = 2). b-actin
mRNA levels were used as an endogenous
control.
(B) Northern blot analysis of 32S and 12S rRNA
precursors in spleens of two animals of each
genotype fed with TAM for 1 week. A probe
specific for the ITS2 region was used to detect
rRNA intermediates. The mature 28S and 18S
forms were visualized by ethidium bromide
staining.
(C) Kaplan-Meyer survival curve for TAM-treated
Rpl11+/+, Rpl11+/lox, and Rpl11lox/lox animals. Log-
rank (Mantel-Cox) test was performed to calcu-
late significance of Rpl11lox/lox relative to the two
other groups of mice (**p % 0.01).
(D) Representative histological sections of intes-
tine stained with H&E from TAM-Rpl11+/+ and
TAM-Rpl11lox/lox animals after 1 week of treat-
ment. A total of three animals per genotype were
analyzed. Scale bars, 200 mm.
(E) Representative histological sections of bone
marrow stained with H&E. A total of two animals
per genotype were analyzed. Scale bars, 100 mm.
(F) Representative histological sections of bone
marrow stained with TER119. A total of two ani-
mals per genotype were analyzed. Scale bars,
100 and 25 mm in the top and bottom images,
respectively.
(G) Representative histological sections of spleen
(left) and liver (right) from TAM-Rpl11lox/lox animals
showing accumulation of hemosiderin (spleen)
and iron aggregates (Perls’ Prussian blue staining
in liver).
Scale bars, 100 and 25 mm in the images and zoom, respectively, in the spleen sections, and 25 mm in the liver sections. In (A), values correspond to the
average ± SD. Statistical t test analysis was performed to calculate significance (*p% 0.05; **p% 0.01; ***p% 0.005). For (C), see legend. See also Figure S2.
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heterozygous mutations in DBA, we examined TAM-Rpl11+/lox
mice for signs of anemia. Interestingly, TAM-Rpl11+/lox mice
had lower RBC levels and macrocytosis compared to TAM-
Rpl11+/+ animals, being these effects more pronounced as ani-
mals aged (Figure 3A; Figure S3A). Histological examination of
the BM indicated a significant decrease in the number of eryth-
roblasts, as measured by nucleated TER119+ cells (Figure 3B).
In support of this, the total mRNA levels of genes involved in
erythrocyte function (Epor, Hbb-h1, Trfc, Alas2, and Ireb2)
were all decreased in TAM-Rpl11+/lox BM (Figure S3B). Further-
more, we observed higher levels of erythropoietin (Epo) mRNA
levels in the kidney, which is indicative of a compensatory
response to stimulate eythropoiesis (Figure 3C). Despite the pro-
nounced decrease in erythroblasts, the BM of TAM-Rpl11+/lox
mice was histologically normocellular (Figure S3C) and had
normal ratios of hematopoietic stem cells (HSCs, Lin-Sca+cKit+)
and progenitor cells (Figure S3D). Also, the sub-populations of
thymic T cells and splenic B cells were all normal in TAM-
Rpl11+/lox mice (data not shown). We conclude that partial loss
of Rpl11 produces a non-lethal anemia as a result of reduced
erythropoiesis.
Direct Involvement of Rpl11 in Erythropoiesis
To test if the BM precursors of TAM-Rpl11+/lox mice had a cell-
autonomous defect in erythropoiesis, we first tested the capacity
of BM cells to form in vitro burst-forming units-erythroid progen-
itors (BFU-E). We observed a tendency toward decreased
BFU-E in the TAM-Rpl11+/lox BM (Figure S4A). To demonstrate
that RPL11 plays a cell-autonomous role in in vivo erythropoi-
esis, we transplanted BM from Rpl11+/+ and Rpl11+/lox donor
mice, both carrying the CreERT2 transgene, into irradiated
SCID mice. Transplanted mice acquired a normal profile of
mature T cells in the thymus, which was in contrast to non-trans-
planted SCID mice, thereby demonstrating successful BM
reconstitution (data not shown). BM-transplanted (BMT) SCID
mice were treated with continuous TAM diet, and we confirmed
the presence of the excised Rpl11lox allele (Rpl11D) in the BM
(Figure S4B). We refer to these transplanted mice and their
controls as TAM-BMT-Rpl11+/lox and TAM-BMT-Rpl11+/+
mice, respectively. Interestingly, RBC and hemoglobin levels
decreased over time in TAM-BMT-Rpl11+/lox animals compared
to TAM-Rpl11+/+ BMT controls (Figure 4A). Remarkably, histo-
logical analysis of the BM indicated a severe decrease in eryth-
roblasts (Figure 4B). Accordingly, TAM-BMT-Rpl11+/lox animals
showed visible signs of weakness and paleness (Figure S4C).
These observations indicate that RPL11 plays an important
and cell-autonomous role in erythropoiesis.
Rpl11 Is Involved in Erythroid Maturation
Having demonstrated that Rpl11 heterozygosity reduces the to-
tal number of erythroblasts, we wondered whether it also
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Figure 3. Rpl11 Deficiency in Adult Mice Leads to Anemia and
Reduction of Erythroid Progenitors
(A) Red blood cell (RBC) values for Rpl11+/+ and Rpl11+/lox mice in TAM diet.
Mice were fed TAM diet at 6 weeks of age. Data correspond to the average ±
SD of six (Rpl11+/+) or seven (Rpl11+/lox) animals. Statistical t test analysis
was performed per time point to calculate significance. Differences between
genotypes were significant (*p % 0.05 or **p % 0.01) starting from 12 weeks
of TAM treatment and beyond.
(B) Representative images of TER119-stained histological sections of
bone marrows from mice that were TAM-treated during 8 (upper panel) or 20
(bottom panel) weeks. Zoom in pictures shows nucleated TER119+ cells. Scale
bars, 100 and 25 mm in the images and zoom in pictures, respectively.
Quantification of the positive area for nucleated cells expressing TER119 is
shown. Data correspond to 8 weeks (n = 3 independent mice per genotype) or
20 weeks (n = 4) of TAM treatment.
(C) Erythropoietin (Epo) mRNA levels measured by qRT-PCR in kidneys from
TAM-treated animals. Data correspond to the same mice as in (B). b-actin
mRNA levels are used as an endogenous control.
Values correspond to the average ± SD. Statistical t test analysis was per-
formed to calculate significance (*p% 0.05; **p % 0.01). For (A), see legend.
See also Figure S3.
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impinges on erythroid maturation. Erythroid maturation can be
divided in five stages (RI to RV) based on the patterns of
TER119 signal (low or high) and CD71 signal (low, medium, or
high) measured by fluorescence-activated flow cytometry
(FACS) (Zhang et al., 2003a). We monitored erythroid matura-
tion in the BM of transplanted animals (TAM-BMT-Rpl11+/+
and TAM-BMT-Rpl11+/lox). Interestingly, we detected a signifi-
cant relative increase in the percentage of RI cells (primitive
progenitors and proerythroblasts) together with a decrease in
the more matured stages (RIII, RIV, and RV) (Figure 4C). Similar
findings were made in the BM of whole-body TAM-Rpl11+/lox
adult mice (Figure S4D), and in Rpl11+/lox fetal livers of TAM-
pregnant mothers (Figure S4E). The fact that fetal livers (which
are very active in erythropoiesis) manifest defective erythropoi-
esis prompted us to isolate erythroid progenitors and measure
proliferation by FACS (using 5-ethynyl-2’-deoxyuridine [EdU]
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Figure 4. Intrinsic Hematopoietic Role of
RPL11 in Anemia
(A) RBC and hemoglobin values from TAM-BMT-
Rpl11+/+ and TAM-BMT-Rpl11+/lox animals are
shown along weeks in TAM diet. Data correspond
to ten to 15 (Rpl11+/+) or ten to 16 (Rpl11+/lox) TAM-
BMT animals, coming from four different donors
for each genotype.
(B) Representative images of histological sections
of bone marrows from TAM-BMT-Rpl11+/+ and
TAM-BMT-Rpl11+/lox animals stained with H&E
(upper) or with an antibody against TER119 (bot-
tom).Scale bars, 400and200mmin the left and right
images, respectively, for each genotype. Quantifi-
cation of the positive area for nucleated cells ex-
pressing TER119 is shown. Data correspond to
eight BM-transplanted animals per genotype
(coming from two BM donors, for each genotype).
(C) Quantification by flow cytometry of the per-
centage of erythroid cells from BMs of TAM-BMT-
Rpl11+/+ and TAM-BMT-Rpl11+/lox animals in the
different stages of erythroid maturation. Regions
are defined based on the expression pattern of
CD71 and TER119 markers. Data correspond to
eight BM-transplanted animals per genotype
(coming from two BM donors, for each genotype).
(D) Cell cycle analysis by flow cytometry after EdU
incorporation and Hoechst staining of total fetal
livers from Rpl11+/+ and Rpl11+/lox embryos (E14.5)
after daily injection of 4OHT in pregnant females
from E11.5 to E13.5.
(E) mRNA levels of Cdkn1a and Bax genes in the
different populations of erythroid progenitors from
Rpl11+/+ and Rpl11+/lox fetal livers, as in (D). mRNA
levels are normalized to b-actin levels.
Values correspond to the average ±SD. Statistical t
test analysis was performed to calculate signifi-
cance (*p % 0.05; **p % 0.01; ***p % 0.005). See
also Figure S4.
incorporation and Hoechst staining).
Interestingly, as it was the case of fibro-
blasts (see Figure 1E), fetal liver cells
also showed evidence of lower prolifera-
tion (significant increase in cells at G1,
and tendency to decrease cells in S) (Figure 4D). Stage RIII
erythroid precursors are the most abundant in fetal livers at
E14.5 (see, for example, Figure S4E), and we also observed a
significant G1 increase in RIII erythroid progenitors from fetal
livers (Figure S4F). We wondered whether we could detect
changes in candidate genes that could account for the impaired
erythropoiesis. In particular, we focused on the cell-cycle inhib-
itor Cdkn1a and on the pro-apoptotic factor Bax, which have
been previously found upregulated in human erythroid cells
and in zebrafish embryos with RPL11 deficiencies (Danilova
et al., 2011; Moniz et al., 2012). Interestingly, several popula-
tions of erythroid progenitors from Rpl11+/lox fetal livers pre-
sented a significant upregulation of Cdkn1a and Bax (Figure 4E).
We conclude that the partial loss of Rpl11 impairs erythroid
maturation, recapitulating the same cellular defects as in hu-
man DBA.
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Altered Transcriptional Profile Associated with Rpl11
Deficiency
To further understand the molecular consequences of Rpl11
deficiency, we performed an RNA-seq-based transcriptional
profiling of the BM hematopoietic progenitors (HPCs; Lin-
Sca1-cKIT+) in TAM-Rpl11+/lox mice and in their corresponding
TAM-Rpl11+/+ controls (n = 4 per genotype). Previous to this,
we confirmed that HPCs from TAM-Rpl11+/lox mice had lower
levels of Rpl11 mRNA than TAM-Rpl11+/+ control HPCs (Fig-
ure S5A). Analysis of the RNA sequencing (RNA-seq) data
revealed a number of differentially expressed genes (false dis-
covery rate [FDR] <0.15) (Figure 5A; Table S1). In agreement
with the impaired erythropoiesis observed in TAM-Rpl11+/lox
mice, genes related to erythrocyte development and function,
such as Uros, Gypa, Aqp1, Sphk1, Rhd, Cd82, Hebp1, and
Hba-a2, were among the genes significantly downregulated in
TAM-Rpl11+/lox HPCs (Figure 5A). By qRT-PCR, we confirmed
that some of these genes were downregulated inRpl11-deficient
HPCs (Figure 5B) but were unaffected in other tissues, such as
liver (Figure S5B). Other genes with diverse functions, such as
cathepsin E (Ctse), which promotes proteolysis, or claudin 13
(Cldn13), which has a structural function, were also downregu-
lated in Rpl11+/lox HPCs (Figures 5A and 5B). A description of
other downregulated genes is shown in Table S1. Regarding
the genes upregulated in TAM-Rpl11+/lox HPCs, we validated
the cyclin-dependent kinase inhibitor p21 (Cdkn1a) and a gene
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Figure 5. Impact of Rpl11 Deficiency on the Transcriptional Profile of Bone Marrow Hematopoietic Progenitors
(A) Heatmap displaying differentially expressed genes (DEGs with FDR <0.15) as estimated by RNA-seq from Rpl11+/+ and Rpl11+/lox hematopoietic progenitor
cells (Lin-Sca1-cKIT+) of TAM-treated animals (n = 4 animals per genotype; 20 weeks of TAM treatment). Gene symbols are shown and relative expression
(log2FC) is scaled in color code (indicated), from dark blue (!3) to dark red (3).
(B) Validation by qRT-PCR of some DEGs found in (A). Fold change over Rpl11+/+ is shown for each gene. Data correspond to the average ± SD of three to four
animals per genotype. Statistical t test analysis was performed to calculate significance (*p% 0.05; **p% 0.01).
(C) Enrichment plots for gene sets related to eukaryotic translation, DNA replication/cell cycle, and DNA repair pathways.
(D) Enrichment plots for gene sets related to MYC, MYB, and TGF-b.
In all the enrichment plots,Rpl11+/lox samples are located to the left. FDR and the number of genes per gene set (n) are indicated in each enrichment plot. See also
Figure S5 and Tables S1 and S2.
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(9030617O03Rik) of unknown function (Figures 5A and 5B). Gene
set enrichment analysis (FDR <0.25) showed that several
transcriptional gene sets related to eukaryotic translation
(including the gene set ‘‘Ribosome’’) were downregulated in
TAM-Rpl11+/lox HPCs (Figure 5C; Table S2). A high number of
gene sets involved in DNA replication/cell cycle and DNA repair
were also downregulated (Figure 5C; Table S2). We found partic-
ularly interesting that potentially oncogenic pathways were upre-
gulated, such as MYC and MYB transcription networks and
transforming growth factor b (TGF-b) signaling pathway (Fig-
ure 5D; Table S2). Remarkably, a very recent report has showed
upregulation of the TGF-b signaling pathway in induced pluripo-
tent stem cells derived from DBA patients with mutations in
RPS19 or RPL15 (Ge et al., 2015).
Partial Loss of Rpl11 Favors Lymphomagenesis
Patients with ribosomopathies, including those with DBA, are
prone to develop cancer, often of hematological origin, although
the mechanisms involved are poorly understood (Narla and
Ebert, 2010; Teng et al., 2013). To address this issue, we tested
whether partial loss of Rpl11 predisposed mice to lymphoma-
genesis. We irradiated mice with a single dose of 5 Gy, and, after
1 week, we fed them with tamoxifen (abbreviated as gIR-TAM
mice). As expected from our above-described findings, gIR-
TAM-Rpl11+/lox mice developed anemia, as measured by the
red blood numbers and hemoglobin blood content (Figure S6A).
Remarkably, gIR-TAM-Rpl11+/lox mice died significantly earlier
than control TAM-Rpl11+/+ mice (Figure 6A). Upon necropsy,
gIR-TAM-Rpl11+/lox mice presented lymphomas, particularly in
the thymus, which in some cases occupied most of the thoracic
cavity (Figure 6B). These observations demonstrate that partial
loss of Rpl11 predisposes to lymphomagenesis.
Rpl11 Deficiency Affects p53 Response and cMYC
Levels
Based on previous literature, two conceivable and non-exclusive
mechanisms could explain the observed susceptibility to cancer
upon partial loss of Rpl11. In particular, ribosome-free RPL11
Figure 6. Rpl11 Deficiency Increases Sus-
ceptibility to Lymphomagenesis in g-Irradi-
ated Mice
(A) Kaplan-Meyer survival curve for g-irradiated
Rpl11+/+ and Rpl11+/lox mice fed TAM diet. Log-
rank (Mantel-Cox) test was performed to calculate
significance (*p% 0.05).
(B) Pictures of g-irradiated TAM-Rpl11+/lox mice
displaying thymic tumors.
(C) Immortalized Rpl11+/+, Rpl11+/lox, and
Rpl11lox/lox MEFs, all bearing the Tg.hUbC-
CreERT2 transgene, were treated with 4OHT for
3 days and then incubated with the following
drugs: ActD, for 6 hr, at the indicated concentra-
tions or 5 nM when not specified; CX5461, for
16 hr, at the indicated concentrations; or doxoru-
bicin, for 6 hr, at 0.5 mM. Levels of the indicated
proteins were measured by immunoblotting.
(D) Primary Rpl11+/+ and Rpl11lox/lox MEFs, all
carrying the Tg.hUbC-CreERT2 transgene, were
treated with 4OHT for the indicated times and
harvested for protein extraction. Levels of the
indicated proteins were measured by immuno-
blotting. The assay is representative of a total of
two assays with different MEF preparations.
(E) Representative histological sections stained for
cMYC from thymuses of Rpl11+/+ and Rpl11+/lox
mice (after 20 weeks of TAM diet). Scale bars, 100
(top images) and 50 (zoom in images) mm. Quan-
tification of cMYC-positive area is shown below.
Data correspond to the average ± SD of four in-
dependent animals per genotype. Statistical t test
analysis was performed to calculate significance
(*p% 0.05).
(F) Representative histological sections of bone
marrow stained for cMYC from TAM-BMT-
Rpl11+/+ and TAM-BMT-Rpl11+/lox mice.
Scale bars, 200 (top images) and 50 (zoom in im-
ages) mm. Pictures are representative of a total of
n = 4 per genotype. See also Figure S6.
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acts as a sensor of ribosome unbalance by activating p53 (Bhat
et al., 2004; Bursa!c et al., 2012; Donati et al., 2013; Horn and
Vousden, 2008; Lohrum et al., 2003; Zhang et al., 2003b) and
by inhibiting cMYC (Challagundla et al., 2011; Dai et al., 2007,
2010). To evaluate the p53 response to ribosomal stress, we
treated MEFs of the three relevant genotypes (all bearing the
Tg.UbC-CreERT2 transgene) with 4OHT for 3 days followed by
low doses of actinomycin D (ActD), which is a well-established
method to induce ribosomal stress (Burger et al., 2010). In addi-
tion to this, we used an RNA polymerase I inhibitor, CX5461,
which activates p53 in an RPL11-dependent manner and has
shown promising pre-clinical anti-tumoral activity (Bywater
et al., 2012; Drygin et al., 2011). Finally, we also tested the radio-
mimetic agent doxorubicin (Doxo), which in addition to DNA
damage also induces ribosomal stress (Burger et al., 2010; Lla-
nos and Serrano, 2010; Zhu et al., 2009). Importantly, the stabi-
lization of p53 in response to all these agents (ActD, CX5461,
Doxo) was severely impaired in 4OHT-Rpl11lox/lox cells, and it
was partially compromised in 4OHT-Rpl11+/lox cells (Figure 6C).
Regarding cMYC, previous investigators have reported that
downregulation of RPL11 in cultured cancer cells results in
increased levels of cMYC protein (Challagundla et al., 2011;
Dai et al., 2007, 2010). In this regard, we have observed above
that Rpl11 heterozygous HPCs present an upregulation of
MYC gene sets (see above Figure 5D). Based on this, we
wondered whether reduced gene dosage of Rpl11 could have
an impact on the levels of cMYC. First, we examined cMYC
levels in primary 4OHT-Rpl11+/+ and 4OHT-Rpl11lox/lox MEFs.
In support of the above-mentioned evidences, cMYC protein
levels were increased inRpl11lox/lox MEFs upon 4OHT treatment,
whereas cMYC levels remained unchanged in Rpl11+/+ MEFs
(Figure 6D). Also, immunohistochemical staining of cMYC
showed a clear and reproducible increase in cMYC levels in
the thymus of TAM-Rpl11+/lox mice compared to TAM-Rpl11+/+
controls (Figure 6E). Of note, we confirmed that TAM treatment
was effective in reducing (by 40%) the levels of Rpl11 mRNA in
the thymus (Figure S6B). Similar observations regarding cMYC
protein levels were made in the spleen of TAM-Rpl11+/lox mice
(Figure S6C) and in the BM of TAM-BMT-Rpl11+/lox transplanted
animals (Figure 6F). Therefore,Rpl11 deficiency, even in the form
of Rpl11 heterozygosity, compromises p53 function and in-
creases cMYC protein basal levels. These two pro-tumorigenic
effects could contribute, alone or combined, to the cancer sus-
ceptibility of Rpl11-deficient mice.
DISCUSSION
In this work, we have set to generate amousemodel of Diamond-
Blackfan anemia (DBA) based on the deficiency of the ribosomal
protein RPL11. A first remarkable observation is the fact that em-
bryonic heterozygous deletion of Rpl11 is lethal, implying that
diploid levels of RPL11 are required for embryonic development.
This is an unusually extremephenotype formicewith deficiencies
in ribosomal proteins (Caldarola et al., 2009), and we are only
aware of one other ribosomal gene, RpS6, that is embryonically
lethal in heterozygosity (Pani!c et al., 2006). Also, inducible com-
plete deletion of Rpl11 in adult mice was lethal within 8 weeks
post-deletion, probably due to intestinal atrophy, and it was
accompanied by bone marrow aplasia and erythropoietic de-
fects. This severe phenotype is not surprising given the essential
role of RPL11 in the formation and function of ribosomes. Human
DBA patients carry heterozygous loss-of-function mutations in
ribosomal genes (Boria et al., 2010; Cmejla et al., 2009; Gazda
et al., 2008; Quarello et al., 2010). For this reason, and consid-
ering the embryonic lethality of constitutively heterozygous
mice, we have focused our work on the effects of inducible het-
erozygous deletion of Rpl11 in adult mice.
A number of mousemodels of DBA and ribosomopathies have
been reported (McGowan and Mason, 2011; Narla and Ebert,
2010), but only a subset of them recapitulate the erythropoietic
defect characteristic of human DBA patients, namely, mice
with partial deficiencies of Rps19 (Devlin et al., 2010; Jaako
et al., 2011), Rps6 (Keel et al., 2012; McGowan et al., 2011), or
Rps14 (Barlow et al., 2010). Similar to these mouse models, we
show that inducible heterozygous deletion of Rpl11 produces a
non-lethal anemia characterized by a severe reduction of eryth-
roblasts in the bonemarrow. In addition, the erythroblasts of het-
erozygous Rpl11 mice present a maturation defect, which is
accompanied by upregulation of the cell-cycle inhibitor Cdkn1a
and the pro-apoptotic factor Bax. In relation to this, erythroid
progenitors from peripheral blood of RPL11-mutated human
DBA patients present a similar erythroid differentiation defect
with upregulation of CDKN1A (Moniz et al., 2012). In addition,
we have observed that a number of genes involved in erythrocyte
differentiation are downregulated in heterozygous Rpl11 he-
matopoietic progenitors. Together, these observations could
explain, at least in part, the reduced number of erythroblasts
and their defective maturation in Rpl11-deficient mice.
Besides the severe defect in erythropoiesis, heterozygous
Rpl11mice did not have other noticeable defects in the hemato-
poietic lineage, presenting normal levels of hematopoietic stem
cells and early progenitors, B cell subpopulations, and T cell sub-
populations. Despite the apparently normal production of non-
erythroid lineages, the analysis of the gene expression profile
of Rpl11 heterozygous hematopoietic progenitors showed an
upregulation of the cell-cycle inhibitor geneCdkn1a and downre-
gulation of a number of mitotic and cell-cycle gene sets.
Compared to other hematopoietic progenitors, erythroblasts
are highly proliferative, and this could render themmore suscep-
tible to a partial reduction in proliferation. Furthermore, normal
mice transplanted with inducible heterozygous Rpl11 bone
marrow also developed anemia and reduced number of erythro-
blasts upon induction of Rpl11 deletion. Together, these obser-
vations suggest that erythropoiesis critically relies on diploid
levels of RPL11. A similar situation is encountered in DBA pa-
tients, where haploid levels of a given ribosomal gene selectively
affect erythropoiesis (Narla and Ebert, 2010).
In addition toanemia,DBApatientsarealsocharacterizedbyan
increased susceptibility to cancer (Ruggero and Shimamura,
2014); however, tumor susceptibility in mouse models of DBA
has remained largely unexplored until now. We have observed
that heterozygous Rpl11 mice are highly susceptible to develop
radiation-induced lymphomas. This phenotype is apparently par-
adoxical given the fact that an impaired ribosome production
should limit cell growth and proliferation; however, it could reflect
the emerging extra-ribosomal functions of RPL11 in tumor
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suppression. In particular, ribosome-free RPL11 acts as a sensor
of ribosome unbalance by activating p53 (Bhat et al., 2004; Loh-
rumetal., 2003;Zhangetal., 2003b)andby inhibitingcMYC (Chal-
lagundla et al., 2011; Dai et al., 2007, 2010). In mouse embryo fi-
broblasts, we have observed that complete or partial deletion of
Rpl11 impairs the activation of p53 by ribosomal stress and by
DNAdamage.Also, fibroblasts, bonemarrow, spleen, and thymus
of heterozygous Rpl11 mice present increased basal levels of
cMYC protein. Therefore, both mechanisms, namely, impaired
p53 response and increased cMYC levels, can conceivably ac-
count for the observed tumor-prone phenotype of heterozygous
Rpl11mice. As a marginal note, the upregulation of cMYC could
also contribute to the impaired erythroid differentiationphenotype
(Acosta et al., 2008; Coppola and Cole, 1986; Geiler et al., 2014).
In summary, we have generated and characterized a mouse
model of DBA based on heterozygous deficiency of Rpl11.
These mice recapitulate the two main features of DBA, namely,
anemia and cancer susceptibility. In the case of anemia, we
have identified a defect in erythroid differentiation associated
with the upregulation ofCdkn1a andBax in erythroid progenitors.
Regarding tumor susceptibility, we present supporting data for
two non-exclusive mechanisms based on the known capacity
of ribosome-free RPL11 to activate p53 and inhibit cMYC. This
mouse model may help to further understand DBA and to test
possible therapeutic approaches.
EXPERIMENTAL PROCEDURES
Generation of a Conditional Rpl11 Knockout Mouse Model
A DNA construct with exons 3 and 4 of the Rpl11 gene flanked by loxP sites
and bearing a neomycin cassette (flanked by FRT sites) in intron 2 was gener-
ated by GeneBridges and electroporated in G4 embryonic stem (ES) cells
(C57BL/6Ncr3 129S6/SvEvTac) at the CNIO Transgenic Mice Unit. Recombi-
nant ES clones were selected by neomycin resistance and screened for inser-
tion of the construct in the 50 and 30 homology arms of the chromosome 4 by
Southern blot and long-range PCR, respectively. The presence of both loxP
sites was confirmed by PCR. One positive clone was aggregated with albino
ES cells (B6(Cg)-Tyrc-2J/J) and injected into pseudo-pregnant albino females.
A 100%male chimera was then mated with CD-1 females in order to check for
the germline transmission and establish the mouse colony. Mice bearing the
neomycin (Neo) resistance gene (Rpl11+/loxfrt) were viable and fertile and
crossed with B6 mice expressing a flipase recombinase (pCAG-Flpe) (Rodrı´-
guez et al., 2000), which recognizes the FRT sites and excises the Neo
cassette. Rpl11+/lox mice were mated with either constitutive (Tg.pCAG-Cre)
(Sakai and Miyazaki, 1997) or with inducible (Tg.hUbC-CreERT2) (Ruzankina
et al., 2007) Cre expressing mice (all in B6 background). The mice used for
this work are in a mixed background (81.25% B6: 6.25% 129Sv: 12.5%
CD1). All animals were maintained at the Spanish National Cancer Research
Centre (CNIO) under specific pathogen-free conditions, in agreement with
the recommendations of the Federation of European Laboratory Animal Sci-
ence Association (FELASA). Mice were fed a standard chow diet ad libitum.
When indicated, standard chow diet was replaced by tamoxifen diet (Teklad,
Harlan Laboratories) to induce activation of the CreERT2 transgene. All animal
procedures were evaluated and approved by the Ethical Committee of the
Carlos III Health Institute, Madrid, Spain (#54-2013-v2).
Cell Culture and Treatments
MEFs were isolated from embryos at day E13.5 and cultured in DMEM (Gibco)
supplemented with 10% fetal bovine serum (Gibco) and 100 U/ml penicillin-
streptomycin (Gibco) in a humidified atmosphere at 37!C, 5%CO2. For immor-
talization, cells were infected with a retroviral vector expressing T121, a
truncated form of the SV40 large T antigen (Sa´enz Robles et al., 1994) and
underwent antibiotic selection. Where indicated, cells were treated with
1 mM 4-hydroxytamoxifen (4OHT; Sigma H7904), actinomycin D (Sigma),
CX5461 (Selleckchem), or doxorubicin (Sigma).
Nuclear/Cytosolic Fractionation
Immortalized MEFs were harvested and nuclear and cytosolic fractions were
obtained by using the NE-PER Nuclear and Cytoplasmic Extraction Kit by
Thermo Scientific, following the manufacturer’s instructions.
Red Blood Cells and Hemoglobin Monitoring
Blood was obtained from submaxillary bleeding, and red blood cell counts,
mean corpuscular volume, (MCV) and hemoglobin levels were measured in
an Abacus Junior Vet Hematology Analyzer.
Bone Marrow Transplantation
Bone marrows (BMs) from animals 6–8 weeks old were isolated by flushing fe-
murs and tibias (RPMI medium supplemented with 15% fetal bovine serum
[FBS] and Pen/Strep) with a 25-G syringe, followed by disaggregation with a
21-G syringe and subsequent filtration through a 70-mm nylon mesh. Erythro-
cytes were lysed in ammonium chloride (STEMCELL Technologies) for 5min at
room temperature, neutralized with fresh medium, and counted. A total of 2.5–
5 millions of cells in Leibovitz medium were injected by tail vein in immunode-
ficient SCID recipient mice (CB17/Icr-Prkdcscid/Crl) of 10–12 weeks old. SCID
mice were irradiated with a single dose of 3.5 Gy the day before to BM
transplantation.
Isolation of Fetal Liver Cells
Pregnant females were intraperitoneally (i.p.) injected with 4OHT (Sigma,
H6278), 2 mg/day dissolved in corn oil, for 3 days before fetal livers collection
at E14.5. Fetal livers were disaggregated with a 25-G syringe in RPMI medium
(supplemented with 15% FBS and Pen/Strep) and passed through a 40-mm
nylon mesh. Erythrocytes were lysed in ammonium chloride (Stemcell Tech-
nologies) for 5 min at room temperature, and cells were counted and
processed for flow cytometry. For cell-cycle analysis, fetal liver cells were
incubated ex vivo with EdU (10 mM) for 30 min and then stained with the
anti-TER119 and anti-CD-71 antibodies for flow cytometry. EdU was labeled
through covalent binding to Alexa Fluor 647 azide using Click-iT chemistry
(Invitrogen) following manufacturer’s instructions. DNA was stained with
Hoechst. Quantification of the different cell-cycle phases was performed in
the total liver cells or in the various erythroid progenitor populations according
to TER119 and CD-71 stainings.
Flow Cytometry
Cells were isolated by flushing (BM) or disaggregating tissues (spleen and
thymus) followed by filtering through a nylonmesh and removal of erythrocytes
by ammonium chloride lysis. 2.5–5 million cells were then blocked in a solution
containing Fc block (CD16/CD32, BD Biosciences #553141) in a 1:400 dilution
and incubated with the following conjugated antibodies for 30min to 1 hr in ice
(spleen and thymus) or at room temperature (BM cells): mouse hematopoietic
lineage eF450 cocktail (eBioscience #88-7772-72), Sca-1-PerCP/Cy5.5 (eBio-
science #45-5981-80), cKIT-APC/H7 (BD Biosciences #560250), CD34-eF660
(eBioscience #50-0341-82), IL7R-AF488 (eBioscience #53-1271-82), FcgRIII/II
(CD16/32)-PE/Cy7 (eBioscience #25-0161-81), CD71-PE (eBioscience #12-
0711-83) and TER119-FITC (eBioscience #11-5921-82). Fluorescence Minus
One (FMO) was used to gate cell populations and commercial anti-mouse or
anti-rat Igk beads (BD Biosciences #552843 or # 552844) to compensate for
fluorochrome spectral overlap during flow cytometry. Cells were analyzed in
an LSR-Fortessa or FACS CANTO (BD Biosciences; FACS Diva software).
Data were analyzed with FlowJo 9.6.2 software.
RNA-Seq-Based Transcriptional Profiling
RNA was prepared by using Direct-zol (Zymo Research) from BM hematopoi-
etic progenitor cells (Lin- Sca1– cKIT+) of TAM-treated animals. Mouse lineage
depletion cocktail (Miltenyi #130-090-858) was used to eliminate mature he-
matopoietic cells. RNA Integrity Number (RIN) was in the range 7.5–9.3 (Agilent
2100 Bionalyzer). 2–8 ng of total RNA was used to synthesize the cDNA
(SMARTer Ultra Low Input RNA Kit, version 3, Clontech #634848). After ampli-
fication with SeqAmp DNA Polymerase (Clontech), "10 ng of cDNA was used
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to prepare the adaptor-ligated library following the ‘‘TruSeq DNA sample prep-
aration guide’’ (part #15005180). The resulting cDNA libraries were sequenced
for 50 bases in a single-read format (Illumina HiSeq2000). Reads were aligned
to the mouse genome (GRCm38/mm10) with TopHat-2.0.10 (Trapnell et al.,
2012) using Bowtie 1.0.0 (Langmead et al., 2009) and Samtools 0.1.19 (Li
et al., 2009), allowing two mismatches and five multihits. Transcripts assem-
bly, estimation of their abundances and differential expression were calculated
with Cufflinks 2.2.1 (Trapnell et al., 2012), using the mouse genome annotation
data set GRCm38/mm10 from the UCSC Genome Browser. Gene Set Enrich-
ment Analysis (GSEA) was performed using annotations from the KEGG,
Reactome and NCI databases. Genes were ranked using the t statistic. After
Kolmogorov-Smirnoff correction for multiple testing, only those pathways
bearing a FDR <0.25 were considered significant. Enrichment plots were
also obtained with GSEA and ranked according to their enrichment score (ES).
Histopathology
Mice organs were fixed in formalin and embedded in formalin/paraffin blocks.
Sections and H&E and immunohistochemistry stainings were performed by
the CNIO Histopathology Unit. Antibodies recognizing TER119 (BD Biosci-
ences, #550565) and c-MYC (Abcam, clone Y69, #ab32072) were used.
Positive cells for the above mentioned antibodies were quantified by using
AxioVision (Zeiss) software.
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Figure S1. Generation of Rpl11 conditional knockout mouse model, related to 
Figure 1.  
(A) Scheme of the wt, loxfrt, lox and delta Rpl11 alleles and location of primers used 
for their identification. Probe and external primers to check for 5’ and 3’ homology 
arms insertion are also shown in the picture. Rpl11 loxfrt allele bears a neomycin 
cassette, flanked by frt sites, that serves for selection of recombinant ES clones. 
The neomycin cassette is excised upon expression of flipase recombinase (Flpe), 
resulting in the Rpl11 lox allele. Exons 3 and 4 of the Rpl11 gene, flanked by two 
loxP sites, are excised once Cre recombinase is expressed giving rise to the Rpl11 ∆ 
allele.  
(B)  Southern blot showing several positive recombinant ES clones for proper insertion 
of the 5’ homology arm of the targeted Rpl11 loxfrt allele. Digestion with EcoRV 
enzyme results in a DNA fragment of 20.2 Kb or 15.1 Kb in the Rpl11 wt or loxfrt 
alleles, respectively. This DNA fragment contains part of the mouse chromosome 4 
external to the 5’ homology arm of the targeted construct. 
(C) Long-range PCR displaying the amplified DNA fragments by the above-indicated 
primers (see location in (A)). A DNA fragment of 9.48 Kb is amplified by Neo-F 
and 3’OUT-R primers when correct insertion of the 3’ homology arm of the 
targeted Rpl11 loxfrt allele in the mouse chromosome 4 occur.  
(D) PCR showing the amplification of the loxP site located in the intron 4 of the 
targeted Rpl11 loxfrt allele. Those recombinant ES clones that bears loxP site in 
intron 4 present two bands. 
(E) Rpl11 delta (Δ) allele is correctly detected by PCR with indicated primers when Cre 
recombinase is present. Mouse embryonic fibroblasts (MEFs) carrying the 
indicated Rpl11 alleles were infected with a plasmid expressing Cre recombinase or 
an empty plasmid. 
(F) PCR showing the Rpl11 lox and wt alleles with the same pair of primers. This is the 
regular PCR-based strategy used for genotyping and confirmation of experimental 
samples.  
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Figure 2. 
Quantification by qRT-PCR of the percentage of presence of the Rpl11 wt allele in 
genomic DNA from tails of mice fed with TAM for 1, 8 and 20 weeks, which is used as 
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Figure S3. Rpl11 deficiency results in impaired erythropoiesis, related to Figure 3. 
(A) Mean corpuscular volume (MCV) of erythrocytes from TAM-Rpl11+/+ and TAM-
Rpl11+/lox mice was measured at the indicated times in TAM diet.  
(B) mRNA levels of different genes involved in erythropoiesis or iron metabolism are 
quantified by qRT-PCR in BM cells from 8-weeks TAM-treated animals. β-actin 
mRNA levels are used as an endogenous control. Data correspond to 3 independent 
animals per genotype, except for Ireb2 where n=2.  
(C) Representative histological sections of normocellular bone marrow from TAM-
Rpl11+/+ or TAM-Rpl11+/lox mice. Scale bars correspond to 200 µm. Bone marrow 
cellularity indicates the total number of bone marrow cells extracted from the 
posterior limbs of each animal.  
(D) Quantification by flow cytometry of the percentage of HSCs and the different 
subsets of hematopoietic progenitors (common lymphoid progenitors “CLPs”, 
common myeloid progenitors “CMPs”, granulocyte-monocyte progenitors “GMPs” 
and megakaryocyte-erythrocyte progenitors “MEPs”) in BMs from 8 or 20 weeks 
TAM-treated animals. The gating strategy for the analyzed populations is shown 
above.  
Values correspond to the average ± SD. Statistical t-test analysis was performed to 
calculate significance (* P≤ 0.05; ** P≤ 0.01; *** P≤ 0.005). 
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Figure S4. Erythrocyte differentiation is compromised in Rpl11 deficient mice, 
related to Figure 4. 
(A) Graph showing the number of colony forming units (CFUs) to evaluate the 
potential of the different myeloid progenitors: erythroid (BFUs, burst-forming 
units), “granulocyte, monocyte” (CFU-GM) or multipotential progenitor 
“granulocyte, erythrocyte, monocyte, megakaryocyte” (CFU-GEMM) cells. The 
assays were performed with bone marrow cells from a total of n=3 independent 
mice per genotype.  
(B) PCR showing Rpl11 alleles performed in bone marrow cells from BM-transplanted 
animals.  
(C) Picture depicting transplanted animals with BMs from Rpl11+/+ or Rpl11+/lox donors 
fed with tamoxifen for 12 weeks. Paleness of a TAM-BMT-Rpl11+/lox mouse is 
particularly notable in the ears. 
(D) Quantification by flow cytometry of the percentage of erythroid cells from bone 
marrows of TAM-Rpl11+/+ and TAM-Rpl11+/lox animals at different stages of 
erythroid maturation.  
(E) Quantification by flow cytometry of the percentage of cells in the different 
maturational erythroid stages from Rpl11+/+ and Rpl11+/lox fetal livers (E14.5) after 
daily injections of 4OHT in pregnant females from E11.5 to E13.5. 
(F) Cell cycle analysis by flow cytometry after EdU incorporation and Hoechst staining 
of RIII erythroid cells from fetal livers as in (E). 
Values correspond to the average ± SD. Statistical t-test analysis was performed to 
calculate significance (* P≤ 0.05; ** P≤ 0.01). 
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Figure S5. Expression of erythrocyte differentiation genes is not altered in adult 
livers from TAM-treated Rpl11+/lox mice, related to Figure 5. 
(A) Rpl11 mRNA levels of HPCs from 20 weeks TAM-treated Rpl11+/+ and Rpl11+/lox 
mice.  
(B) mRNA levels of the indicated genes of livers from 20 weeks TAM-treated Rpl11+/+ 
and Rpl11+/lox mice. mRNA levels are normalized to β-actin housekeeping levels.  
Values correspond to the average ± SD. Statistical t-test analysis was performed to 
calculate significance (* P≤ 0.05; *** P≤ 0.005). 
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Figure S6. Anemia in γ-irradiated TAM-Rpl11+/lox mice, related to Figure 6. 
(A) Red blood cells (RBC) and hemoglobin values for γ-irradiated TAM-Rpl11+/+ and 
TAM-Rpl11+/lox mice. Differences between genotypes were significant (**P≤ 0.01 
or *P≤ 0.05) for all time points with the exception of that corresponding to 8 
weeks. 
(B) Rpl11 mRNA levels from thymuses of TAM-Rpl11+/+ and TAM-Rpl11+/lox mice (20 
weeks). β-actin mRNA levels are used as an endogenous control. 
(C) Representative histological sections, stained against cMYC, from spleens of TAM-
Rpl11+/+ and TAM-Rpl11+/lox mice (20 weeks). Scale bars correspond to 100 µm 
(top images) and 50 µm (zoom in images). Pictures are representative of a total of 
n=4 per genotype. 
Values correspond to the average ± SD. Statistical t-test analysis was performed to 
calculate significance (* P≤ 0.05; ** P≤ 0.01; *** P≤ 0.005). For panel (A), see legend. 
 
Supplemental Tables 
 
Table S1. Differentially regulated genes in Rpl11-deficient hematopoietic 
progenitors, Related to Figure 5 
Annotated ranked list of those genes significantly downregulated, in blue, and 
significantly upregulated, in red, (FDR (q-value) < 0.15) in TAM-Rpl11+/lox HPCs 
compared to TAM-Rpl11+/+ controls. q-values and log2FC are indicated. MGI, 
UniProt, and Ensembl databases were used for biological processes and molecular 
functions annotations.  
 
Table S2. Differentially regulated gene sets in Rpl11-deficient hematopoietic 
progenitors, Related to Figure 5 
Gene Sets with FDR (q-value) < 0.25. Eukaryotic translation (green), DNA 
replication/cell cycle (blue), DNA repair (yellow), iron metabolism (pink) and cancer 
related (orange) pathways are depicted in the indicated colors. Gene size, source and 
status (up or down) of the analyzed pathways are shown in the table.  
Supplemental Experimental Procedures 
 
Southern blot analysis 
Approximately 15 µg of DNA from recombinant ES clones were digested o/n at 37ºC 
with EcoRV enzyme (ROCHE). The probe was generated by PCR amplification using 
the following primers: Forward 5’-GAC TCA CCG AAG GAC AGG AC-3’ and 
Reverse 5’-TGC CTA GTT GTG TCT CCC AGT-3’.  
 
Long-range PCR 
Genomic DNA from recombinant ES clones were amplified by PCR using LA Takara 
enzyme and the following conditions: 1 min 94ºC, 30x (98ºC 10 sec, 58ºC 15 sec, 68ºC 
10 sec), 72ºC 10 min. Primers were designed in order to amplify a DNA fragment of 
9,418 bp (Neo F + 3’ OUT R) comprised between the Neomycin cassette and the outer 
region of the 3’ homology arm. Internal controls of amplification were also designed to 
amplify a DNA fragment of 7,815 bp (Neo F + 3’ IN R) comprising the Neomycin 
cassette and the inner region of the 3’ homology arm in those recombinant clones of ES. 
Primers were also ordered for amplifying a region of 6,638 bp (Rpl11 F + 3’ IN R) 
present in all ES samples (non recombinant and recombinant) as a control for PCR. 
Primers used for this strategy are listed below: Neo F: 5’- GCC TTC TAT CGC CTT 
CTT GAC GAG-3’; Rpl11 F1: 5’-GCA TAA TCA TTG GTT GGG CCT GAT AG-3’; 
3’IN R: 5’-GGC CAC TGA TGG TAA CGG TTT GC-3’; 3’OUT R: 5’-CAC GGG 
GAG GGG CAA CTA ACC-3’. 
 
PCR-based genotyping for the Rpl11 alleles 
To check the Rpl11 deletion, genomic DNA isolated from mouse tissues or cells 
following standard procedures were subjected to PCR by using AmpliTaq DNA 
polymerase (N8080152 Applied Biosystems). The genotyping PCR primers are listed 
below: 
 Rpl11  F1: 5’-GCA TAA TCA TTG GTT GGG CCT GAT AG-3’ 
 Rpl11  F2: 5’-CAC TAT GAT AAC GGC CAT TCC-3’ 
 Rpl11  R1: 5’-CCG GAT GCC AAA GGA CCT GAC-3’ 
 Rpl11  R2: 5’-CAC TAT GAT AAC GGC CAT TCC-3’ 
 CRE  Fw: 5’-CGG TCG ATG CAA CGA GTG ATG AGG-3’ 
 CRE  Rv: 5’-CCA GAG ACG GAA ATC CAT CGC TCG-3’ 
CRE recombinase transduction 
Packaging 293T cells were transfected at a density of 5x106 cells/p100 with 
XtremeGene HP transfection agent (ROCHE). 4 µg of retroviral plasmid (pBabe-empty 
or pBabe-CRE) was used for transfection. 0.8x106 primary MEFs/p100, bearing 
Rpl11+/+ or Rpl11+/loxfrt alleles, were transduced with the viral supernatants for 6 h and 
puromycin (2 µg/mL) selection was added the following day. Fibroblasts were collected 
for gDNA extraction at 3 days after complete selection.  
 
Immunoblotting 
Cells were harvested and lysed in NET buffer. Identical amounts of whole lysates were 
resolved on 4–12% SDS/PAGE gels (NuPAGE, Invitrogen) and transferred to 
nitrocellulose membranes. Blots were blocked in TBS, 0.2% Tween, 5% BSA and 
incubated with the primary antibodies anti-RPL11 (Proteintech), anti-GAPDH (71.1, 
Sigma), anti LAMIN A/C (N-18, Santa Cruz Biotechnology), anti-p53 (C1C12, Cell 
Signaling) and anti-cMYC (D84C12, Cell Signaling) and subsequently incubated with 
the corresponding secondary anti-IgG HRP antibodies (Dako). Signals were detected by 
standard ECL procedures. 
 
Northern blot analysis of rRNA precursors 
Tissues were homogenized in a Precellys homogenizer. Total RNA was isolated from 
cells and tissues using TRI-reagent (Sigma) following the manufacturer’s instructions. 
1.5 µg of total RNA were loaded onto a 1.2% MOPS/formaldehyde agarose gel and 
underwent electrophoresis. RNAs were transferred to a Hybond N+ nylon membrane 
(Amersham) through capillarity and fixed by UV crosslinking. Membranes were 
prehybridized in 6X SSC, 5X Denhardt's solution, 0.1% SDS, 1 µg/ml salmon sperm 
DNA at 45˚C for 3 hours. The ITS2 probe (5′- ACC CAC CGC AGC GGG TGA CGC 
GAT TGA TCG -3′) labeled with [γ"32P]"ATP (Perkin Elmer) through PNK terminal 
labeling was then added to the membrane and incubated at 45˚C overnight. Membranes 
were washed in 2X SSC, 0.1% SDS and 1X SSC, 0.1% SDS and underwent 
autoradiography. 
 
EdU incorporation assay in MEFs 
Primary MEFs were seeded (3000 cells/well) onto µclear bottom 96-well plates 
(Greiner Bio-One) and treated with 4OHT for 3 days. Analysis of DNA synthesis by 
EdU incorporation was performed using Click-iT chemistry (Invitrogen) following 
manufacturer’s instructions. Briefly, cells were incubated with EdU (10 µM) for 30 min 
and then, fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 and 
incubated with Click-iT reaction cocktail (containing Alexa Fluor 647 azide). DAPI was 
use to counterstain cells. A total of 40 fields/well were acquired with a 20x 
magnification lens in the Opera HCS system (Perkin Elmer). Images were segmented 
using the DAPI staining to generate masks matching cell nuclei from which 
fluorescence intensity signals were calculated by using Acapella High Content Imaging 
and Analysis software (Perkin Elmer). 
 
Colony Forming Units assay For, the, colony, forming, units, (CFU), assay,, 5000, cells, of, adult, BM, from,TAM, fed,mice, (8,weeks),were, plated, in, duplicates, in,methylcellulose, (Methocult,M3434,,StemCell, Technologies), in, p35, non"adherent, plates., Colonies, were, scored, at, 10,days,according,to,their,cellular,morphology.,
 
RNA isolation and quantitative real time PCR (qRT-PCR) 
Up to 1 µg of total RNA was reverse transcribed into cDNA using iScript First Strand 
cDNA synthesis kit (BioRad #170-8891). Real-time PCR was performed using SYBR 
Green master mix (Applied Biosystems) in a 7500 Fast Real-Time PCR (Applied 
Biosystems). All reactions were performed in triplicates and normalized to β-Actin 
mRNA levels as an endogenous control. The sequences of the primers used are:  
Alas2  Fw 5’-TGG GCT AAG AGC CAT TGT CCT-3’ 
 Rv 5’-GTA GGT GTG GTC CTG TTT CTT C-3’ 
β-actin  Fw 5’-GGC ACC ACA CCT TCT ACA ATG-3’ 
  Rv 5’-GTG GTG GTG AAG CTG TAG CC-3’ 
Bax  Fw 5’- GAC AGG GGC CTT TTT GCT A-3’ 
 Rv 5’- TGT CCA CGT CAG CAA TCA TC-3’ 
Cdkn1a  Fw 5’-GTG GGT CTG ACT CCA GCC C-3’ 
 Rv 5’-CCT TCT CGT GAG ACG CTT AC-3’ 
Cldn13  Fw 5’-GAC TTT CCC CGT TGC ATT GA-3’ 
 Rv 5’-CGC ATC CAG AGT CCA CTA CA-3’ 
Ctse  Fw 5’-GCC CCT CAG AAG ACA TCA GT-3’ 
 Rv 5’-CGA TGG AGA TGG TGC CAA AG-3’ 
Epo  Fw 5’-ACT CTC CTT GCT ACT GAT TCC T-3’ 
 Rv 5’-ATC GTG ACA TTT TCT GCC TCC-3’ 
Epor  Fw 5’-GGG CTC CGA AGA ACT TCT GTG-3’ 
 Rv 5’-ATG ACT TTC GTG ACT CAC CCT-3’ 
Gypa  Fw 5’-TGG TGG CTT CAA CTG TAG GT-3’ 
 Rv 5’-GAT AAT CCC TGC CAT CAC GC-3’ 
Hba-a2  Fw 5’-GGA TCC CGT CAA CTT CAA GC-3’ 
  Rv 5’-CAA GGG AGA GAA GAA GGG CA-3’ 
Hbb-h1  Fw 5’-GAA ACC CCC GGA TTA GAG CC-3’ 
  Rv 5’-GAG CAA AGG TCT CCT TGA GGT-3’ 
Ireb2  Fw 5’-TTC TGC CTT ACT CAA TAC GGG T-3’ 
 Rv 5’-AGG GCA CTT CAA CAT TGC TCT-3’ 
Rhd  Fw 5’-GGG TGC AGG GAA CAA TCT TG-3’ 
 Rv 5’-GAC CTT CTC GTC GGC AAA TC-3’ 
Rik  Fw 5’-TGC TGC ACA AAA GAT TCC TG-3’ 
 Rv 5’-TAG AAA CAC CGG CAA TGA CA-3’ 
Rpl11  Fw 5’-ATG GCG CAA GAT CAA GGG G-3’ 
 Rv 5’-GAC TGT GCA GTG AAC AGC AAT-3’ 
Trfc  Fw 5’-GTT TCT GCC AGC CCC TTA TTA T-3’ 
 Rv 5’-GCA AGG AAA GGA TAT GCA GCA-3’ 
 !
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The main goal of this thesis was the study of the ribosomal stress pathway in different settings, 
with emphasis on tumor suppression. In the first section we demonstrated that, in mouse pluripotent 
stem cells, imbalanced ribosome biogenesis results in the activation of the ribosomal stress pathway, 
which constitutes an additional checkpoint that safeguards the integrity of stem cells. Next, we 
exploited the ribosomal stress pathway as a potent trigger of p53-mediated responses in cancer cells; 
for this, we performed a chemical screen that led to the identification of compounds that alter 
nucleolar integrity and activate p53, in the absence of detectable DNA damage. Finally, we generated 
a mouse model for Rpl11 haploinsufficiency that recapitulates the hallmarks of DBA, including cancer 
predisposition.  
 
The ribosomal stress pathway in mouse pluripotent stem cells  
 
The ribosomal stress pathway emerged more than 10 years ago as a new p53-activating 
pathway that monitors ribosome integrity (Zhang and Lu, 2009). Ribosome biogenesis is the most 
demanding energetic process in proliferating cells. Mouse embryonic pluripotent cells present 
extremely fast proliferation rates (8-10h duplication time), reaching cell cycles of less than 5 h in the 
epiblast. In order to meet the elevated energetic demands that these highly proliferating cells require, 
the rate of ribosome biogenesis needs to be extremely high. Consistent with this, RPs are more 
abundantly expressed in mESCs compared to differentiated cells (Kondrashov et al., 2011), and, 
interestingly, a decrease in rDNA transcription is associated to differentiation. This implies a tight 
coupling of replication and transcription of rRNA genes and translation of ribosomal proteins. In 
higher eukaryotes, replication and transcription are temporally separated to prevent collisions between 
the machineries involved (Bertoli et al., 2013). However, replication-transcription conflict might arise 
in heavily transcribed loci, such as rDNA genes. In mammalian cells, rDNA transcription is cell cycle-
regulated, gradually increasing during G1 and reaching its maximum peak in S and G2, while 
remaining inactive in mitosis by phosphorylation of UBF, the master regulator of RNA pol I-driven 
transcription (Drygin et al., 2010; Klein and Grummt, 1999). Decrease in rRNA synthesis and 
ribosome assembly is, indeed, a prerequisite for the exit of cell cycle during mitosis (Heix et al., 1998; 
Kuhn et al., 1998). This mechanism differs from that of RNA pol II-transcribed genes, whose 
transcripts levels are maximum during G1-S transition and repressed when replication takes place 
(Bertoli et al., 2013), thus providing a temporal gap between transcription and replication. As an 
additional level of complexity, any perturbation that slows down protein synthesis, such as defective 
ribosomes, decreases rDNA transcription (Drygin et al., 2010) and would impact, ultimately, in the 
proliferation rate. Thus, ribosome biogenesis must be tightly coupled to proliferation by achieving 
appropriate levels of rRNA synthesis and ribosome assembly during specific windows of the cell 
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cycle. Failure in coupling both processes will render mouse pluripotent stem cells particularly 
sensitive to accumulate mutations, compromising integrity of their progeny. 
 
The ribosomal stress pathway is in charge of monitoring ribosome biogenesis, but its 
functionality in pluripotent stem cells was unknown. Of note, 15 pluripotency factors, including 
OCT4, have been found to be associated to rDNA in mESCs and hESCs (Zentner et al., 2014). The 
ribosomal stress pathway relies on p53 as the ultimate effector. The role of p53 as a guardian of 
genome integrity in mouse pluripotent stem cells was initially dismissed because the majority of p53 
protein is cytoplasmic in these cells (Aladjem et al., 1998; Sabapathy et al., 1997a; Solozobova et al., 
2009). In addition, some DNA damaging agents, such as ionizing radiation (γ-irradiation), 
radiomimetic agents (doxorubicin) or nucleotide depletion are capable of transiently stabilizing p53 in 
mESCs, but trigger apoptosis independently of p53 (Aladjem et al., 1998; Corbet et al., 1999; 
Solozobova et al., 2009). In contrast, UV radiation and oxidative stress induce a p53-mediated 
apoptotic response in mESCs (Chao et al., 2000a; Corbet et al., 1999; Han et al., 2008). In this 
context, the functionality of the ribosomal stress pathway and the role of p53 in this response had 
remained unaddressed in embryonic stem cells. Only one report, published by the time our work was 
being peer-reviewed, demonstrated that p53-dependent apoptosis can be elicited in mESCs through 
RPL11-MDM2 by loss of the nucleolar protein PICT1 (Sasaki et al., 2011). 
 
In this section of our study we have shown that p53 is active in mESCs and iPSCs in response 
to ribosomal stress, triggered either by treatment with ActD or by Rpl37 depletion. As a proof-of-
concept of the functionality of the ribosomal stress pathway, we have detected increased binding of 
RPL11 to MDM2 upon induction of ribosomal stress by low concentrations of ActD (a well-known 
inducer of the ribosomal stress pathway). Transcriptional upregulation of p53 target genes, including 
p21, Mdm2, Puma, Bax and Noxa, depends on RPL11 and p53, therefore confirming the activation of 
the ribosomal stress pathway. We have also determined that mouse pluripotent stem cells respond to 
perturbations in ribosome biogenesis by eliciting an apoptotic response that depends on p53. This 
apoptotic response is also dependent on Puma and Bax, two pro-apoptotic p53 target genes that 
participate in the p53-mediated apoptosis response. From our work we can conclude that mouse 
pluripotent stem cells possess an additional checkpoint surveillance pathway that monitors ribosome 
biogenesis homeostasis. The ribosomal stress pathway could be of particular relevance in 
developmental stages with a high cell proliferation rate, such as gastrulation (O’Farrell et al., 2004), 
by preventing defective cells to continue throughout specific cell lineages.   
 
Our results also shed light to the paradoxical role of p53 in mESCs. As mentioned in the 
introduction section, mESCs undergo p53-dependent apoptosis upon UV or oxidative stress, but not 
ionizing irradiation. UV-induced photolesions are inefficiently repaired in rDNA (Balajee et al., 
Discussion 
83!
1999). This could explain why UV, but not γ-IR, severely compromise nucleolar integrity (Al-Baker et 
al., 2004; Kurki et al., 2004; Moné et al., 2001; Rubbi and Milner, 2003; Stixova et al., 2014) resulting 
in mislocalization of nucleolar proteins (Kurki et al., 2004; Moore et al., 2011) and blocking of 
transcription (Batista et al., 2009). All these events potentially lead to ribosomal stress (Shav-tal et al., 
2005; Sirri et al., 2008). Supporting UV-induced ribosomal stress, exposure of osteosarcoma cells to 
UV, but not to γ-IR, activates p53 through RPL11 (Bhat et al., 2004; Macias et al., 2010) and, 
alternatively, UV light induces degradation of RPL37 which ultimately results in ribosome unbalance 
and activation of the ribosomal stress pathway (Llanos and Serrano, 2010). Interestingly, oxidative 
stress also causes reorganization of nucleolar proteins by inhibiting RNA pol I transcription through 
JNK2 activity (Mayer et al., 2005), which would lead to activation of the ribosomal stress pathway.  
 
Based on this, we speculate that UV radiation and oxidative stress trigger a p53-mediated 
apoptosis response in pluripotent stem cells by disturbance of the nucleolus and activation of the 
ribosomal stress pathway (Figure 6).  
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Figure 6. Scheme showing the leading stresses triggering apoptosis in mESCs. 
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Small molecule compound screen to identify non-genotoxic activators of 
p53 through the ribosomal stress pathway 
 
Cancer cells resemble mouse pluripotent stem cells in their high proliferation rates, mainly 
due to their ability to bypass cellular checkpoints. In order to sustain the elevated protein synthesis 
levels, cancer cells increase the size and number of nucleoli, the ribosome factories (Montanaro et al., 
2008). Several proto-oncogenes and tumor suppressors control RNA pol I transcription machinery in 
response to proliferative cues, such as nutrients and cell cycle dynamics (Drygin et al., 2010). 
However, cancer cells hijack RNA pol I activity by modulating tumor suppressors and oncogenes, 
which in turn make them addicted to high rates of rRNA synthesis in order to sustain rapid 
proliferation (Drygin et al., 2014; Nguyen et al., 2015). Thus, the nucleolus becomes a very attractive 
target in order to halt uncontrolled proliferation of cancer cells. Many chemotherapeutic drugs inhibit 
RNA pol I function at different levels and result in nucleolar disruption, such as actinomycin D, 
doxorubicin or cisplatin; however, their mechanism of action is non-selective and they can result in 
the acquisition of oncogenic mutations associated to genotoxic stress that ultimately result in tumour 
relapse (Quin et al., 2014). Few selective inhibitors of RNA pol I-mediated transcription, such as CX-
5461 or BMH-21, have shown antitumorigenic activities in the absence of DNA damage, while 
leaving healthy cells undamaged (Bywater et al., 2012; Drygin et al., 2011; Peltonen et al., 2010, 
2014). Interestingly, cancer cells with higher rates of rRNA synthesis that retain a wild-type p53 status 
are extremely susceptible to these inhibitors (Scala et al., 2015). Around 85-90% of blood cancers 
have wild-type p53 upon initial diagnosis, which make these patients appropriate for therapy with 
nucleolar stress agents. In this manner, the selective RNA pol I inhibitor CX-5461 is being 
successfully tested (phase I; clinical trial ID ACTRN12613001061729) in patients with advanced 
hematologic malignancies, including high-grade lymphoma, myeloma and acute leukemia. The 
discovery of novel genotoxic-free nucleolar disruptors is of special interest to circumvent the 
drawbacks of DNA damage-inducing drugs. To test large drug collections we have designed a 
nucleolar morphology-based screen to identify compounds that disturb nucleolar integrity. For that we 
have used a U2OS cell line stably expressing the GFP-tagged protein RPL37, previously generated in 
our lab (Llanos and Serrano, 2010). GFP signal allowed us to determine nucleolar morphology and 
assign an automatic nucleolar disruption score to rank potential candidates from two small chemical 
compounds libraries. This technical approach is robust, fast and cheap, since relies on GFP 
fluorescence and does not depend on immunofluorescence staining, which is usually expensive, time 
consuming and associated to side problems, such as inconsistent staining patterns. 
 
Firstly, we tested an in-house made library of 640 compounds representative of the full 
collection (≈ 55,000 compounds) of the Experimental Therapeutics Program at the CNIO. Secondly, 
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we tested the Johns Hopkins University chemical library comprising 1524 compounds approved for 
medical use. We successfully identified and validated three related acridine derivatives that cause 
nucleolar disruption: CID-765471, ethacridine and aminacrine, being the last two compounds already 
approved for medical use as antiseptics. All these three compounds show antitumorigenic activity by 
activating p53 in the absence of detectable DNA damage. This makes these non-genotoxic compounds 
highly attractive for cancer treatment since most chemotherapeutic drugs induce DNA damage to kill 
cancer cells, with the risk of increase the mutational load of surviving cells.  Habria que aclarar que 
estos agentes no son genotoxicos! Ya lo pongo en la frase subrayada en amarillo, aniado coletilla de 
“non-genotoxic compunds” después para hacer más énfasis.  
 
Acridine derivatives comprise a large group of DNA intercalating agents that display different 
ranges of cellular toxicity according to their reactive groups. For example, platinum-based acridines 
are highly genotoxic (Galdino-Pitta et al., 2013; Suryadi and Bierbach, 2012), while acridine itself and 
its derivative CID-765471 activate p53 in a non-genotoxic manner (Dudgeon et al., 2010; Peltonen et 
al., 2010; Wang et al., 2005). However, the exact mechanism of p53-activation was not understood. 
We have addressed this question and we have demonstrated that CID-765471 causes nucleolar 
disruption by blocking rDNA transcription in a mechanism that involves, but does not require, 
selective degradation of the RNA pol I subunit RPA194. Nucleolar disruption, in turn, activates p53 
through RPL11. The selective degradation of RPA194 is a shared feature with the recently 
characterized acridine-derivative BMH-21 (Peltonen et al., 2014). This suggests that acridine 
derivatives might all induce degradation of RPA194 and, therefore, disorganization of the RNA pol I 
holoenzyme, beyond intercalating into DNA, as an alternative mechanism to stall rDNA transcription. 
The activation of the ribosomal stress pathway by CID-765471 is common to CX-5461; however, CX-
5461 is structurally non-related to acridines. This observation leads us to reason that any perturbation 
affecting RNA pol I activity would ultimately activate p53 through the ribosomal stress pathway. 
More importantly, our findings contribute to set the basis for additional studies on the 
chemotherapeutic value of non-genotoxic acridine derivatives.   
 
As a footnote, the simplicity of our platform provides a very powerful tool for testing 
additional libraries. Genetic libraries designed to target nucleolar proteins, such as DNA/RNA 
helicases, kinases or GTP-based proteins, are good candidates to widen the spectrum of genotoxic-free 
compounds with capacity to disrupt the nucleolus and activate p53.  
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Rpl11 haploinsufficiency leads to abnormal erythroid maturation, defective 
ribosomal stress pathway and increased susceptibility to γ-IR induced 
lymphomagenesis 
 
As we and others have previously shown, RPL11 constitutes one of the central hubs that 
modulates the ribosomal stress pathway in response to perturbations in ribosome biogenesis, thus 
resulting in activation of p53 in somatic, tumor and pluripotent stem cells (Bywater et al., 2012; 
Macias et al., 2010; Morgado-Palacin et al., 2012, 2014). However, Rpl11 abrogation studies are 
restricted so far to the analysis of somatic/tumor cell lines, and a few in vivo studies in Zebrafish 
(Chakraborty et al., 2009; Danilova et al., 2011). Such in vivo studies have shown that morpholino-
mediated downregulation of Rpl11 in Zebrafish is linked to defects in brain development, 
hematopoiesis and metabolism (Chakraborty et al., 2009; Danilova et al., 2011). Strikingly, no 
mammalian organisms with full or conditional RPL11 abrogation have been generated thus far, 
hampering the modeling of the specific contribution of this protein to human diseases such as DBA. 
 
To understand the in vivo role of RPL11 in a mammalian organism, we have generated the 
first mouse model of Rpl11 haploinsufficiency. Rpl11 heterozygosity during embryogenesis or 
homozygous conditional deletion of Rpl11 in adult mice is lethal. Partial loss of Rpl11 in adult mice 
recapitulates DBA, including impaired rRNA processing and defective erythroid maturation. 
Importantly, Rpl11 abrogation promotes γ-IR-induced lymphomagenesis, at least in part by a defective 
ribosomal stress pathway and high basal levels of c-MYC oncoprotein. In summary, we have 
demonstrated that this mouse model is a powerful tool for modeling human congenital defects such as 
DBA and for studying cancer predisposition and, in particular, the role of a defective ribosomal stress 
pathway in oncogenic events.  
 
Embryonic lethality of Rpl11 heterozygous mice  
 
As we have shown, heterozygous ablation of Rpl11 results in embryonic lethality, suggesting 
an essential role for RPL11 during embryonic development. This striking phenotype is extremely 
unusual for mouse models bearing partial deficiencies in ribosomal proteins (Caldarola et al., 2009). 
We are only aware of one other ribosomal gene, Rps6, whose partial loss results in embryonic lethality 
at early developmental stages (Panić et al., 2006). Rps6 heterozygous embryos die at E8.5, presenting 
defects since the beginning of gastrulation (E5.5) when ribosome biogenesis is intensely upregulated 
to meet the demands of a dramatic increase in the rate of proliferation and differentiation (Snow, 
1977). Interestingly, embryonic lethality is only partially rescued until E12.5 in a p53 null 
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background, which indicates the existence of both p53-dependent and p53-independent mechanisms 
that monitor ribosome biogenesis during development.  
 
Of note, ribosomal proteins are ubiquitously expressed in the organism; however, their 
expression levels vary notably among different RPs and such differences are cell- and tissue-specific 
(Kondrashov et al., 2011; Xue and Barna, 2012). One of the most paradigmatic examples is RPL38. 
Rpl38 transcripts are highly expressed in the developing somites and neural tube of mouse embryos, 
and haploinsufficiency of Rpl38 causes axial skeleton remodeling defects by perturbing the translation 
of a subset of Homeobox mRNAs (Kondrashov et al., 2011). Similar to Rpl38 haploinsufficiency, 
partial loss of Rps7 (Watkins-Chow et al., 2013) or Rpl24 (Oliver et al., 2004) affects the skeletal 
tissue patterning and produces some additional malformations. In Zebrafish, loss of RPs or rRNA 
modifications leads to developmental defects (Higa-Nakamine et al., 2012; Uechi et al., 2006). 
Development defects in Rpl38 and Rps7 haploinsufficient mice are not rescued in the absence of p53, 
in support of extra-ribosomal functions of RPs independently of p53-mediated cell cycle arrest. In this 
regard, the characterization of the extra-ribosome function of Rpl11 during embryonic development 
might be also useful to understand why Rpl11, but not Rpl5 or Rps19, mutations are preferentially 
associated to thumb malformations in DBA (Cmejla et al., 2009; Gazda et al., 2008; Quarello et al., 
2010). Our mouse model will unveil whether Rpl11 is involved, for example, in Shh or Fgf signaling 
pathways that determine the digit patterning and the number of phalanges during limb development 
(Sanz-Ezquerro and Tickle, 2003; Suzuki, 2013).  
 
Complete abrogation of Rpl11 abrogation in adults is lethal 
 
To overcome the extreme developmental phenotype of Rpl11 heterozygous mice that hamper 
the characterization of its role in adult tissues, we decided to perform conditional ablation of Rpl11 in 
adults. For that, we generated mice with three different genotypes (Rpl11+/+, Rpl11+/lox and Rpl11lox/lox) 
bearing a transgene of a ubiquitous tamoxifen-inducible Cre recombinase (Tg.UbC.CreERT2 
(Ruzankina et al., 2007)). For clarity purposes, and unless specifically mentioned, we will refer 
hereafter to tamoxifen-treated mice or MEFs as Rpl11+/+ (or wild-type), Rpl11+/lox (or  heterozygous), 
and Rpl11lox/lox (or null). Bone marrow transplanted animals followed by tamoxifen treatment will be 
referred as BMT-Rpl11+/+ or BMT-Rpl11+/lox. Animals subjected to whole body γ-irradiation, followed 
by tamoxifen treatment, will be referred as γ-IR Rpl11+/+ or γ-IR Rpl11+/lox.  
 
Adult Rpl11 null mice die within 8 weeks after starting the tamoxifen treatment; they present 
intestinal atrophy and bone marrow aplasia, which suggests that highly proliferative tissues are the 
first to be affected by drastic reduction of RPL11. We have also described that adult Rpl11 null mice 
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present a severely reduced number of erythroid precursors (Ter119+ nucleated cells). Concomitant 
with erythroid defects, accumulation of hemosiderin is visualized in spleen and liver, suggesting a 
compromised iron recycling, presumably from an anemic condition. Lethality of adult mice with 
complete loss of Rpl11 is not surprising given the essential function of RPL11 in the ribosome.  
 
Partial loss of Rpl11 recapitulates DBA features 
 
Human DBA patients carry heterozygous mutations in ribosomal genes, which is sufficient to 
provoke evident symptoms that compromise their health (Boria et al., 2010; Cmejla et al., 2009; 
Gazda et al., 2008; Quarello et al., 2010). For this reason and due to the embryonic lethality of 
constitutive Rpl11 heterozygous mice, we decided to focus our research on the effects of inducible 
heterozygous deletion of Rpl11 in adult mice. Several mouse models of DBA and ribosomopathies 
have been reported (McGowan and Mason, 2011; Narla and Ebert, 2010), but only a subset of them 
recapitulate the erythropoietic defect characteristic of human DBA patients, namely, mice with partial 
deficiency of Rps19 (Devlin et al., 2010; Jaako et al., 2011), Rps6 (Keel et al., 2012; McGowan et al., 
2011) and Rps14 (Barlow et al., 2010). Interestingly, our mouse model for Rpl11 haploinsufficiency 
recapitulates the main DBA features, including impaired rRNA processing, anemia as the cause of 
decreased erythroid progenitors, and cancer predisposition.  
 
1. Impaired rRNA processing !
RPL11, similar to many other ribosomal proteins of the large subunit, participates in the 
maturation of intermediate 32S rRNA, which gives rise, after further processing, to the 28S and 5.8S 
rRNAs (Robledo et al., 2008b; Zhang et al., 2007). Analysis of the rRNA processing of DBA patients-
derived lymphoblastoid cells with mutations in Rpl11, as well as knockdown of Rpl11 in HeLa cells, 
revealed defective processing of 32S rRNA, being this species together with 12S rRNA and 5.8S 
precursors accumulated (Gazda et al., 2008; Robledo et al., 2008b). Study of 32S pre-rRNA 
maturation in inducible Rpl11 haploinsufficient and null MEFs (E13.5), as well as in adult spleens 
from these animals, confirmed the defective rRNA maturation observed in DBA, thus recapitulating 
another feature of this disease.  
 
2. Defective erythroid maturation !
 Rpl11+/lox adult mice manifest macrocytic anaemia at levels that are compatible with life and 
elevated levels of Epo mRNA (coding for erythropoietin) in kidneys, consistent with the physiological 
response to restore normal levels of erythropoiesis. They also present a reduced number of BFU-Es 
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(erythroid progenitors), a severe reduction in the number of erythroblasts (nucleated Ter119+ cells) 
and a blockage at the early stages of erythroid maturation. Furthermore, normal mice transplanted with 
inducible heterozygous Rpl11 bone marrow also developed anaemia and loss of erythroblasts upon 
Rpl11 deletion. In agreement with this, many of the genes significantly downregulated in Rpl11+/lox 
HPCs are related to erythrocyte development and function. These erythroid-related genes remain 
unaffected in other tissues, such as liver. Commitment towards the erythroid lineage was partly 
compromised since we detected a negative trend in the number of BFU-E, the first erythroid 
committed cells. Although mRNA levels of the core erythroid transcription factors Gata1, Tal-1 and 
Klf1 (Doré and Crispino, 2011; Keller et al., 2006; Weiss et al., 1997; Wontakal et al., 2012) were not 
affected in Rpl11+/lox HPCs, translation of these transcripts could be hampered, similarly to what has 
been reported for Gata1 upon knockdown of several RPs, including RPL11 (Ludwig et al., 2014). It 
would be of interest to check whether GATA1 protein levels are affected and whether mRNA 
expression of target genes of the erythroid core transcription network is also downregulated.  
 
Cell cycle profiles of Rpl11 deficient fetal liver cells revealed that erythroblasts are arrested in 
G1 phase. Also, we observed mRNA upregualtion of the cell cycle inhibitor Cdkn1a (p21) and the 
pro-apoptotic factor Bax during all stages of erythropoiesis, implying cell cycle arrest and induction of 
the apoptotic response as determinants of impaired maturation. Levels of p21 mRNA were also 
significantly increased in Rpl11+/lox HPCs, in agreement with observations in hematopoietic 
progenitors from DBA patients (Dutt et al., 2011). All these features recapitulate the anaemia 
phenotype observed in primary hematopoietic cells from DBA patients carrying mutations in Rpl11 
(Moniz et al., 2012).  
 
Why are erythroblasts exquisitely sensitive to ribosome dysfunction? 
 
It is still puzzling why the erythroid lineage is preferentially affected, over other cell types, in 
a condition of ribosomal protein haploinsufficiency. In support of this, we have demonstrated that only 
erythropoiesis is severely affected in Rpl11+/lox adult mice, while hematopoietic stem cells, progenitors 
and lymphopoiesis (B and T cell differentiation) remain largely unaffected.  
 
Ribosomal proteins are ubiquitously expressed in all cell lineages; however, severe defects are 
only manifested in erythroblasts. Several hypotheses have been postulated in order to explain the 
vulnerability of the erythroid lineage to perturbed ribosome homeostasis: 1) inefficient translation of 
globin that leads to free heme groups that result in oxidative stress and finally, haemolysis of 
erythrocytes (Narla and Ebert, 2010), 2) defective ribosome biosynthesis at early stages of 
erythropoiesis to sustain high production of proteins prior to chromatin condensation and enucleation 
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(Sieff et al., 2010), 3) reduced translation of mRNAs required for erythrocyte function (Horos et al., 
2012; Ludwig et al., 2014; Pereboom et al., 2014), and 4) selective p53 activation in the erythroid 
lineage that triggers cell cycle arrest and apoptosis in proerythroblasts (Dutt et al., 2013; Jaako et al., 
2015).  
 
Nonetheless, there are certain caveats in some of the proposed hypothesis. Regarding the first 
theory, haemoglobin levels are normal in DBA patients (Narla et al., 2011) and haemolytic anaemia 
has not been reported in DBA since failure relies in erythroid progenitors rather than in mature red 
blood cells.  
 
Concerning the second and third theories, defective erythropoiesis should be the outcome of 
any ribosomal protein deficiency impinging on translation. Compromised translation of essential 
transcripts for erythrocyte commitment and development has been reported in several anemic RP-
deficient mouse models and human cells as the main cause for erythropoiesis failure (Horos et al., 
2012; Ludwig et al., 2014; Pereboom et al., 2014). For instance, although Gata1 transcripts levels 
remains unaffected in Rps19-, Rpl11-, Rpl5-, or Rps24-depleted human primary erythrocyte cells, 
Gata1 mRNA translation is severely hampered upon ribosome protein deficiency (Ludwig et al., 
2014). Inefficient Gata1 translation reduces expression of Gata1 targets required for erythropoiesis, 
such as c-KIT (Munugalavadla and Kapur, 2005). In agreement, erythroid progenitors with reduced 
levels of Rps19 express lower amounts of c-KIT (Sieff et al., 2010), which could contribute to reduced 
proliferation of erythroblasts. In addition, impaired polysome recruitment of a set of transcripts 
involved in erythrocyte development and function, including Bag1 and Csde1, occurs in Rps19- and 
Rpl11-deficient erythroid cells (Horos et al., 2012). Furthermore, translation of Bcat1 transcripts, 
required for the synthesis of branched-chain aminoacids, is also decreased in lymphoblastoid cells 
from DBA patients that bear mutations in RPS9 or RPL11 (Pereboom et al., 2014). Remarkably, 
dietary supplementation of L-leucine alleviates anaemia in DBA Rps19-deficient animals by activating 
mTOR and thus, boosts translation of proteins in a p53-independent manner (Jaako et al., 2012; Narla 
et al., 2014; Payne et al., 2012). Gene set enrichment analysis showed that transcriptional profiling of 
eukaryotic translation is impaired in Rpl11+/lox HPCs, but we did not follow an approach to evaluate 
translation activity in Rpl11 deficient cells so whether translation of certain transcripts is preferentially 
affected upon loss of Rpl11 in our model needs confirmation by, for instance, ribosome profiling. 
 
However, not all ribosomal protein insufficiencies result in anaemia. Rpl29, Rpl22, Rps20 and 
Rps7 haploinsufficient mice do not show erythroid defects (Keel et al., 2012; Nieminen et al., 2014; 
Watkins-Chow et al., 2013) although they display other abnormalities, such as skeletal growth defects, 
impaired αβ T-cell development, dark skin hyperpigmentation and eye malformations, respectively 
(Anderson et al., 2007; Kirn-Safran et al., 2007; Watkins-Chow et al., 2013). This further supports the 
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notion that ribosomal protein deficiency results in tissue-specific phenotypes and point towards 
shortage of specific RPs as one of the lead cause for failure in erythropoiesis. 
 
Intriguingly, acinar cells of the exocrine pancreas, but not erythroblasts, posses the highest 
protein synthesis rate in mammals (Logsdon CD, 2013), so, concomintnatly with a defective ribosome 
byosinthesis (possibility 2 above), it would be expected that pancreas resulted also affected. 
Deficiency of certain ribosomal proteins and factors involved in rRNA processing impair p53-
independent pancreas development in Zebrafish (Provost et al., 2012, 2013; Qin et al., 2014). In 
agreement with this, mutations in SBDS, a nucleolar protein involved in ribosome assembly, cause 
exocrine pancreas insufficiency in patients with Shwachman-Diamond syndrome (SDS) (Stormon et 
al., 2010; Tulpule et al., 2013), a disease included in the group of ribosomopathies. Nevertheless, 
defects in the exocrine pancreas have not been described in DBA patients. Therefore, translation 
deficit by ribosome shortage does not explain the vulnerability of erythroid cells over the rest of 
lineages. It would be of interest to test whether SBDS deficiency causes impaired translation of certain 
transcripts, and if so, whether these transcripts are required for a correct pancreas function.  
 
Cell cycle arrest and apoptosis triggered by selective activation of p53 in erythroid cells has 
been highlighted to be key for DBA pathogenesis. Dutt et al. (Dutt et al., 2011) showed that ribosomal 
protein-deficient erythroid, but not myeloid or megakaryocyte, cells accumulate p53 and its target p21. 
By treating healthy CD34+ hematopoietic cells with nutlin-3, a well-known p53 activator, they 
recapitulate accumulation of p53 selectively in erythroid cells and defective erythropoiesis in the 
absence of ribosome biogenesis dysfunction, similarly to defects observed upon knockdown of Rps14 
or Rps19. Interestingly, treating Rps14- or Rps19-deficient cells with pifithrin-α, which blocks the 
transcriptional transactivation activity of p53, rescues erythroid maturation. These findings point 
towards p53 accumulation as one of the underlying causes of DBA pathogenesis. Failure of erythroid 
maturation, as well as developmental defects, are restored in a p53-null background in several models 
of ribosomal protein haploinsufficiency, among them Rps19 (Danilova et al., 2008; Jaako et al., 2011), 
Rps14 (Barlow et al., 2010), Rps6 (McGowan et al., 2011) and Rpl11 in Zebrafish (Chakraborty et al., 
2009; Danilova et al., 2011). Remarkably, anatomical defects, impaired T-cell development and dark 
skin hyperpigmentation in ribosomal protein-deficient models with no anaemia are also restored in a 
p53-deficient background (Kirn-Safran et al., 2007; McGowan et al., 2008; Nieminen et al., 2014; 
Watkins-Chow et al., 2013). On the contrary, Rpl5 mutant mES cells, Rpl5- and Rpl11-depleted 
human lung fibroblasts and Rpl11-deficient fibroblasts did not display basal accumulation of p53 
(Fumagalli et al., 2009, 2012; Morgado-Palacin et al., 2015; Singh et al., 2014; Teng et al., 2013b) and 
p53 deletion does not rescue the G2/M cell cycle arrest observed in Rpl5 mutant mESCs (Singh et al., 
2014). These observations could be reconciled by taking into consideration that activation of p53 
relies on both RPL5 and RPL11 for monitoring ribosome biogenesis function through the ribosomal 
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stress pathway. Thus, in the case of deficiency of the ribosomal stress transducer complex 
(RPL11/RPL5/5S rRNA) p53 is not selectively activated. Analysis of erythroid differentiation and 
study of proliferative and apoptosis responses during the different erythroid stages in Rpl11 
haploinsufficient mice null for p53 would further clarify this question.  
 
Erythroid blood malignancies (acute erythroid leukemia and its subcategory pure erythroid 
leukemia) in which the predominant neoplastic blasts are erythroid, are very rare, counting for less 
than 5% of all cases of adult acute myeloid leukemia, group in which they are classified (Hasserjian et 
al., 2010). Hence, selective sensitivity to p53 activation in the erythroid lineage could protect erythroid 
cells over the rest of hematopoietic lineages from becoming tumoral. 
 
So far, the scenario of possibilities explaining DBA pathogenesis is increasingly complex, and 
additional hypotheses can be also considered. In myelodysplastic syndromes, it has been proposed that 
defective ligand-receptor signaling (c-KIT and Epo), rather than reduced levels of c-KIT or Epo 
receptors, could be one of the causes of impaired erythropoiesis (Fontenay-Roupie et al., 1999). This 
same theory could apply to DBA and it would be of interest to characterize downstream signaling 
pathways to c-KIT and Epo receptors. c-KIT and Epo signalling pathways are particularly important at 
the earlier stages when erythroblast depend on them for expansion and maturation. Expression of 
downstream proteins of Epo signalling, such as JAK2 or STAT5, is not affected in a DBA mouse 
model for Rps19 deficiency (Ludwig et al., 2014) although their activity have not been checked. We 
observed reduced levels of Epor in Rpl11 deficient HPCs so failure in fundamental signalling 
pathways could also contribute to the DBA pathogenesis.  
 
Finally, it is worth mentioning that many chemotherapeutic drugs approved for treatment of 
human cancers, such as cisplatin, result in severe anaemia (Groopman and Itri, 1999). Cisplatin 
induces ribosomal stress by means of inhibition of RNA pol I-mediated transcription and nucleolar 
disruption (Burger et al., 2010; Llanos and Serrano, 2010). Vulnerability of erythroblasts to 
perturbations in ribosome biogenesis could explain at least in part the chemotherapy-induced anaemia 
in cancer patients.  
 
3. Cancer predisposition   !
More than 20% of DBA patients develop cancer by around 46 years of age, including blood 
malignancies and solid tumours (Vlachos et al., 2012). To date, cancer incidence in mouse models for 
DBA (Rps19-deficient or mutant) or for deficiency of other RPs presenting anaemia has not been 
evaluated. Interestingly, haploinsufficiency of Rps6 in the fruit fly and certain RP genes in Zebrafish 
results in increased tumour incidence (Amsterdam et al., 2004b; Stewart and Denell, 1993; Watson et 
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al., 1992). One of the main goals of this thesis was to address whether partial loss of Rpl11 predispose 
to cancer and thus recapitulate the features of the human DBA condition. For that, we subjected mice 
to whole body γ-irradiation (γ-IR) followed by induction of Rpl11 deletion one week later and 
monitored tumour appearance.     
 
Fractionated or a single acute dose of whole body γ-irradiation (γ-IR) elicits thymic lymphoma 
due to oncogenic mutations resulting from single and double-strand breaks. Although the thymus is 
the target organ for tumorigenesis upon exposure to γ-IR, cells with oncogenic potential are primitive 
hematopoietic stem/progenitor cells, since shielding bone marrow or transplanting non-irradiated bone 
marrow cells prevents γ-IR-induced thymic lymphomagenesis (Kominami and Niwa, 2006). We have 
shown that partial loss of Rpl11 accelerates the appearance of thymic lymphoma upon one acute dose 
of whole body γ-irradiation (5Gy; Figure 7A and 7B, manuscript III), concomitant with 
splenomegaly and, in certain cases, hepatomegaly. Of note, Rpl11 gene dose was normal at the 
moment of γ-IR, meaning that haploinsufficiency of Rpl11 favours tumour progression rather than 
initiation. However, we do not know whether partial loss of Rpl11 could be a driving force per se 
during cancer onset. Although inconclusive, it is worth mentioning in this regard that two out of 11 
Rpl11 haploinsufficient mice in a non-irradiated cohort died between 58-70 weeks presenting tumours 
in spleen or splenomegaly, hepatomegaly and increased thymus size, while all their control 
counterparts remained alive at least 75 weeks later (data not shown). This could suggest that Rpl11 
deficiency by itself migth promote lymphomagenesis in the absence of irradiation. Accelerated onset 
of lymphomageneis in Rpl11 deficient mice is apparently paradoxical since impaired ribosome 
production should slow down cell growth and proliferation. This could reflect emerging extra-
ribosomal functions of RPL11 in tumour suppression, and several non-exclusive mechanisms can be 
proposed. 
 
3.1. Defective p53 surveillance pathway in response to ribosomal stress 
 
Previous works in Zebrafish have shown that Rpl11 ablation, contrary to cell lines-based 
studies, results in p53 activation; concurrently, the reported defects in brain development, 
hematopoiesis and metabolism are rescued in a p53-null background deficiency (Chakraborty et al., 
2009; Danilova et al., 2011). However, we observed normal basal levels of p53 in Rpl11 deficient 
fibroblasts and defective p53 activation upon ribosomal stress in primary MEFs treated with ActD, 
doxorubicin or CX-5461 (Figure 7C, manuscript III). This is not surprising considering that RPL11 
is central in the ribosomal stress pathway and thus reduced levels of RPL11 would compromise this 
response.  
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Immunohistochemical analysis of bone marrow biopsies from DBA patients has shown 
upregulation of p53 (Dutt et al., 2011). In our model, only half of the Rpl11+/lox mice (two out of four 
analyzed) presented a clear accumulation of p53 in BM (data not shown). A more detailed analysis 
should be conducted to determine whether p53 accumulates in BM from Rpl11+/lox mice and, if so, if 
accumulation results from remaining Rpl11 levels (one functional gene dose) or from alternative 
mechanisms, such as enhanced p53 translation by RPL26 (Takagi et al., 2005). Notably, histological 
analysis detecting p53 activation has been only carried out in BM biopsies from human DBA patients 
with mutations in Rps19 (Dutt et al., 2011). It would be therefore of great interest to analyze 
peripheral blood cells or BM biopsies from Rpl11 mutant DBA patients to understand whether it 
correlates with p53 activation status.  
 
3.2. Elevated expression of c-MYC and dysregulation of potential oncogenic pathways 
 
Finally, geneset analysis revealed several potential oncogenic pathways upregulated upon 
partial loss of Rpl11 in adult HPCs; among them, MYC and MYB transcription networks and TGF-β 
signalling pathway. Remarkably, a very recent report showed the upregulation of the TGF-β signalling 
pathway in iPSCs derived from DBA patients with mutations in Rps19 or Rpl5 (Ge et al., 2015). We 
also observed elevated levels of cMYC protein in Rpl11-depleted fibroblasts and hematopoietic 
organs, more strikingly in thymus, from Rpl11 heterozygous mice treated for 20 weeks.  
 
Overexpression of c-MYC alone is a driver mutation in haematological malignancies, 
including thymic lymphomas (Morton and Sansom, 2013). Interestingly, translocations resulting in c-
MYC overexpression can occur upon fragmented ionizing radiation in human breast cells (Wade et al., 
2014), thus selecting c-MYC-driven cells as triggers of breast cancer. RPL11 regulates cMYC activity 
by several means, including activation of p53, impaired recruitment of c-MYC co-activators and 
control of c-MYC mRNA stability. Thus, Rpl11 deletion could favour an oncogenic environment for 
the accelerated lymphomagenesis through deregulated levels of cMYC in normal tissues. Interestingly, 
Rps19 deficiency cooperates with PIM kinase to increase c-MYC protein levels (Fröjmark et al., 
2010). This leads to the question of whether upregulation of c-MYC levels and activity, resulting in 
ribosomal stress, is a common feature in DBA pathogenesis. Additionally, increased levels of c-MYC 
could contribute to the anaemia phenotype since overexpression of this oncogene prevents normal 
erythroid differentiation in erythroleukemia cells (Acosta et al., 2008; Coppola and Cole, 1986; Geiler 
et al., 2014).  
 #  
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Concluding remarks on the cancer predisposition in Rpl11 haploinsufficient mice !
It seems contradictory that reduced ribosome biosynthesis could cause uncontrolled cell 
growth. However, delayed cell cycle progression might increase the selective pressure for mutations 
that overcome reduction in ribosome biogenesis and the negative feedback on the cell cycle. This, 
together with upregulation of c-MYC and potential oncogenic pathways, as well as impaired p53 
surveillance may finally contribute to cancer development. It would be of interest to test whether 
increased gene dose of Rpl11 could potentiate p53 surveillance and delay the appearance of tumours in 
c-MYC-driven tumours.    
 
 Importantly, the ribosomal stress pathway has been shown to safeguard cells in vivo, together 
with ARF/MDM2 signalling, in an oncogenic c-MYC-driven lymphomagenesis model (Macias et al., 
2010; Schmitt et al., 1999) and in a chemical-induced skin cancer model (squamous cell carcinoma) 
(Sasaki et al., 2011). Interestingly, the type of cancer registered in RPL11 mutant DBA patients 
(DBAR) is squamous cell carcinoma (Vlachos et al., 2012). Intriguingly, other oncogenic events, such 
as inactivation of pRb or Ras overexpression, do not induce the ribosomal stress pathway. 
Interestingly, ARF/MDM2, but not RPL11/MDM2, signalling is required for restraining tumour 
aggressiveness in a mouse model of prostate cancer triggered by pRb inactivation (Pan et al., 2011). It 
remains to be determined whether inactivation of RB family members induces ribosomal stress. These 
findings suggest a direct and exclusive role of c-MYC in hijacking ribosome biogenesis as a tactic to 
drive tumorigenesis.  
 
 In summary, we have generated a mouse model of Rpl11 haploinsufficiency that recapitulates 
the anaemia and cancer susceptibility reported in human DBA patients. Findings are summarized in 
Figure 7. Based on our results, high tumour predisposition could be due two non-exclusive 
mechanisms: defective p53 surveillance and increased levels of basal c-MYC in heterozygous Rpl11 
fibroblast and hematopoietic organs. Nonetheless, we are still distant from unravelling the common 
molecular mechanism, if any, underlying any type of ribosomal protein deficiency in this disease. The 
feedback loop of RPL11 and c-MYC and the defective p53 surveillance can explain, at least in part, 
tumour predisposition in DBA patients with Rpl11 mutations but it might be irrelevant when other 
ribosomal proteins are mutated. Haploinsufficiency of other RPs could impinge on tumour 
susceptibility by modulating other cellular processes. Cancer predisposition in DBA is still unexplored 
and further studies in this field would shed light on DBA pathogenesis. Additionally, our Rpl11 
haploinsufficient mouse model can be used to test the effectiveness of certain treatments and to 
personalize therapies for those patients with Rpl11 mutations.  
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Figure 7. Partial loss of Rpl11 recapitulates DBA and promotes lymphomagenesis.  
The scheme shows the molecular features and pathologies of Rpl11 happloinsufficient mice.  
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Con la elaboración de este trabajo de Tesis hemos alcanzado las siguientes conclusiones: 
 
 
1. La vía de estrés ribosomal es funcional en células madre embrionarias de ratón y en células 
madre pluripotente inducidas. 
 
 
2. Las células pluripotentes de ratón sometidas a estrés ribosomal activan una respuesta de 
apoptosis mediada por p53. 
 
 
3. La morfología del nucléolo puede ser explotada para la identificación de compuestos que 
tengan como diana la biogénesis del ribosoma.  
 
 
4. Ciertos compuestos derivados de acridina inhiben la transcripción del ADN ribosomal, 
inducen la degradación de la subunidad de la RNA pol II RPA194, y causan desintegración 
del nucléolo . 
 
 
5. Ciertos derivados de acridina activan p53 en células de cáncer a través de la vía de estrés 
ribosomal en ausencia de daño.  
 
 
6. La deleción constitutiva de un alelo de Rpl11 es letal en ratones, así como la deleción 
inducible de ambos alelos en adultos.  
 
 
7. La ablación de un alelo de Rpl11 en ratones adultos recapitula las principales patologías de la 
anemia de Diamond-Blackfan, incluyendo un procesamiento defectivo del RNA ribosomal, 
anemia macrocítica debido a defectos en la maduración eritroide, y una mayor predisposición 
a cáncer.  
 
 
8. La acelerada linfomagénesis inducida por radiación en ratones haploinsuficientes para Rpl11 
puede deberse a una función defectuosa de p53 y a mayores niveles basales de la proto-
oncoproteína c-MYC.  
 !
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From the work carried out during this Thesis, we have reached the following conclussions: 
 
 
1. The ribosomal stress pathway is operative in mouse embryonic stem cells and induced 
pluripotent stem cells.  
 
 
2. Mouse pluripotent stem cells elicit a p53-mediated apoptotic response following ribosomal 
stress. 
 
 
3. Nucleolar morphology can be exploited for the identification of small molecule compounds 
that target ribosome biogenesis. 
 
 
4. Acridine derivatives cause nucleolar disruption by inhibiting rDNA transcription and 
promoting degradation of RPA194 
 
 
5. Acridine derivatives actívate p53 through the ribosomal stress pathway in the absence of 
damage in cancer cells 
 
 
6. Constitutive loss of one allele of Rpl11 is lethal in mice, as well as inducible deletion of both 
alleles in adults. 
 
 
7. Partial loss of Rpl11 in adult mice recapitulates the main features of DBA, including impaired 
rRNA processing, macrocytic anemia due to a defective erythroid maturation, and cancer 
predisposition.  
 
 
8. Accelerated whole body irradiation-induced lymphomagesis in Rpl11 haploinsufficient mice 
could be due to defective p53 surveillance and higher basal levels of the proto-oncoprotein c-
MYC.  
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